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ABSTRACT 
 
Computer-aided drug discovery (CADD) represents a very useful tool to search for potential drug 
candidates and plays a strategic role in the discovery of  new potential therapeutic agents for both 
pharmaceutical companies and academic research groups. Nevertheless, the modelling of  biological 
systems still represents a challenge for computational chemists, and, at present, a single computational 
method able to face such challenge is not available. Computational tools are therefore evolving in the 
direction of  combining molecular-mechanic (MM), molecular dynamics (MD), and quantum-mechanical 
(QM) approaches in order to achieve an overall better simulation of  the actual molecular behaviour. In 
addition, many sampling methods have been developed and applied for the characterisation and 
comparison of  the collective motions of  protein structures related to the dynamics of  proteins, protein 
folding  and ligand-protein docking simulations. This prompted us, as computational medicinal chemists, to 
develop various CADD approaches, depending on the specific case under study, integrating theoretical and 
experimental data. In particular, the research activity carried out during the three years of  my PhD led to: i) 
the development of  three-dimensional (3-D) pharmacophore models for the analysis of  3-D structure-
activity relationships (SARs) of  bioactive compounds, ii) the identification of  new molecular targets, iii) the 
simulation of  large-scale protein conformational changes, iv) the simulation of  protein/protein and 
ligand/protein interactions, and v) the design of  new bioactive compounds. Computational studies were 
always performed in the frame of  multi-disciplinary projects guided by a unique research strategy, which 
involved several international and national research groups, and were carried out by integrating and 
validating our computational studies with the experimental data coming from the other researchers 
involved in the various projects. 
The results obtained enabled to: i) identify a new class of  anticancer agents against paclitaxel resistant 
cancer cells, ii) provide important information on the mechanism of  action of  cationic porphyrins, a novel 
class of  proteasome conformational regulators with great potentiality as “lead” pharmacophores, and iii) 
optimise the cellular pharmacokinetic and pharmacodynamic properties of  a new series of  antimalarial 
agents.  
In addition, I spent a training period abroad of  eight-months at the Institute of  Research in Biomedicine 
(IRB) in Barcelona, under the supervision of  prof. Modesto Orozco, during which I have had the 
opportunity to extend my computational background by learning and, then, performing metadynamic and 
MD simulations, investigating the open/close conformational transition of  20S human proteasome by 
molecular dynamics simulations. 
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Chapter 1 
 
Background 
 
1.1 Brief Overview of Drug Discovery 
 
“A lucky accident dropped the medicine into our hands”; this is a sentence of  how a publication of  the 
year 1886 from Arnold Cahn and Paul Hepp in the Centralblatt für Klinische Medizin started off. The 
history of  drug discovery is studded by serendipity events, in which extensive knowledge of  biological 
systems were lacking and a lot of  working hypotheses were inaccurate in many cases. Historically, drugs 
were discovered through an experimental screening of  compound libraries of  molecule, generally natural 
compounds, which bind the natural target and modulate their activity. Subsequently, the design of  new 
drugs was based on lead optimisation through repetitive chemical modifications to enhance both their 
potency and pharmacological proprieties. Today the case of  lucky accidents have been left on the back-
burner, with the aim to identify compounds with pharmacological interest, that can be used in the 
treatment of  diseases, by using a rational approach.1 Since drugs mediate their effect in the human body by 
particular interactions of  the drug molecule with its target(s), then, to design new drugs, the 
comprehension of  the etiology of  the disease and the structure of  the molecular target(s) where the ligand 
(drug) will bind, represent crucial issues. Actually, the first stage of  the drug discovery pipeline is, indeed, 
represented by the identification/selection of  the molecular target(s) for the pathology of  interest (Figure 
1).  
 
 
Figure 1. General description of Drug Discovery pipeline. 
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Drug targets are frequently badly defined in the literature, both for pharmaceutical product placed on the 
market and for potential therapeutic agents in discovery and development. In this regard, a revised 
complete map of  molecular targets of  approved drugs was published, in which were considered a total of  
893 human and pathogen-derived biomolecules by means of  which 1,578 Food and Drug Administration 
(FDA) approved drugs effect.2 Among the 893 biomolecules targeted by the drugs, there are 667 human 
genome-derived proteins and 189 pathogen-genome derived proteins (Table 1 and Figure 2). 
 
Table 1 | Molecular targets of  FDA-approved drugs.  
 
Drug  target class 
Targets Drugs 
Total targets 
Small molecule 
drug targets 
Biological 
drug targets 
Total drugs 
Small 
molecules 
Biologics 
Human protein 667 549 146 1,194 999 195 
Pathogen protein 189 184 7 220 215 5 
Other human 
biomolecules 28 9 22 98 63 35 
Other pathogen 
biomolecules 9 7 4 79 71 8 
Table adapted from Santos R. et al. (2017) (http://dx.doi.org/10.1038/nrd.2016.230). 
 
Analysis of  these drug targets highlighted the continued predominance of  protein families towards the 
various human disease areas (Table 1 and Figure 2). 
 
 
Figure 2. Right: distribution of  human drug targets by gene family. Left: distribution by the fraction of  drugs targeting those 
families. Figure adapted from Santos R. et al. (2017) (http://dx.doi.org/10.1038/nrd.2016.230). 
 
Once the biomolecular target has been identified/selected, drug discovery activities typically proceed with 
1) the hit identification phase, in which chemical compounds with a good likelihood of activity against the 
target are identified, 2) the lead generation phase, in which hit compounds are tailored in potency toward the 
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target, and finally 3) the lead optimisation phase, in which lead compounds are optimised, by generating 
druggable molecules (i.e., capable to employ their pharmacological features in patients)3 (Figure 1).  
The first step aims at the identification of a molecular scaffold that will be recognised by the selected 
biological target (the protein) and design a model to reproduce the pathology under study. The goal of the 
second step, lead generation, is to select a lead compound, that is, a molecule that will manifest drug-like 
features in terms of target potency and selectivity, generally obtained through several rounds of hit 
modifications and structure-activity relationship (SAR) analysis. The third step is the optimisation of lead 
compound chemical-physical properties in such a way that it may move to the drug development phase, 
SARs are rationally explored in the lead optimisation step, too. Progressively, the drug goes beyond the 
preclinical stage of animal pharmacology and toxicology analysis, as well as formulation, studies of stability, 
and quality control measures, the whole process (drug discovery and preclinical trials) may take from three 
to six years. Finally, if the drug is promoted in all the steps previously described, the drug pass to clinical 
trials in humans, and, if approved, goes to the market after an additional period of about ten years. 
 
1.2 Computer Aided-Drug Discovery (CADD) 
 
To bring a drug to the market is a long run process that costs billions of  dollars, it is a lengthy, costly, and 
difficult process with a high attrition rate of  new therapeutic discovery.4,5 Indeed, the probability of  a 
failure in the drug discovery is high, about 90% of  the new drugs entering clinical trials fail to get the 
FDA-approval and reach the consumer market. In this scenario, computer-aided drug discovery (CADD) 
gained close attention both in the pharmaceutical industry and at the academic level. CADD can operate as 
a virtual shortcut, contributing in the expedition of  the discovery process and potentially decreasing the 
cost of  research and development. Nowadays, the massive increase in computational power in combination 
with efficient software, is leading to more targeted approaches for the development of  novel drugs6 (Figure 
3). 
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Figure 3. Drug discovery pipeline composed of three phases: “hit identification”, “lead generation” and “lead optimisation”. Multiple 
computational approaches can be used to each phase of drug discovery and development pipeline. 
 
Accordingly, in the last few decades, the impact of  computational chemistry on drug discovery has been 
amplified and several theoretical methods that were once not available for efficient drug discovery are 
widely used for the hit identification and lead generation steps. Currently, CADD is broadly employed in 
the biomedical area, as well as, to accelerate and simplify hit identification, hit-to-lead selection, optimise the 
pharmacokinetic and toxicity profiles, and escape safety problems. Overall, computational methods are in 
favour of the identification of chemical scaffolds that may interfere in an efficient way with the target 
functions, generating a positive pharmacological response. Biochemical and pharmacological data on the 
new compounds can be used to compute predictions in order to lay the groundwork for more suitable 
models that can be built, driving to the design of refined compounds.7 
 
1.2.1 Classification of CADD approaches 
 
CADD methods can be broadly classified into two groups, such as, Target-Based Drug Discovery (TBDD) 
and Ligand-Based Drug Discovery (LBDD). As a general rule, the target-based approaches are employed 
when structure about the molecular target and its experimental data are available.8 These approaches 
include structural and bioinformatics analysis, docking calculations, and molecular dynamic simulations.9 
The ligand-based approaches,10 on the contrary, calculate the physical-chemical properties of  bioactive 
molecules which are characterised by a common mechanism of  action, and can be used also when the 
target structure is unknown. This kind of  approach often drive to the generation a pharmacophore model 
specifying the structural characteristics held accountable for the observed biological activity. At any rate, 
both approaches have the purpose to rationalise available SARs and to design novel compounds.  
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1.2.1.1 Target-Based Drug Design (TBDD) 
 
The TBDD is based on the capability to define and study 3-D biomolecular structures. The basic idea of  
this approach is that the likelihood of  a molecule to interact with a given target, showing a desired biologic 
effect, is subordinate to its tendency to interact with a specific binding site on protein itself.8 To be able to 
use TBDD tools is necessary to known the target structures. The information about the target are generally 
acquired experimentally by Nuclear Magnetic Resonance (NMR), Electron Microscopy or X-ray diffraction 
methods. X-ray crystallography is still considered today the most important tool of  structural biology, 
supplying a lot of  high-resolution protein structures, in the states of  unbound/bound receptor and ligand 
(Brookhaven Protein Data Bank, PDB, www.rcsb.org).11 However, while the analysis of  a singular X-ray 
structure in many cases provides considerable information about the active site(s) and function of  protein, 
it can also induce to consider the proteins as inflexible entities. Differently, protein flexibility is recognised 
as critical for protein-ligand or protein-protein interactions and protein conformational changes are 
essential in order to carry out its biological functions.12 In spite of  their limitations, X-ray structures can 
even so supply important information regarding intrinsic dynamic of  proteins,12 for instance, making a 
comparison of  several structures resolved under distinct conditions. Furthermore, it is possible to achieve 
additional understanding of  the protein-ligand interaction dynamics by combining the structural and 
bioinformatics analysis of  the resolved X-ray structures with NMR studies.13  
The huge gap between the number of  available protein sequences and experimentally solved protein 
structures could be filled by the aid of  computational methods. Theoretical structure prediction can be 
divided into two extreme camps: ab-initio method9,10,14 and homology modelling.15,16 The first approach has 
fold prediction from physical chemistry principles as one of  its goals. The second method predicts the 3-D 
structure of  a given protein sequence based primarily on its sequence similarity to one or more proteins of  
known structures.17 Regarding the first approach, its main limitation is that we do not know precisely the 
physical procedure by which a protein chain obtains its native 3-D structure. Hydrophobic and electrostatic 
forces play critical roles, as well as in living systems protein-protein interactions (PPIs). But exactly how 
these proprieties create the final shape of  a protein is still a riddle. The biologist Cyrus Levinthal, in the late 
1960s, mentioned that one might assume that an unfolded amino acid chain to arrange a stable 3-D 
conformation by identifying the minimum energy situation. However, considering rotational atomic bonds 
and all the degrees of  freedom for an amino acid chain, it should be necessary more time compared to the 
age of  the universe for even a simple protein in order to assume its appropriate native conformation.18 
Conversely, also intricate proteins are structured within seconds or even less, showing undoubtedly that do 
not find an energy of  global minimum (GM) by means of  a random search of  precise conformation. 
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Indeed, they always seem to find a fold-up with the same shape enough to be crystallised. In this respect, 
many scientists have esteemed “Levinthal’s Paradox”, proposing that proteins do not necessarily yearn for 
energy of  GM but ideally safeguard sufficiently deep energy wells to survive possible biological 
perturbations, by giving up energy in an efficient manner to several functions. “Proteins are obviously not 
optimised for stability”, probably because they require an unfolded structure in several situations.19 
Nowadays, homology modelling plays a central role in determining protein structure; its importance has 
been steadily expanding because of  the increasing reliability and accuracy of  the method. In fact, a protein 
sequence with over 30% identity to a known structure can often be predicted with an accuracy equivalent 
to a low-resolution X-ray structure.17 The ongoing efforts in solving protein structures by homology 
modelling are progressing toward a new step in the development of  this technique, the aim is to predict the 
“native state of  proteins,” and not merely to “predict the structure” (with regard to the α-carbon scaffold) 
of  a target sequence. Indeed, numerous studies have showed the effect of  conformational diversity also on 
tamplate-based modelling approaches,20 since a given template can have several conformers sampling an 
ample conformational space.21 
In any case, with the purpose of  simulating ligand-protein interactions, latest mechanistic models have to 
be put into context.22-25 Proteins show an ensemble of  conformational states/substates in solution and the 
interaction with other proteins and/or smaller ligands, influences these native states/substates by stabilising 
only one of  them.22 In fact, in accordance with Le Châtelier’s principle, the protein-ligand complex 
formation moves equilibrium in favour of  the regeneration of  the interacting conformers. In this context, 
in recent time developed mechanistic models, such as “conformational-selection”23 and “induced-fit”24 (Figure 4), 
overcome the old but still popular “lock-and-key” model.  
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Figure 4. “Conformational-selection” and “induced-fit” models of  binding. The two different models are characterised by the the 
binding site conformation when the ligand binds. During “conformational-selection” the ligand selects the configuration of  the 
binding site whereas during “induced-fit” the bound form of  the complex is shaped after binding of  the ligand.  
 
The “conformational-selection” model relies on the fact that, as stated above, the selected protein conformation 
pre-exists in solution, so that the ligand selectively recognises it, causing a shift of  the equilibrium toward 
that conformation. On the other hand, once a ligand binds to the target protein in the bioactive 
conformation and interacts with key amino acids, the protein conformation may be modified or become 
locked, relying on the mechanism of  action of  ligand-protein complex.26 According to the “induced-fit” 
model, a protein undergoes a conformational change upon ligand binding and this conformational 
rearrangement results in a protein-ligand complex with tighter binding. Taking into account both models, 
the overall scenario, includes a first molecular recognition step (conformational-selection) followed by a 
subsequent reorganisation of  the formed complex to reach its closest energy minimum (induced-fit).25 
For the above reasons, to understand the molecular mechanisms underlying conformational changes of  
proteins is of  primary importance for the design of  new drugs, and, consequentially, in ligand-protein 
interaction simulations is essential to take into account protein flexibility. Many computational methods 
have been developed and applied for the characterisation and comparison of  the collective motions of  
protein structures related to the dynamics of  proteins,27-30 protein folding31-34 and ligand-protein docking 
simulations.35,36 Proteins are complex biomolecules and they usually have energy landscapes with many 
local energy minima separated by high-energy barriers, and this is a restricting factor for whole sampling as 
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simulations can come to a standstill in local minima. The collective conformational transitions through 
which proteins move, globally take place in microseconds to seconds timescales while molecular dynamic is 
circumscribed to discrete time-steps, no more than a few femtoseconds. Therefore, in spite of  multi-thread 
parallelisation computing means, a classic Molecular Dynamic (MD) simulation is impracticable to sample 
such conformational transitions and a more suitable techniques are required. Consequently, a variety of  
innovative and complex techniques have been developed and applied in order to overcome the free energy 
sampling problem, such as, parallel tempering (using Monte Carlo method to define probabilistic 
exchanging systems states),37 metadynamics,38,39 simulated annealing (SA),40 discrete molecular dynamics 
(dMD),41,42 and a multitude of  new sampling algorithms are constantly flourishing.43,44 The more suited 
method shall be selected on the basis of  physical and biological system properties under study. As an 
example, while classic MD produces a single trajectory at a specific temperature, allowing kinetic 
characteristics to be straight obtained, SA (as well as a lot of  improved sampling methods) does not, 
nevertheless, it is suitable for very flexible systems and is marked by an enhanced sampling efficiency.45,46 
With a view to improving the quality of  the dynamic simulations, hybrid approaches have also been 
developed47-51 and introduced in many molecular docking software until today, enlarging the degree of  
protein flexibility esteemed throughout the conformational sampling. Of  course, once again, no individual 
method attained optimum results, according to type of  the system under consideration and the application 
of  research.52 
Finally yet importantly, to generate dependable model, it is essential to set up the MD simulation in the 
framework of  a broader study of  both the ligand and the protein target, just as the investigation of  the 
molecular mechanism of  action. In fact, the calculation protocol has to be tailored to the system, taking 
into account whether the ligand binding site is known or not, and, in the former case, if  it arises in the 
allosteric or in an orthosteric site, what sort of  biological response is brought about by the formation of  
each complex, etc. Equally important is to take into consideration the target as a functional biological 
entity, to evaluate if  it show an activity as monomer or dimer or part of  a multi-protein complex, as well as, 
to recognise both of  the nature and the number of  Protein Interaction Domains (PIDs) and Short Linear 
functional Motifs (SLiMs) (http://elm.eu.org/).53,54 Indeed, a lot of  ligand-protein interactions take place 
with conserved hot spot residues who belong to PIDs and/or SLiMs.55-57 Therefore, such investigation is 
especially relevant when the ligand binding site is not known and/or the effect is explained through an 
allosteric mechanism. 
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1.2.1.2 Ligand-Based Drug Discovery (LBDD) 
 
The LBDD approach entails the examinations of biologically active compounds known to be 
charachterised by the same mechanism of action. It is regarded as an indirect approach to the drug 
discovery since it does not required knowledge of the target structure at issue. There are two distinct 
approaches of LBDD:  
 the selection of compounds based on chemical similarity to known active compounds, 
 the build of a Structure-Activity Relationship (SAR) 3-D model that foretells biological activity by 
means of the chemical structure.  
LBDD is based on the similar property principle which asserts that molecules with comparable structures 
have a clear likelihood to have comparable properties.58 
Molecular characteristics can consist of properties such as molecular weight, geometry, shape, surface 
areas, ring content, rotatable bonds, inter-atomic and bond distances, atom types, planar systems,  
electronegativities, polarisabilities, symmetry, atom distribution, topological charge indices, functional 
group composition, aromaticity index, solvation properties, and many others.59 These descriptors are 
engendered through the use of quite some methods, among which Molecular-Mechanics (MM) or 
Quantum-Mechanics (QM) tools60,61 and are categorised in accordance with the “dimensionality” of the 
chemical description from which they are computed.62 In this way, the most important descriptions for 
building predictive pharmacophores are easily identified. The same basic rules are efficient for molecular 
similarity search, where geometrical and physico-chemical likeness among active compounds are employed 
to recognise new compounds with pharmacological activity of many that can be virtually screened.63 
Structural and electronic descriptors are employed to build a QSAR, where the collection of  active and/or 
inactive ligands are evidenced by a set of  mathematical descriptors capable to depict the physicochemical 
and structural features of  such compounds. A model is therefore generated to identify the relationship 
among those descriptors and their experimental activity, maximising the predictive power. Lastly, the model 
is used to foresee activity for a library of  test compounds that were coded with the same descriptors.  
The International Union of Pure and Applied Chemistry (IUPAC) officially described a pharmacophore as 
“the ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular 
interactions with a specific biological target structure and to trigger (or to block) its biological response”.64 
In terms of activity, it is the spatial positioning of functional groups that a molecule (or drug) must include 
in order to obtain a sought-after biological response. Therefore, an efficient pharmacophore will consist of 
information about functional groups that interact with the target, type of non-covalent interactions and 
inter-atomic distances. Most common properties employed to describe pharmacophores are H-bond 
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acceptors/donors, basic/acidic groups, partial charge, aliphatic and aromatic hydrophobic moieties. A 3-D-
pharmacophore would reproduce how key amino acids are arranged in the binding site of a target protein.65 
For instance, a key amino acid residue which is acting as H-bond acceptor should be in the proximity of a 
H-bond donor in the pharmacophore model, promoting the protein-ligand interaction. Pharmacophore 
features have been employed widely in drug discovery for virtual screening, de novo design, lead 
optimisation66 and a target binding site pharmacophore model can be employed to sift a compound library 
to identify putative hits.  
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Chapter 2 
 
Presentation of  the Work 
 
Computer-Aided Drug Discovery (CADD) still represents a challenge for computational chemists, and, at 
present, a single computational method able to face such challenge is not available. This prompted us, as 
computational medicinal chemists, to develop various CADD approaches, depending on the specific case 
under study, integrating the theoretical and experimental data in a unique research strategy.  
In the present dissertation, I review the research activity carried out during the three years of  my PhD, 
which included: i) the development of  3-D-pharmacophore models for the analysis of  3-D structure-
activity relationships (SARs) of  bioactive compounds, ii) the identification of  new protein targets, iii) the 
simulation of  large-scale protein conformational changes, iv) the simulation of  protein/protein and 
ligand/protein interactions, and v) the design of  new bioactive compounds.  
 
The overall methodological approach used for the Target-Based studies is reported in the flowchart below 
(Figure 5).  
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Figure 5. Schematic depiction of  the methodological approach used in the molecular modelling studies. Dashed square 
indicates a discretionary step. Figure reproduced from Persico M. et al. (2016) with permission of  WILEY-VCH Verlag GmbH 
& Co. KGaA (http://dx.doi.org/10.1002/minf.201501028). 
 
The first step consists in the investigation of  the electronic and conformational details of  the ligands under 
study (which can be either known or putative or newly designed), and it is performed by a combination of  
simulated annealing/Molecular-mechanics (SA/MM) and Quantum-Mechanics (QM) calculations. Ligand 
analysis also aims at the identification of  the common structural features possibily involved in target 
recognition. When the considered ligand is represented by a protein structure, it is subjected to the same 
kind of  analysis performed on the protein target(s). The target protein structure(s) is subjected to a 
detailed structural and bioinformatics analysis, such as: i) inspection of  all the available 3-D-structures, 
including investigation of  the molecular interactions with co-crytallysed ligands and postion and 
conservation of  water molecules, ii) sequence alignment (PROMALS3-D),67  iii) mapping of  experimentally 
identified functional amino acids, iv) secondary structure prediction calculations 
(http://www.predictprotein.org/), v) identification of  structurally conserved regions (SCRs), and vi) 
identification of  Protein Interaction Domains (PIDs) and Short Linear functional Motifs (SLiMs).53,54 
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The bioinformatics analysis becomes crucial when the experimental structure of  the target is not complete 
or not available at all; on this occasion, it has to be verified if  is still possible to generate a protein 
homology model by relying on the experimental structure of  closely connected proteins.  
The Homology Building technique includes the following main steps: 
 identification of  the adequate template structure(s), 
 sequence alignment between target and template, 
 copying coordinates for confidently aligned target and template portions, 
 building missing atom coordinates of  the target structure, 
 evaluation and model refinement.  
 
The information acquired from the analysis of  the ligand and target structures (cyan box  in Figure 5) will 
constitute the starting point to set up the subsequent dynamic docking calculations (magenta box in Figure 
5). During the docking procedure, the hypothesised starting complex is subjected to disruptive effect in 
order to generate a user-defined number of  possible complexes. The docking procedure is based on a 
combined Monte Carlo/SA approach57,68,69 The Monte Carlo method is useful for simulating systems with 
many coupled degrees of  freedom, and, based on statistical mechanics, it generates suitable distinct 
conformations of  a system, which correspond, in this case, to as many ligand-protein complex structures. 
The obtained Monte Carlo complexes are then subjected to the SA temperature-reducing scheme to 
improve the ligand-fixing into the binding site.70 Indeed, SA is an approach that reduces a minimisation of  
a function of  large number of  variables to the statistical mechanics of  equilibration (annealing).  
Throughout the docking calculations, the conformational space of  both of  the ligand and the protein 
binding domain area is explored. Importantly, the putative binding domain area is enlarged to the whole 
protein target, thus allowing to fully investigate ligand binding sites and/or modes, as well as, ligand-
induced protein large-scale conformational changes. On the other hand, since these latter are frequently 
dominated by motions of  conserved structural/functional protein domains, then, conformational 
constraints are applied to backbone hydrogen bonds (α-helices) and φ and ψ torsion angles (β-sheets) of  
those secondary structures classified as highly conserved by the previous structural and bioinformatics 
analysis. Water molecules can be constrained with a force constant too, in accordance with their function 
and conservation. The rest of  the system is free to move without restrictions.  
The obtained complexes are processed to a final structure optimisation without any conformational 
21 | P a g e  
 
restraint and, then, classified by their conformational and non-bonded interaction energy. The choice of  
the method to be used for the calculation of  non-bonded interactions is selected in accordance to the 
results of  test-docking calculations.  
At the end (green box in Figure 5), the quality of  the resulting docked structures is calculated by inspecting 
structural parameters using structure-validation software (e.g., Procheck71 and Molprobity72). The validity of  
the model is anyway constantly challenged and integrated by experimental data coming from rationally 
designed experimental studies (i.e., structural, biochemical, pharmacological) (green box in Figure 5).  
A somehow divergent, Ligand-Based, computational protocol has been applied for the design of  redox-
active chemotherapeutics, which couples the complete sampling of  the conformational space of  the 
ligands, by using a combination of  empirical (MD/MM) and semi-empirical (i.e., PM6 and PM7;73,74 
Eigenvector Following routine75) (summarised in Figure 6). 
 
 
Figure 6. Schematic depiction of  the CADD approach for redox-active chemotherapeutics. Dashed square indicates an 
discretionary step. Figure reproduced from Persico M. et al. (2016) with permission of  WILEY-VCH Verlag GmbH & Co. 
KGaA (http://dx.doi.org/10.1002/minf.201501028). 
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According to the case under consideration, the ligands can be evaluated in the neutral, ionised, and/or 
radical state. As preliminary step, the predominant ionic state(s) at the evaluated pH(s) of  all the doable 
tautomeric forms of  the ligands under study and their log D value(s) are calculated (cyan box in Figure 6). 
For instance, in the case of  the antimalarial endoperoxides described in Chapter 5, all the possible 
tautomeric forms of  the ligands are considered, as well as, their prevalent ionic species at physiological, 
cytoplasmic, and Plasmodium falciparum (Pf) food vacuole (FV) pH values (i.e., 7.4, 7.2, and 5.5). Then, the 
conformational space of  the ligands is sampled through numerous cycles of  SA calculations followed by 
MM/QM energy minimisation (magenta box in Figure 6). The number of  cycles and the temperature 
range to be used are chosen by considering the number and the nature of  torsional degrees of  the ligands. 
The employ of  a very high initial temperature permit to examine the conformational space overstepping 
any torsional barriers. In fact, at this point, the purpose is to sample the conformational space in a 
comprehensive way, by recognising all possible minima and obtain the starting structures for the following 
QM calculations (i.e., semiempirical and DFT). In this view, to increase the variance of  the MM starting 
conformers, more than one set of  SA/MM calculations can be carried out, modifying the value of  the 
dielectric constant in accordance with the simulated chemical environments. The MM conformers are then 
subjected to QM full geometry optimisation. In QM calculations, solvation effects are computed by the 
Polarizable Continuum Model (PCM)76-78 in which the solvent is represented by infinite dielectric medium 
characterised by the relative dielectric constant of  the bulk. QM conformers within 5 kcal/mol from the 
GM are examined and assembled into families taking into account their torsional angle and inter-atomic 
distance values. Considering the available SAR data, a possible redox reaction mechanism driving to the 
formation of  toxic radical species can be hypothesised. Therefore, starting from the structures of  the 
chosen QM conformers, the distinct species along the supposed reaction pathway of  the hypothesised 
mechanism of  action are produced and subjected to additional calculations, this may cosist of  docking and 
DFT studies in complex with the redox partner (in this case free heme). Based upon the accomplished 
results supposed bioactive conformers are recognised79 for each ligand, and a pharmacophore model can 
be generated (magenta box in Figure 6). The computational models require to be constantly integrated with 
experimental data in an iterative process.  
The developed pharmacophore model can be then employed to carry out pharmacophore-based searches 
in 3-D-molecular databases (green box  in Figure 6),80,81 selecting the resulting hits on the basis of  the 
compatibility of  their presented biological activity (PubChem BioAssay database)82,83 with the activity 
profile of  the search compounds. The information acquired from this analysis can be employed either to 
additional confirm the 3-D-pharmacophore model and to recognise new molecular scaffolds useful for the 
rational design of  novel ligands. 
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My research activity has been carried out in the frame of  several multidisciplinary projects, each guided by 
a coordinated computational/experimental strategy. These studies involved several international and 
national research groups, and were carried out by integrating and validating our computational studies with 
the experimental data coming from the other researchers involved in the various projects. The projects in 
which I partecipated, together with the subject of  the study and the heads of  the other research groups 
involved, are herein listed: 
 
 “Allosteric Inhibitors of  the GBP1-PIM1 Complex” 
 Dr. Antonio E. Alegria, Department of  Chemistry, University of  Puerto Rico at Humacao, USA;  
 Dr. Cristiano Ferlini, Biomedical Research Center of  Danbury Hospital Research Istitute, USA; 
 Dr. Sanjay V. Malhotra, Frederick National Laboratory for Cancer Research, USA; 
 Dr. Ajay Kumar, School of  Environmental Affairs, Universidad Metropolitana, San Juan, Puerto 
Rico, USA; 
 Prof. G. Scambia, Dipartimento di Ginecologia, Università Cattolica del Sacro Cuore di Roma. 
 
“Cationic Porphyrins as Tunable Gatekeepers of  the 20S Proteasome” 
 Prof. Milardi, Istituto di Biostrutture e Bioimmagini (IBB) - CNR UOS di Catania; 
 Prof. A. M. Santoro, Istituto di Biostrutture e Bioimmagini (IBB) - CNR UOS di Catania; 
 Prof. R. Purrello, Dipartimento di Scienze Chimiche, Università di Catania; 
 Prof. M. Coletta, Dipartimento di Scienze Cliniche e Medicina Traslazionale, Università di Roma 
Tor Vergata; 
 Prof. R. Fattorusso, Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, 
Seconda Università degli Studi Napoli; 
 Prof. R. Paolesse, Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma Tor Vergata-
Via della Ricerca Scientifica. 
 
 “Design of  Redox-active Chemotherapeutics” 
 Dr. D. D. Dhavale, Garware Research Centre, Department of  Chemistry, University of  Pune; 
 Prof. O. Taglialatela-Scafati, Dipartimento di Farmacia, Università di Napoli “Federico II”; 
 Prof. D. Taramelli, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano;  
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 Prof. C. Trombini, Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum, 
Università di Bologna. 
 
In addition, I spent a training period of  eight-months at the Institute of  Research in Biomedicine (IRB) in 
Barcelona, under the supervision of  prof. Modesto Orozco, during which I had the opportunity to extend 
my computational background by learning and, then, applying innovative molecular dynamics algorithms to 
simulate large-scale protein conformational transitions, such as, those occurring in the 20S human  
proteasome.  
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Chapter 3 
 
 
3.1 Allosteric Inhibitors of the GBP1-PIM1 Complex  
 
The management of solid malignancies is in many cases characterised by natural occurrence of drug 
resistance. Frequently, despite the initial response to therapy, cancer cells evolve a resistant phenotype that 
leads to a fatal advancement of the illness. Mechanisms that cause drug resistance are subordinated by 
several functional pathways. Biochemical studies showed that, in the case of paclitaxel resistant ovarian 
cancer cells, the overexpression of III β-tubulin plays a key role in the evolution of drug resistance to 
paclitaxel, inasmuch promotes the incorporation of the large-GTPase GBP1 (Guanylate-Binding Protein 1) 
into microtubules.84-87 Once in the cytoskeleton, GBP1 binds to prosurvival kinases PIM1 (Proviral 
Integration of Moloney virus) and initiates a signalling pathway that induces resistance to paclitaxel.88,89  
GBP1 is a large GTP-binding protein, belonging to the Dynamin and Mx family of GTPases,90 and it is 
structurally divided into two domains: a compact globular αβ-domain (amino acids 1-278; LG domain) and 
an elongated purely α-helical domain (amino acids 312-592; helical domain). These two domains are linked 
by a short intermediate region (amino acids 279-311), which consists of a two-stranded β-sheet and a α-
helix.91-95 Similar other members of the Dynamin family, throughout GTP hydrolysis GBP1 undergoes 
structural changes driving to self-assembly. Intra-protein communication is fundamentals to the protein 
allosteric mechanisms, allostery has now been studied on the inside of a single protein domain96 and its 
explanation pushed out to involve any shift in protein structure and function at one site consequent from 
modification at another. 
Biochemical studies demonstrated that i) the intermediate region plays a significant role in GTPase activity 
through allosteric interactions, thus acting as an internal GAP (GTPase Activating Protein),97 and ii) the 
GTPase activity is coupled to structural changes in the C-terminal sub-domain α12/α13.98-100 The 
interruptions of critical ionic contacts between the LG domain and helical domain has been showed to 
cause an increased GTPase activity, GMP production, and GBP1 oligomer formation.98 Moreover, the 
determination of PIDs53 and SLiMs,54 including maintained hot spot residues which have a functional and 
structural ability of adaptation, can account for the ability of GBP1 to accommodate not only other 
proteins with complementary binding domains and/or motifs (i.e., protein-protein interactions; PPIs), but 
also small compounds based on different scaffolds (i.e., protein-ligand interactions).101 Consequently, many 
studies showed that ligands are recognised by proteins employing well-defined binding sites, 
complementary in shape and physicochemical features to the accommodated small ligands.102 Accordingly, 
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if two binding sites of distinct proteins share a common motif, it is probable that ligands or ligand portions 
that bind at one binding site will also be identified in the respective part of the other binding site.103-105 
Following this rationale, starting from the natural lead podophyllotoxin (1; Figure 7) and considering semi-
synthetic analogues, such as, Etoposide (2; Figure 7), our investigations led to the identification of a new 
podophyllotoxin derivative (NSC756093; 3 in Figure 7) as the first, potent inhibitor of the GBP1-PIM1 
interaction, indicating the interface between the catalytic and the helical domain of GBP1 as the binding 
site, whose occupancy is able to prevent the formation of the GBP1-PIM1 complex through an allosteric 
mechanism.106 
 
 
Compound X Y-Z R1 R2 R3 R4 R5 
1 CH CH-CH 6,7-OCH2O OCH3 OCH3 OCH3 -OH 
2 CH CH-CH 6,7-OCH2O OCH3 OH OCH3 
O
O
O
OH3C
OHHO  
3 N C=C 6-OCH3 H H H -CH2CH2OH 
 
Figure 7. Structures of Podophyllotoxin (1), Etoposide (2), and NSC756093 (3). Figure adapted from Andreoli M. et al. (2014) 
with permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
 
In order to identify specific inhibitors of the III β-tubulin/GBP1/PIM1 functional gateway in paclitaxel 
resistant cells, a series of forty-four 4-aza-podophyllotoxins (4-APTs) derivatives was synthesised by the 
research group of Dr. M. Sanjay and was screened in the NCI-60 cell panel (Table 2).  
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Table 2 | Structures of 4-Aza-podophyllotoxins (4-APTs).  
  
 
N
O
O
R4
R3
R2
B C D
E
R1
OH
 
 
Compound R1 R2 R3 R4 
NSC750210 6,7-OCH2O OCH3 OCH3 OCH3 
NSC750716 6,7-OCH2O OCH3 OCH3 H 
NSC750717 6,7-OCH2O OCH3 H H 
NSC750211 6,7-OCH2O H H H 
NSC750718 6,7-OCH2O OCH3 OH OCH3 
NSC750499 6,7-OCH2O H OCH3 H 
NSC756083 6,7-OCH2O Cl H H 
NSC750212 6,7-(CH2)3 OCH3 OCH3 OCH3 
NSC751500 6,7-(CH2)3 OCH3 OCH3 H 
NSC750719 6,7-(CH2)3 OCH3 H H 
NSC750213 6,7-(CH2)3 H H H 
NSC751501 6,7-(CH2)3 OCH3 OH OCH3 
NSC751502 6,7-(CH2)3 H OCH3 H 
NSC756084 6,7-(CH2)3 Br H H 
NSC756085 6,7-(CH2)3 Cl H H 
NSC756086 6,7-(CH2)3 Cl Cl H 
NSC750720 6,7-O(CH2)2O OCH3 OCH3 OCH3 
NSC750721 6,7-O(CH2)2O OCH3 OCH3 H 
NSC750722 6,7-O(CH2)2O OCH3 H H 
NSC750723 6,7-O(CH2)2O H H H 
NSC751503 6,7-O(CH2)2O OCH3 OH OCH3 
NSC751504 6,7-O(CH2)2O H OCH3 H 
NSC756087 6,7-O(CH2)2O Br H H 
NSC756088 6,7-O(CH2)2O Cl H H 
NSC759089 6,7-O(CH2)2O Cl Cl H 
NSC756090 6-OCH3 OCH3 OCH3 OCH3 
NSC756091 6-OCH3 OCH3 OCH3 H 
NSC756092 6-OCH3 OCH3 H H 
NSC756093 6-OCH3 H H H 
NSC756094 6-OCH3 H OCH3 H 
NSC756095 6-OCH3 Br H H 
NSC756097 6,7-OCH3 OCH3 OCH3 OCH3 
NSC756098 6,7-OCH3 OCH3 OCH3 H 
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NSC756099 6,7-OCH3 OCH3 H H 
NSC759100 6,7-OCH3 H H H 
NSC756102 6,7-OCH3 H OCH3 H 
NSC756103 6,7-OCH3 Br H H 
NSC756104 6,7-OCH3 Cl H H 
NSC756105 6,7-OCH3 Cl Cl H 
NSC756106 6-CH2CH3 OCH3 OCH3 OCH3 
NSC756108 6-CH2CH3 H H H 
NSC756110 6-CH2CH3 Br H H 
NSC756111 6-CH2CH3 Cl H H 
NSC756112 6-CH2CH3 Cl Cl H 
Table adapted from Andreoli M. et al. (2014) with permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
Thirty-one compounds exhibited significant growth inhibition and were subjected to the COMPARE 
Analysis method.107  
Results evidenced that some of  these ligands are active on paclitaxel-resistant cells with a spectrum of  
cytotoxicity similar to that of  other anticancer drugs, all interfering with the dynamicity of  the 
cytoskeleton. Moreover, it was possible to identify five clusters with different structural homologies (Figure 
8). 
 
 
 
Figure 8. Schematic representation showing the most active twenty-one 4-APTs obtained by the COMPARE analysis. On the 
vertical axis, with different colours are represented the five different 4-APTs clusters. Figure reproduced from Andreoli M. et al. 
(2014)  with permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
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Starting from these results, and in order to evaluate the ability of  these compounds to interfere with the 
GBP1-PIM1 complex, the twenty-one 4-APTs found to be more active have been tested in Surface 
Plasmon Resonance (SPR) assays, carried out by the research group of  Dr. C. Ferlini (Danbury Hosptial, 
USA). Since tubulin isoforms (α and β) are not usable for in vitro assays, as the their active conformation 
requires post-transcriptional modifications not obtainable with current recombinant technology, these 
studies were performed considering only GBP1 and PIM1, which can be expressed in vitro. The SPR results 
showed that i) the signal generated by the GBP1:PIM1 interaction is dose-dependent in a range of  8.25-
140 nM with a KD of  38 ± 14 nM and ii) only the NSC756093 (3; Figure 7) compound is capable of  
inhibiting the GBP1:PIM1 interaction at 65%, with a correlation between concentration and inhibition 
rates (Figure 9). 
 
 
 
Figure 9. A Graphic representing the eleven compounds that were capable of producing an inhibition of the binding around 10-
20%, while only 3 was able to inhibit 65% of the GBP1:PIM1 interaction. B The inhibition of the GBP1:PIM1 interaction by 3 
was dose-dependent and statistically significant as compared with the control without drug (p < 0.001, Anova). Representative 
biosensograms are shown in C (NSC756093) and D (NSC756090). In all the experiments, CA was used as negative control and 
the maximum signal was calculated with GBP1 without inhibitors. Figure reproduced from Andreoli M. et al. (2014) with 
permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
 
To further confirm the ability of  3 to inhibit the GBP1:PIM1 interaction, co-immunoprecipitation (co-IP) 
studies in SKOV3 ovarian carcinoma resistant to paclitaxel, were also performed. The cells were treated for 
three hours with 100 nM both of  the active compound (3) and of  an inactive compound (NSC756090). 
The results have shown that treatment with 3 inhibits GBP1:PIM1 interaction even in vitro, while treatment 
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with Dimethylsulfoxide (DMSO) or inactive compound (NSC756090) does not result in any modulation of  
the GBP1:PIM1 interaction (Figure 10). 
 
 
 
Figure 10. A Representative co-IP of  PIM1 and GBP1 in SKOV3 cell line treated with 3 (3 h at 100 nM). The signal was 
revealed using anti-GBP1 antibody detected as a specific band of  67 kD. Lane 1: input of  SKOV3 lysate. Lane 2: flow through 
co-IP. Lane 3: flow through control. Lane 4: co-IP. PIM1:GBP1 (antibody anti-PIM1). Lane 5: co-IP. Negative control (antibody 
anti-IGg). The presence of  the signal in lane 4 means no interference in the GBP1:PIM1 binding in DMSO and the inactive 
NSC756090; the absence of  detectable signal in the presence of  3 means that the compound is able of  inhibiting the 
GBP1:PIM1 interaction. B Bar chart showing the densitometric analysis of  the experiment shown in A, performed in two 
independent experiments. A significant (double asterisks = p < 0.001, Anova) suppression of  the co-IP was noticed in both 
experiments only with the compound 3. Figure reproduced from from Andreoli M. et al. (2014) with permission of ACS 
Publications (http://dx.doi.org/10.1021/jm5009902). 
 
In the next paragraph, I desscribe some computational approaches performed in order to investigate the 
molecular recognition mechanism and identify a putative binding site of new class of potential drugs. 
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3.2 Identification of NSC756093 Putative Binding Site 
 
Starting from this biological results and in order to identify a potential binding site for 3 on GBP1 and/or 
PIM1, a detailed structural and bioinformatics analysis was performed. Since compounds 1,  2, and 3  share 
a common structural skeleton, consisting of  the polycyclic B-D system and the phenyl ring E (Figure 7), 
then, not only on the X-ray structures of  the two protein targets (i.e., GBP1 and PIM1) were considered in 
the anlysis, but also those of  i) 2 in complex with TopoisomeraseIIβ (TopoIIβ) and DNA (PDB ID: 
3QX3) and ii) 1 in complex with Tubulin (PDB ID: 1SA1).  
The comparison of  the 2/TopoIIβ/DNA complex with the 1/Tubulin complex by superimposing the 
common B-D polycyclic system of  the ligands revealed a striking overall similarity (Figure 11) with both 1 
and 2 mediating molecular interactions at the interface between two different protein domains, such as:  
 monomers of  α and β Tubulin for 1, 
 Winged Helix Domain (WHD) and Topoisomerase-Primase domain (TOPRIM) for 2 (in such a 
case DNA is also finds itself  implicated).  
 
 
 
Figure 11. Superimposition of  the X-ray structure of  the 2-TopoIIβ complex (orange; PDB ID: 3QX3) on the X-ray structure 
of  1-Tubulin complex (green; PDB ID: 1SA1) by fitting the A-D rings of  the ligands. The yellow circle highlights the position 
of  the fitted ligands. Proteins are displayed as ribbons, ligands are displayed as CPK. DNA is omitted, for clarity of  presentation. 
Figure reproduced from Andreoli M. et al. (2014) with permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
 
On the other hand, the results obtained by the Eukaryotic Linear Motifs Resource (ELM) server53 revealed 
that the binding sites of  the two ligands are characterised by several common consensus sequences 
contained in functional protein-protein interaction motifs (Figures 12 and 13). 
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Figure 12. A Overview of  the 2 binding site in TopoIIβ-DNA complex (PDB ID: 3QX3). TopoIIβ (white) and DNA (violet) 
are displayed as ribbons. 2 is displayed in stick and coloured by atom type (C = green, O = red, H = white). B Detailed view of  
protein motifs involved in etoposide binding site. Key interacting residues are displayed in stick and underlined in the sequence; 
key consensus sequence residues are in bold. 2 is displayed as ball and stick and coloured by atom type. Protein motifs involved 
in the binding site are displayed as ribbons and coloured: DOC_WW_Pin1_4 motif  (orange); MOD_GlcNHglycan and 
MOD_GSK3_1 motifs (yellow). Hydrogens are omitted for sake of  clarity. Figure reproduced from Andreoli M. et al. (2014) 
with permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
 
 
 
Figure 13. A Overview of  1 binding site on α/β Tubulin heterodimer (PDB ID 1SA1). Tubulin is displayed as ribbons and 
coloured in white. 1 and α-Tubulin GTP nucleotide are displayed in stick and coloured by atom type (C = green, O = red, N = 
blue, P = magenta, H = white). B Detailed view of  protein motifs involved in 1 binding site. Key interacting residues are 
displayed in stick and underlined in the sequence; key consensus sequence residues are in bold. 1 is displayed as ball and stick and 
coloured by atom type. Protein motifs involved in this binding site are displayed as ribbons and coloured: LIG_FHA_1 motif  
(magenta); CLV_NDR_NDR_1 motif  (blue); CLV_PCSK_SKI1_1 motif  (cyan); MOD_GlcNHglycan and MOD_GSK3_1 
motifs (yellow). Hydrogens are omitted for sake of  clarity. Figure reproduced from Andreoli M. et al. (2014) with permission of 
ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
 
It is noteworthy that similar ligand substructures (e.g., phenyl ring E) were found to bind to similar 
consensus sequences, while different ligand substructures (e.g., substituent R5) bind to different consensus 
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sequences (Figures 12B and 13B).  
The same structural and bioinformatics analysis carried out on TopoIIβ and Tubulin was also performed 
on the X-ray structures of  PIM1 and GBP1. In both proteins, numerous consensus sequences of  
functional protein motifs have been identified, but only in GBP1 a 3-D dimensional combination of  
protein motifs similar to that found in active sites 1 and 2 was found (Figure 14). 
 
 
 
Figure 14. 3-D combination of  protein patterns found in the GBP1 X-ray structure (PDB ID: 1DG3). 
 
It is important to point out that these motifs are located at the interface of  two GBP1 structural domains, 
such as, the LG domain and the helical domain. According to these results, this site was hypothesised as 
the possible interaction site for our aza-podophyllotoxin derivative 3. 
In order to validate the 3:GBP1 interaction hypothesis, dynamic docking studies have been performed on 
the putative complex using a Monte Carlo/SA approach. The whole system was left free to move 
throughout the course of  docking calculations, only the backbone of  Structurally Conserved Regions 
(SCRs) was restrained by a force constant to avoid unrealistic results (for details see Chapter 2 and the 
Experimental Section). Calculations were performed preserving the water molecules present in the 
reference crystallographic structure of  GBP1 (PDB ID: 1DG3). In particular, in order to evaluate the role 
played by the water molecules in the catalytic site, two sets of  docking calcualtions were performed: one 
where the water molecules in the GBP1 nucleotide binding site were left fully free to move during the 
simulation, and the other where they are constrained by applying a tether force. Finally, in order to test the 
thermodynamic stability of  the obtained complexes, they were subjected to a simulated annealing (SA) 
procedure. The resulting complexes were, then, classified according to their conformational energy values 
and the lowest energy complex was chosen as the most representative one.  
The quality of  the molecular model generated by docking calculations was evaluated using the Procheck 
server (http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/),71 and the results obtained showed a 
12/13 
LG 
domain 
GBP1 
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structure quality similar to that of  the reference GBP1 crystallographic structure (PDB ID: 1DG3) both 
for the acid backbone and side chains (Ramachandran Plot and Main-chain parameters; Appendixes I and 
II respectively). 
 
The results obtained from dynamic docking calculations showed that:  
 3 remains linked to the interface between the LG domain and helical domain even if, after the 
simulated annealing procedure, the ligand rotates by ~ 180 ° compared to the position adopted in 
the Monte Carlo docked complex (Figure 15),  
 3 binding site contains three consensus sequences belonging to functional protein motifs also 
identified on the binding site of  1 and 2 (Figure 16). 
 
 
 
Figure 15. Overall view of  3-GBP1 starting A, docked B, and annealed C complexes. GBP1 structure is displayed as ribbons, 
where the LG domain is in cyan, the connecting region in blue, the helical domain in red and α12/α13 in orange. 3 is displayed 
as CPK and coloured by atom type (C = green, O = red, N = blue, H = white). Key interacting residues between LG domain 
and α12/α13 are displayed in stick, coloured by atom type and labelled. Figure reproduced from Andreoli M. et al. (2014) with 
permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
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Figure 16. A Overview of  3 binding site in GBP1 (white) in the final annealed complex. GBP1 is displayed as ribbons. 3 is 
displayed in stick and coloured by atom type (C = green, O = red, N = blue, H = white). B Detailed view of  protein motifs 
involved in 3 binding site. Key interacting residues are displayed in stick and underlined in the sequence; key consensus sequence 
residues are in bold. 3 is displayed as ball and stick and coloured by atom type. Protein motifs involved in this binding site are 
displayed as ribbons and coloured: LIG_FHA_1 motif  (magenta); CLV_NDR_NDR_1 motif  (blue); MOD_GlcNHglycan 
motif  (yellow). Hydrogens are omitted for sake of  clarity. Figure reproduced from Andreoli M. et al. (2014) with permission of 
ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
 
Comparison of  the results of  docking studies with the results obtained from the bioinformatics and 
structural analysis performed on the 2-TopoIIβ and 1-Tubulin complexes showed other interesting results 
regarding the interactions occurring between the consensus sequences identified on the three binding sites 
(GBP1, Tubulin, and TopoIIβ) and the respective ligand substrates considered (Table 3). 
 
Table 3 | Consensus sequences of  the functional motifs found in the binding site of  1, 2, and 3.  
 
Ligand  
Sub-structures 
Consensusa Sequences Protein Target 
Ring D 
252LRK254 Tubulin 
226IRK228 GBP1 
Ring E 
235MSGV238 Tubulin 
479DSAK482 TopoIIβ 
166EDSAD170 GBP1 
R5 
177VSTAVVE183 Tubulin 
547ERTLALK553 GBP1 
amotif  amino acids involved in molecular interaction are highlighted in bold.  
36 | P a g e  
 
 
In particular, the phenyl ring E of  the three ligands interacts with a protein motif  having a consensus 
sequence maintained in the three binding sites and coloured in yellow in Figures 12, 13, and 16. The 
polycyclic system of  2 establishes π-π interactions and H-bonds with surrounding nucleotides (Figure 6) 
similarly to what happens to the 1 polycyclic system in Tubulin and the 3 polycyclic system in GBP1 
(nucleotides are replaced by aromatic amino acids). On the other hand, the D ring, preserved just in 1 and 
3, in both binding sites, is oriented toward the same consensus sequence, blue-coloured in Figures 12 and 
16 (Table 3). In addition, even smaller and fairly similar groups such as R5 of  1 and 3 (Table 3) are oriented 
to a consensus sequence belonging to a linear pattern present in both binding sites and coloured in 
magenta in Figure 12 and 16. Thus, similar ligand substructures correspond to protein motifs containing 
common consensus sequences. On the contrary, specific ligand substructures such as the substituent R5 
present in 2 (Table 3), represented by a bulky glycoside residue, or as A ring of  1, substituted with a 6-
OCH3 group in 3, are oriented toward protein motifs that do not have similar consensus sequences to 
those found in the other complexes. 
All of  these results indicate that the molecular skeleton, composed of  the B-D rings and the pendant 
phenyl ring E, is able to interfere at the interface of  two protein domains. This interface is characterised by 
the presence of  various consensus sequences contained in functional protein motifs and the different 
selectivity for a specific ligand differ in according to the substituents introduced on the common skeleton. 
Conversely, even small changes in the ligand structure can drive the binding to a different combination of  
protein motifs, that is, to different protein targets. Finally, the same ligand could recognise a similar pattern 
of  protein motifs on different protein targets. In this view, it is to be noted that 2 is able to inhibit the 
TopoIIβ also by binding to the ATPase domain.108 
The obtained 3-GBP1 annealed complex, shown that 3 is almost completely "embedded" in the GBP1 
binding pocket with only the D ring and its upper part, including the R5 substituent, partially exposed to 
the solvent (Figure 17). 
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Figure 17. A. 3-GBP1 annealed complex. The ligand is displayed as CPK and coloured by atom type (C = green, O = red, N = 
blue, H = white), the solvent accessible surface of  the protein is displayed as solid (transparency = 50%) and coloured in white, 
protein backbone is displayed as white ribbon. B. solvent accessible surface of  3 in complex with GBP1. Figure reproduced 
from Andreoli M. et al. (2014) with permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
Accordingly, 3 is the only compound capable of  inhibiting the GBP1:PIM1 interaction, as well as, the less 
bulky compound of  the series. In fact, all the other derivatives have the bulk substituents on B and E rings 
compared to 3 (Table 2). In order to rationalise the inactivity of  all the 4-APTs tested and, at the same 
time, to validate the 3:GBP1 interaction model, the NSC756092, NSC756094, NSC756095, NSC759100, 
and NSC756108 compounds were subjected to a thorough conformational analysis that included dynamic 
and molecular-mechanic calculations followed by mechanical calculations (for details see the Experimental 
Section). As shown in Table 2, all these compounds show a minimum extra-volume at the several 
substituents, differently by 3. Conformers within 5 kcal/mol from the global energy minimum (GM) were 
overlapped, through the common structural B-D skeleton, on 3 in complex with GBP1. All possible 
orientations of  their substituents were considered and all possible steric impediments with the protein were 
analysed. It turned out that the replacement of  the E ring in the meta position, with either a methoxy 
group (NSC756092) or a bromine atom (NSC756095), is not tolerated due to a steric clash with the T549 
and L579 side chains, and with the A169 and V172 backbone. The side chain of  L579 and the A169 
backbone are also involved in steric clashes with the methoxy substituent present in the “para” position of  
E ring in the compound NSC756094. On the other hand, replacement on B ring with a further methoxy 
group in position 7, such as in NSC759100 compound, causes steric impediments with the S173, T279, 
K278 and K280 backbones. Finally, replacing the methoxy group on C6 with an ethyl chain, such as in the 
NSC756108 compound, shown steric clashes with the L278 and E545 side chains (Figure 18). 
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Figure 18. Superimposition of  A NSC756095 and NSC756094, B NSC756100 and C NSC756108 PM7 conformers (carbons in 
orange) on the bioactive conformation of  3 (carbons in green). Bioactive conformation of  3 is displayed in sticks while 
conformers are displayed as lines. GBP1 amino acids (carbons in magenta) involved in steric clashes are labelled and displayed as 
CPK (transparency = 50 %). Heteroatoms are coloured by atom type (O = red, N = blue, H = white). Figure reproduced from 
Andreoli M. et al. (2014) with permission of ACS Publications (http://dx.doi.org/10.1021/jm5009902). 
 
Although at first glance, the ethylene chain and the methoxy group may occupy a similar molecular volume, 
however, they are oriented differently to the plane of  the polycyclic system. The methoxyl group, due to 
the conjugation of  oxygen with the aromatic ring, is placed on the same plane as the polycyclic system (sp2 
geometry). Conversely, the ethylene chain protrudes outside the ring plane (sp3 geometry). In accordance 
with the observed steric clashes, the energy minimisation of  all possible GBP1 complexes with 
NSC756092, NSC756094, NSC756095, NSC759100, and NSC756108 conformers did not provide any 
acceptable solution since the ligand bioactive conformation showed a ΔE from the GM of  more than 10 
kcal/mol.  
According to the results obtained from docking calculations, 3 links to the interface between LG domain 
and helical domain of  GBP1, where the key interactions that regulate the GBP1 function preside. In fact, 
the conformational equilibrium that exists between LG and the helical domain governs the catalytic activity 
of  GBP1 and its oligomerisation ability.91,97 In other GTPases (e.g., Ras, Rho) this regulation is carried out 
by other protein partners (e.g., GAP and GEF).109 Analysing all conformational changes resulting from 
GBP1 dynamic docking calculations, a significant movement of  the 4’ (LG domain) respect to α12/α13 
(helical domain) is observed. Thus compound 3, by influencing the interactions between the LG and the 
helical domain of  GBP1, could induce GBP1 to adopt conformations incompatible with PIM1 binding. 
 
To validate the results obtained from molecular modelling studies, a series of  GBP1 mutants (single and 
double deletions in the human sequence) were designed and expressed and their effect of  the formation of  
the GBP1:PIM1 complex was evaluated. In addition, in order to evaluate the impact of  these mutations on 
GBP1 oligomerisation, kinetic analysis have been performed both in the presence of  GDP and the non-
hydrolysable analogue of  GTP, GppNHp (1 μM in PBST) (Tabella 4). 
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Table 4 | Kinetic analysis of  a panel of  GBP1 mutants for the GBP1:PIM1 interaction assessed with SPR 
technology.  
 
Protein/Mutants 
KD (nM) in PBST  
(1μM GppNHp*) 
KD (nM) in PBST 
(1μM GDP) 
GBP1 67±20 30±10 
R227E/K228E >10,000 >10,000 
R48A 29±2.1 21±0.1 
K51A 50±10 26±11 
D184A 80±5 77±3 
Q72A 62±2 161±17 
D103N 21±1 15±0.1 
R227A/R228A 137±14 61±4 
1-481 (C-terminal deletion) 52±4 68±8 
*Guanosine 5′-[β,γ-imido]triphosphate trisodium salt hydrate,  non-hydrolysable GTP analogue. 
Table adapted from Andreoli M. et al. (2014)  with permission of  ACS Publications  (http://dx.doi.org/10.1021/jm5009902). 
 
 
Indeed, it is clear from the literature that GBP1 wild-type (wt) is a monomer both in its free form and 
when binds to GDP; differently, it is a dimer when binds either to GTP and non-hydrolysable GppNHp, 
while it is a tetramer during GTP and GDP hydrolysis, as well as, when in complex with the transition state 
mimetics GDP-AlF3 and GMP-AlF4.
91,110 On the other hand, the other mutants reduce the GBP1 ability to 
oligomerise and therefore affect its catalytic activity being located close to the catalytic site (R48A, K51A, 
D184A) or switches regions (Q72A and D103A).92,94,98,110  
The results obtained using the designed mutants evidenced that only the R227E/K228E double mutant is 
able to determine a complete decoupling of  the GBP1-PIM1 complex, both in the presence of  GDP and 
GppNHp, concluding that residues R227 and K228 play a crucial role in:  
 the catalytic activity, 
 the ability of  omo-oligomerisation of  GBP1,98 
 the ability to interact with PIM1.  
 
The R227E/K228E and R227A/K228A double mutants is located at the putative 3 binding site on GBP1, 
at the interface between the LG and the helical domain (Figure 19). 
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Figure 19. Overview of  GBP1 (A; PDB ID: 1DG3) and 3-GBP1 annealed complex B. GBP1 structure is displayed as solid 
ribbons, with the LG domain in grey, the connecting region in red, and α12/α13 of  helical domain in green. 3 is displayed as 
CPK and coloured by atom type (C = orange, O = red, N = blue, H = white). The solvent accessible surface of  both GBP1 and 
3-GBP1 annealed complex is displayed as solid (transparency=90%). Key interacting residues between LG domain and α12/α13 
are displayed in stick, coloured by atom type and labelled. Figure reproduced from Persico M. et al. (2016) with permission of 
Wiley-VCH Verlag GmbH & Co. KGaA (https://doi.org/10.1002/minf.201501028). 
 
The positive charges present on the side chains of  R227 and K228 (4’ helix; LG domain) are coupled to 
four negative charges present on the side chains of  residues of  glutamate E556, E557, E563 and E568 
(α12/α13 helices; helical domain). Consequently, in R227E/K228E mutant, the substitution of  R227 and 
K228 with two negatively charged glutamate residues induce a moving away of  the LG domain from the 
helical domain. Accordingly, the R227A/K228A double mutant, is unable to determine the same 
decoupling effect on protein-protein interaction. The results obtained from mutagenesis studies are in 
agreement with the results obtained from docking calculations since also 3 unsettle such interactions 
between the 4’ helix and α12/α13 helices (Figure 19). Indeed, the presence of  3 induces the break of  the 
interactions between R227 and K228 and the glutamate residues present on α12, as occurs in the mutant 
R227E/K228E, thus, inhibiting the formation of  GBP1-PIM1 complex.  
The obtained results support the hypothesis that the pocket where the 4-APTs bind is an allosteric site 
capable of  controlling both the GBP1 active conformation and its ability to interact with protein partners, 
such as PIM1.  
The investigation has proceeded with the modelling of the GBP1-PIM1 complex111 by employing a similar 
docking protocol, adjusted for protein-protein interaction studies112 (see Experimental Section). 
41 | P a g e  
 
Calculations were performed considering the GBP1 and PIM1 structures as “ligand” and “target”, 
alternatively.  
Results showed that the calculated PIM1 binding site partially overlap with 3 (or GTP) binding site, and, 
more importantly, it interacts with GBP1 regions indicated to be critical for the allosteric regulation of 
GTP hydrolysis, including the inter-region (Figure 20). 
 
 
Figure 20. A. Ionic interactions occurring between GBP1 (left) and PIM1 (right) in the calculated structure of the GBP1-PIM1 
complex. Involved residues are labelled and interactions are evidenced as arrows with the exception of K29-D151 interaction, 
for clarity of presentation. Residues with a net positive or negative charge are coloured in blue or red, respectively. Proteins are 
displayed as ribbons, the solvent accessible surface of the contacting region of the two proteins is shown as solid. B. Overall 
view of GBP1-PIM1 complex. GBP1 structure is displayed as ribbons. The LG (Large GTPase) domain is in cyan, the 
connecting region in blue, the helical domain in red and α12/α13 in orange. W114 (magenta), I304 (yellow) and L309 (green) are 
displayed as CPK and coloured by atom type (O = red and N = blue). D103, D108 and key interacting residues between LG 
domain and α12/α13 are displayed in stick, coloured by atom type and labelled. The solvent accessible surface of PIM1 is 
displayed as solid (transparency = 75%) and coloured in grey. Figure reproduced from Persico M. et al. (2015) with permission 
of Elsevier (http://dx.doi.org/10.1016/j.ejmech.2014.07.093). 
 
 
 
In the calculated GBP1-PIM1 complex, the interaction of R227 and K228 with the cluster of negatively 
charged residues on the helical domain are conserved. Comparing the two obtained docked complexes (i.e., 
3-GBP1 and PIM1-GBP1) and the available GBP1 X-ray structures, it can be observed that the 
simultaneous binding of 3 and PIM1 to GBP1 is not possible.  
Moreover, our results indicate that the conformational changes provoked by GTP hydrolysis are not 
compatible with the formation of the GBP1-PIM1 complex too. To further investigate this issue, we 
decided to model the Full Length (FL) structure of human GBP1 in complex with a mimetic of the 
transition state of GTP hydrolysis (GDP•AlF3).
111 Indeed, only the X-ray structure of the LG domain in 
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complex with GDP•AlF3 is available and the FL model was built by combining the coordinates of two 
GBP1 X-ray structures and then adding several missing loops (Figure 21, A and B). Two sets of Monte 
Carlo/SA calculations were performed and two final docked complexes were obtained (Figure 21, C and 
D). The second set of calculations (complex 2; Figure 21D) was performed tethering the R48 residue in 
the catalytic site to the position found in the X-ray structure of the LG domain in complex with the GTP 
transition state analogue (Figure 21B). 
 
 
Figure 21. Overview of LG domain of: A GppNHp-bound GBP1FL (PDB ID: 1F5N); B GDP•AlF3 bound GBP1LG (PDB ID: 
2B92); C GDP•AlF3 bound GBP1FL complex 1 and D GDP•AlF3 bound GBP1FL complex 2. GBP1 structure is displayed as 
ribbons in lines, where the LG domain is in grey (except the SwitchII loop in cyan), the connecting inter-region in red, the 
helical domain in green. The Guanine Cap, the α0, α2, α3, α4, α4’, α6, α7, α12 and α13 helices are labelled. The SwitchII loop, 
the α2, α3, α4’, α6 and α13 helices are evidenced as solid ribbons. W114 (magenta), I304 (yellow) and L309 (cyan) are displayed 
as CPK and coloured by atom type (O = red and N = blue). D103, D108 and key interacting residues between LG domain and 
α12/α13 are displayed in stick, coloured  by atom type and labelled. The solvent accessible surface of GBP1 is displayed as solid 
(transparency = 90 %). GppNHp and GDP•AlF3 (orange) are displayed in stick and coloured by atom type. Figure reproduced 
from Persico M. et al. (2016) with permission of Wiley-VCH Verlag GmbH & Co. KGaA 
(https://doi.org/10.1002/minf.201501028). 
43 | P a g e  
 
Subsequently, two sets of Monte Carlo/SA calculations were performed and two final docked complexes 
were obtained (Figure 21, C and D). The second set of calculations (complex 2; Figure 21D) was 
performed tethering a R48 residue in catalytic site, since the latter crucial for the catalysis and otherwise 
exposed to the solvent, to the position found in the X-ray structure of the LG domain in complex with the 
GTP transition state analogue (Figure 21B).  
GBP1 conformational changes observed in the resulting complexes (Figure 21, C and D) are in agreement 
with the reported experimental data on the coupling of GTP hydrolysis (LG domain) with structural 
changes taking place at the C-terminal helical domain, and transmitted by the inter-region to the catalytic 
site.98-100 In particular, similarly to the binding of 3, GTP hydrolysis was hypothesised to inhibit 
PIM1:GBP1 interaction through an allosteric mechanism involving the ionic contacts between the LG 
domain (R227 and K228 on the α4’ helix) and the helical domain (α12 and α13) of GBP1. Such 
conformational changes are not compatible with the modelled GBP1-PIM1 complex, indicating that GTP 
is likely to compete with PIM1 for GBP1 binding.  
This hypothesis was finally challenged by experimental studies on the effects of the addition of GTP on 
the GBP1-PIM1 interaction.111 It resulted that GBP1 efficiency in binding PIM1 is decreased by the GTP 
(and not GDP) rate. This makes sense considering that the cytoskeletal gateway of paclitaxel resistance 
represents a pro-survival adaptation mechanism which is activated in hypoxia, when GTP level decrease 
and GDP level increase.88 Since GBP1 binds to GTP and pro-survival kinases using alternative 
conformational states, or, in other words, GTP hydrolysis and PIM1 binding stabilise alternative GBP1 
conformations, then, GBP1 functions can be regulated depending on the rate of the interacting partners. 
In this view, it has been demonstrated98,99 that GTP hydrolysis is also coupled to GBP1 oligomerisation and 
localisation, indeed, GBP1 in the free form, as well as, in the presence of GMP and GDP, is a monomer, 
while it is a dimer with the non hydrolysable GTP analogue GppNHp, and forms larger oligomers, most 
likely tetramers, with GTP and the GTP transition state analogue GDP•AlF3. Accordingly, decreased GTP 
levels can switch the function(s) of GBP1 favoring its binding to pro-survival kinase, such as, PIM1. Taken 
together, the results of this investigation shed some light on GBP1 allosteric mechanisms regulating its:   
 oligomerisation (with related cellular localisation),  
 GTPase activity,  
 binding to pro-survival kinases.  
 
Knowledge of these mechanisms led to the identification of a new anticancer agent against paclitaxel-
resistant cancer cells able to inhibit GBP1:PIM1 interaction and paves the way for the development of new 
allosteric inhibitors of such PPi, capable to block the conformation of GBP1 in the “GTP status”. 
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Chapter 4 
 
4.1 Cationic Porphyrins as Tunable Gatekeepers of the 20S Proteasome 
 
Proteasomes are barrel-shaped proteolytic assemblies involved in the regulation of  the physiological 
degradation of  intracellular macromolecules. The anomalous proteins are habitually degraded by the 
ubiquitin-proteasome system (UPS), which it is necessary for the non-lysosomal degradation and clearance 
of  short-lived, misfolded, mutant and damaged proteins in eukaryotic cells.113 This is accomplished through 
a series of  enzyme-mediated reactions that first identify and covalently link abnormal proteins with 
multiple ubiquitin molecules as a signal for degradation.  
The central role of  proteasome enzymes in oncogenes processing explains why its inhibition has become a 
new promising strategy in cancer therapeutics. The human proteasome consists of  an empty cylindrical 20S 
proteolytic core particle (CP), made up by non-catalytic and catalytic protein subunits, which can be capped 
by one or two regulatory particles (RPs) (i.e., 19S, PA28, and PA200), consisting in additional protein 
complexes. The RPs have the function of  recognising polyubiquitin tags attached to protein substrates and 
initiate the degradation process, which are multisubunit proteases found in the cytosol, perinuclear regions 
and nucleus of  eukaryotic cells.  
The 20S CP is made up by four packed rings, each including seven protein subunits, classified into α and β 
types: two α-subunit rings (antechambers) border two central β-subunit rings (catalytic chambers)114-116 
(Figure 22). 
 
Figure 22.  Left: 3-D-structure of  20S human proteasome (PDB ID: 4R3O); α subunit rings are labelled and coloured in pink 
(α1), orange (α2), brown (α3), light green (α4), cyan (α5), magenta (α6), and grey (α7); β subunit rings are labelled and coloured in 
grey. Right: detailed top view of  the α subunit ring; α subunits are coloured in pink (α1), orange (α2), brown (α3), light green 
(α4), cyan (α5), magenta (α6), and grey (α7); the entrance gate of  the CP channel  is circled in red.  
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The outer rings comprise seven different α-subunits, none of  which has catalytic activity, but which serve 
as an anchor for the multisubunit ATPase-containing PA700 (19S) regulator (700 kDa) that binds to form a 
complex referred to as the 26S proteasome (Figure 23).  
 
 
Figure 23. Schematic representation of  composition and organisation of  the 20S proteasome and their intracellular activators. 
Figure adapted from McNaught K. S. et al. (2001), Nature (http://dx.doi.org/10.1038/35086067). 
 
Linking of  the 19S regulatory complex serves two functions: it opens the channel through the 20S 
proteasome, which is normally gated by the amino termini of  the α-subunits, and it unfolds ubiquitinated 
proteins to allow entry to the catalytic core; both processes require ATP.117 The PA 28 (11S) regulatory 
(REG) complex can also bind to the 20S proteasome and open the channel through the complex, but this 
process is ATP-independent, and mediates the degradation of  non-ubiquitinated short peptides(Figure 
23).117 
In the catalytic chambers, there are two duplicates of  three different proteolytically active β subunits (i.e., 
β1, β2, and β5) exhibiting caspase-like (PGPH-L), trypsin-like (T-L), and chymotrypsin-like (ChT-L) 
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activity.118-120  (Figure 24).  
 
Figure 24. 3-D-structure of  20S human proteasome (PDB ID: 4R67) in complex with Bortezomid; α subunit rings are labelled 
and coloured in pink (α1), orange (α2), brown (α3), light green (α4), cyan (α5), magenta (α6), and grey (α7); the β subunit r ings 
are coloured in grey, with the exception of  the catalytic β subunits labelled and coloured in yellow. The ligands are displayed in 
CPK and coloured by atom type (C = grey, O = red and N = blue). 
 
The access of  proteasome substrates to the catalytic site(s) is finely regulated through the gating 
mechanism. The opening of  the gate implies conformational changes displacing the α-subunit tails and it is 
induced by the RPs, although it can occur also in absence of  them.121 Indeed, it has been recently 
demonstrated that an equilibrium between the open and closed CP conformation exists in vitro in absence 
of  any ligand. The modulation of  this equilibrium by exogenous ligands represents an attractive 
therapeutic approach for the cure of  a number of  diseases, first of  all, cancer. Indeed, considering the 
relevant increase of  the intracellular CP upon oxidative stress, its inhibition may bring about the 
accumulation of  misfolded proteins in cancer cells, and, ultimately, lead to cell-cycle arrest and cell 
death.122-124 Bortezomib, a dipeptide boronate acting as competitive covalent inhibitor of  all proteasome 
catalytic sites, was approved by the FDA for the treatment of  several hematological tumors and, in 
particular, multiple myeloma. Unfortunately, the use of  Bortezomib as an anticancer agent showed severe 
limitations due to its side effects and resistance phenomena.125,126 Therefore, the search of  new molecules, 
that inhibit proteasome activity by binding to sites far away from the catalytic centers, may be a promising 
anticancer strategy. In this context, in 2012 the first scientific work evidencing the anti-proteasome ability 
of  cationic porphyrins was published.127 These studies showed that micromolar amounts of  some of  the 
tested porphyrins (Figure 25) reversibly inhibit the catalytic activities of  20S. In particular, in this paper was 
reported a selection of  porphyrins comprising the tetra-cationic porphyrin (H2T4 - meso-tetrakis(4-N-
methylpyridyl) porphyrin), the tetra-anionic porphyrin (H2TPPS - meso-tetrakis(4-sulphonatophenyl)-
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porphyrin) and tris- and bi-cationic substituents (Figure 25). 
 
 
 
Figure 25. Chemical structure of  all the porphyrin derivatives used in previous study. Figure reproduced from Santoro A. M. et 
al. (2012), J. Am. Chem. Soc. (http://dx.doi.org/10.1021/ja300781u). 
 
From this preliminary screening some structure activity relatioships (SARs) came to light: i) the 20S 
inhibitory activity is not due to the metal-coordination properties of  the porphyrin system, ii) the 20S 
inhibitory activity increase with the number of  positively charged nitrogens present in the structure (Figure 
26), with no inhibitory activity observed for the neutral or negatively charged analogues.  
 
 
 
 
Figure 26.  Residual chymotryptic-like (ChT-L) activity of  20S proteasome in cell lysates with di-, tri- and tetra-cationic 
porphyrins at 1 μM. Data are related to control sample normalised to 100%. Figure reproduced from Santoro A. M. et al. (2012), 
J. Am. Chem. Soc. (http://dx.doi.org/10.1021/ja300781u). 
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Accordingly, the most potent compound resulted the tetra-cationic derivative H2T4, showing similar 
potency against the three proteasome catalytic activities (PGPH-L, T-L, and ChT-L) (Figure 27). Generally, 
the proteasome ChT-L activity is mostly probed in order to measure the activity of  proteasome; indeed, 
previous reports indicate that the chymotryptic substrate is the most proteasome-specific of  those 
examined128 (Figure 27 ). 
 
 
 
Figure 27. Concentration-response plot of  H2T4 for Chymotryptic-like (ChT-L), Caspase-like (PGPH-L), and Tryptic-like (T-L) 
residual activities on human 20S from cell lysates. Figure reproduced from Santoro A. M. et al. (2015) with permission from the 
Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5sc03312h). 
 
Inspired by these results, we performed our studies on the title compound - H2T4 - and two of  its isomers, 
ortho-H2T4 and meta-H2T4
129 (Figure 28).  
 
 
 
Figure 28.  Structures of  the cationic porphyrins derivatives: H2T4, meta-H2T4, and ortho-H2T4. 
 
In order to investigate the interaction of  H2T4 with 20S human proteasome at the molecular level, 
computational studies were integrated and validated with experimental data coming from the other 
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research groups involved in the project, such as: 
 
 Prof. Milardi, Istituto di Biostrutture e Bioimmagini (IBB) - CNR UOS di Catania; 
 Prof. A. M. Santoro, Istituto di Biostrutture e Bioimmagini (IBB) - CNR UOS di Catania; 
 Prof. R. Purrello, Dipartimento di Scienze Chimiche, Università di Catania; 
 Prof. M. Coletta, Dipartimento di Scienze Cliniche e Medicina Traslazionale, Università di Roma 
Tor Vergata; 
 Prof. R. Fattorusso, Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, 
Seconda Università degli Studi Napoli; 
 Prof. R. Paolesse, Dipartimento di Scienze e Tecnologie Chimiche, Università di Roma Tor Vergata-
Via della Ricerca Scientifica. 
 
 
4.2 The Electrostatic Map of Proteasome α-Rings Encode the Rules for Designing Allosteric 
Porphyrin-based Inhibitors. 
 
In vitro inhibitory data (IC50s) of  the the new derivatives (Figure 28) confirmed and expanded previous 
SARs indicating that, not only the number, but also the relative positioning of  the protonated pyridine 
nitrogen atoms, play a key role on the inhibition of  the catalytic activities of  20S (Figure 29). 
 
 
Figure 29.  Comparison of  the IC50 values of  para-H2T4 - meso-tetra(4-N-methyil-pyridyl) porphyrin -, meta-H2T4 - meso-tetra(3-
N-methyilpyridyl) porphyrin - and ortho-H2T4 - meso-tetra(2-N-methyil-pyridyl) porphyrin - determined for the ChT-L (black), T-
L (red), and PGPH-L (blue) peptidase activities of  the CP. Figure reproduced from Santoro A. M. et al. (2015) with permission 
from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5sc03312h). 
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Thus, at first, a 3-D-pharmacophore model of  the lead compound H2T4 was generated by assuming the 
four protonated nitrogen atoms as crucial interaction points, taking into account the H2T4 X-ray structures 
present in the Cambridge Structural Database (CSD; http://www.ccdc.cam.ac.uk) (Figure 30A). 
 
 
Figure 30. A. H2T4 pharmacophore and related inter-atomic distances. The experimentally determined structure of  H2T4 (CSD 
code: OBOZAI) is displayed in stick with the pyridine nitrogen atoms evidenced in CPK. B. Top view of  the 20S human 
proteasome (PDB ID: 4R3O); only the α ring is shown for clarity of  presentation. C. Zoom of  the top view of  the 20S human  
proteasome (PDB ID: 4R3O); the four Asp residues are displayed as CPK and coloured in red and the suitable inter-residue 
distances for a possible interaction with the H2T4 pharmacophore are reported. D. Positioning of  H2T4 in the putative binding 
site; the potential interactions between H2T4 and the 20S proteasome are shown: the amino acid residues involved in ionic and 
cation-π interactions are displayed as CPK and coloured in red and yellow, respectively. H2T4 is coloured by atom type (C: green; 
N: blue). The a subunits are coloured in pink (α1), orange (α2), brown (α3), light green (α4), cyan (α5), magenta (α6), and grey 
(α7). Figure reproduced from Santoro A. M. et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5sc03312h). 
 
 
Then, I assessed the capability of  the 20S human proteasome to arrange the planar, rigid and positively 
charged pharmacophore of  H2T4 by mapping the spatial positioning of  negatively charged amino acids on 
the protein surface, as well as in the known functional and inhibitor binding sites (pharmacophore fitting 
procedure). The structural and bioinformatics analysis was carried out taking into account all the 
experimentally determined conformational states (closed, semi-closed, and open) and the sequence 
homologies among the different species were computed using the PROMALS3-D server (http:// 
www.prodata.swmed.edu/promals3-D/promals3-D.ph).67 Firstly, the available experimentally determined 
structures of  20S were downloaded from the Brookhaven Protein Data Bank (http://www.rcsb.org) and 
subjected to a structural and bioinformatics analysis. Then, an homology model of  the 20S human 
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proteasome α-subunits was built. It must be mentioned here that, after the completion of  molecular 
modelling studies, the X-ray structure of  the human 20S proteasome was solved and deposited in the 
Brookhaven Protein Data Bank (PDB ID: 4R3O). Consequently, the structural parameters were compared 
using a structure evaluator software (i.e., MolProbity)72 which calculated the degree of  similarity between 
the model and the X-ray structure. It resulted a 100% match of  secondary structures (i.e., α-helices, turns, 
and β-strands) and a RMSd value on all α-carbons of  0.61 Å. Acquired outcome throw out all the 20S 
catalytic sites and addressed us to suppose the substrate gate as the most plausible ligand binding site, for 
the competitive inhibition of  20S catalytic activities (Figure 30B), due to the presence of  four Asp residues 
on the N-terminal tails of  α1, α5, α6, and α7 which showed a reasonable spatial positioning for a 
conceivable interaction with the positively charged H2T4 nitrogens (Figure 30C). Moreover, the four nearby 
aromatic residues could help the binding by instituting polarised π-π interaction with the pyridine rings 
(Figure 30D). In this way, H2T4 was situated at its supposed binding site on the human proteasome model 
and the acquired complex was utilised as beginning structure for the completely dynamic docking protocol. 
Docking calculations were performed using the CVFF force field130 and the Cell_Multipole method for 
non-bonded interactions.131 In spite our docking calculations requires a beginning complex, it has to be 
pointed out that to completely investigate all conceivable binding sites and modes, the binding domain was 
defined as the whole α-ring of  the human 20S proteasome and distance constraints were applied only to 
structurally conserved regions (see below and the Experimental Section for details). This enabled a 
complete exploration of:  
 ligand binding sites and/or modes,  
 ligand-induced protein large-scale conformational changes.  
Initially, a Monte Carlo/minimisation method69 for the stochastic conformational sampling was used and a 
maximum of  20 adequate complexes, by selecting the minimum energy state from the previous cycle, were 
generated. In order to guarantee a broad variability of  the structures to be progressively minimised, an 
energy tolerance value of  106 kcal mol-1 from the previous structure was utilised. Following, an energy test 
and a structure similarity evaluation were adopted to select the 20 acceptable structures, with an energy 
range of  50 kcal mol-1 and rms tolerance = 0.3 kcal Å-1 respectively. Subsequently, the obtained complexes 
were subjected to simulated annealing (SA) calculations, during which the temperature of  the system was 
linearly decreased from an initial (500 K) to a final (300 K) temperature. A temperature equivalent to 500 K 
was applied with a view to overcoming torsional barriers, in this manner allowing a complete 
rearrangement of  both the protein and the ligand (see Experimental Section for details). All calculations 
were performed by applying constraints only to H-bonds (α-helices) and ψ and φ torsion angles (β-sheets) 
of  some structurally conserved regions, by employing several force constant values in conformity with the 
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results of  secondary structure prediction calculations (http://www.predictprotein.org/). Specifically, a 
force constant of  100 (high), 10 (medium), and 1 (low) kcal mol-1 was used to H-bonds (α-helices) and ψ 
and φ torsion angles (β-sheets) by following secondary structure prediction score. The remaining atoms of  
the protein was left without constraints and free on its movement. The quality validation of  the obtained 
complexes was then estimated by employing an all-atom structure valuation software (i.e., MolProbity).72 
Docking studies revealed interesting outcomes about H2T4 capacity to inhibit the 20S proteasome 
behaving like a “plug” of  the CP entrance gate. In the first place, all the complexes obtained by this 
dynamic docking procedure, either by Monte Carlo and SA calculations, always presented H2T4 bound to 
the CP access channel, interacting with the located N-terminal residues of  the α-subunits (Figure 31). 
 
 
Figure 31. Top view of  the dynamic docking results obtained for H2T4: A Monte Carlo and B SA. The backbone of  the starting 
complex is displayed as solid ribbons and coloured in grey, the one of  the calculated complexes is displayed as line ribbons and 
coloured in orange. The cluster of  negatively charged residues at the entrance gate of  the CP channel is displayed as CPK and 
coloured in grey (starting complexes) and red (calculated complexes). The porphyrin ligands are coloured by atom type (C: 
green; N: blue; H: white) and displayed as CPK. In (A) the α-subunits and the position of  the catalytic b subunits are labelled. 
Figure reproduced from Santoro A. M. et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5sc03312h). 
 
It is noteworthy that the H2T4 binding mode of  the selected final SA complex (the one characterised by 
the most favourable non-bonded interaction energy) significantly differed from the (starting) Monte Carlo 
complex (Table 5; Figure 32 ). 
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Table 5 | Non-bonded interaction energies (kcal/mol) of  the 20S-H2T4 complexes obtained by Monte 
Carlo and SA calculations.  
 
Cplx Non-bonded interaction energies (kcal/mol) 
 
Monte Carlo 
simulation 
Simulated Annealing 
simulation 
1 -58.009 -63.827 
2a -36.088 -92.754 
3 -48.788 -51.330 
4 -54.795 -71.749 
5 -43.954 -51.868 
aSelected complex 
Table adapted from Santoro A. M. et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5sc03312h). 
 
In the Monte Carlo complex H2T4 binds to the gate assuming a position perpendicular to the α-ring plane 
and interacts with only two of  the four Aspartate residues (Figure 32A). After the SA procedure, H2T4 
resulted fully stuck into the gate, parallel to the α-subunits plane, interacting with the whole cluster of  
functional residues of  the predicted binding site (α1 (F9, D10), α3 (Y5), α5 (Y8, D9), α6 (Y6, D7), and α7 
(Y8, D9)) (Figure 32B). 
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Figure 32. Results obtained by the dynamic docking procedure. H2T4-20S Monte Carlo A and SA B complexes. The α-subunits 
are displayed as line ribbons and coloured in grey. H2T4 is displayed as CPK and coloured by atom type (C: green; N: blue). The 
amino acid residues involved in ionic and cation-π interactions are displayed as CPK and coloured in red and yellow, respectively. 
Protein van der Waals volume is displayed as transparent surface (bottom representation). Figure reproduced from Santoro A. 
M. et al. (2015) with permission from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5sc03312h). 
 
 
Importantly, on the basis of  these results, an experimental kinetic investigation on the interaction between 
H2T4 and 20S proteasome by stopped flow UV spectroscopy and NMR studies was carried out by 
professor M. Coletta and R. Fattorusso, respectively (Figure 33A and B). 
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Figure 33. A. Kinetics of  fluorescent product formation, obtained by mixing 2nM 20S proteasome, 100 mM of  substrate Suc-
LLVY-AMC and different concentrations of  H2T4 porphyrin, namely 0 (O), 0.3 mM (X) 3 mM (+) and 10 mM (*). B. Low-field 
(left) and high-field (right) 1H NMR spectra of  H2T4 (172 mM) (a) in Tris-HCl (20 mM) pH 7.6, NaCl (150 mM) solution, and 
(b) in the presence of  20S (860 nM); (c) 1H NMR STD spectrum of  H2T4 in the presence of  20S (860 nM). 1H chemical shift 
assignment has been reported for H2T4 in presence of  20S proteasome. Figure reproduced from Santoro A. M. et al. (2015) with 
permission from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5sc03312h). 
 
The kinetic investigations highlighted the ability of  H2T4 to inhibit the CP by a competitive mechanism 
and by a multiphasic pattern. In particular, the resulting kinetic data confirmed that there is a first faster 
interaction of  H2T4 with the N-terminal tails of  the α-subunits, likely corresponding to the first 
encountering of  the porphyrin with the α-subunits plane (Figure 32A), followed by a tighter binding to the 
closed CP gate, which corresponds to the inhibition event and can be referred to the formation of  the 
more stable porphyrin-protein complex (Figure 32B). On the other hand, the NMR studies showed that 
the major driving force in porphyrin/proteasome interaction are the methyl-pyridine moieties of  H2T4. 
For the purpose of  validating our protein-ligand complex model, meta-H2T4 and ortho-H2T4 derivatives 
were exposed to the same dynamic docking procedure used to H2T4 obtaining interesting results too. 
Indeed, the docking simulation, contrarily to what observed for H2T4 and in agreement with the varied 
spatial positioning of  their protonated nitrogen atoms, revealed that meta-H2T4 and ortho-H2T4 do not 
remain bound to the identified N-terminal Aspartate residues at the 20S gate (Figure 34). In the complex 
presenting the most favourable non-bonded interaction energy (Figura 34 and Table 6 ), they bind at a side 
of  the gate, interacting only with F9 (α1) and Y6 (α6) (meta-H2T4) and Y8 (α5) (ortho-H2T4). 
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Table 6 | Non-bonded interaction energies (kcal/mol) of the 20S-meta-H2T4 and 20S-ortho-H2T4 
complexes obtained by SA calculations. 
 
Cplx Non-bonded interaction energies (kcal/mol) 
 
20S-meta-H2T4  
complexes 
20S-ortho-H2T4  
complexes 
1a -44.569 -108.642 
2 -71.200 -89.385 
3 -46.433 -84.523 
4b -88.350 -30.610 
5 -62.243 -37.593 
6 -83.360 -82.561 
7 -36.456 -72.742 
8 -60.625 -52.663 
9 -49.381 -79.814 
10 -58.207 -104.267 
11 -47.554 -50.418 
12 -38.331 -48.609 
13 -58.209 -44.056 
14 -35.057 -81.299 
15 -44.122 -48.068 
16 -0.774 -49.181 
17 0.574 -80.797 
18 -24.133 -56.376 
19 0.314 -60.809 
20 -75.163 -70.525 
aSelected complex for ortho-H2T4; bSelected complex for meta-H2T4 
Table adapted from Santoro A. M. et al. (2015) with permission from the Royal Society of Chemistry 
(http://dx.doi.org/10.1039/c5sc03312h). 
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Figure 34. Comparison of  the dynamic docking results obtained for A meta-H2T4, and B ortho-H2T4. The starting complex is 
displayed as solid ribbons and coloured in grey, the one of  the calculated complexes is displayed as line ribbons and coloured in 
orange. The cluster of  negatively charged residues at the entrance gate of  the CP channel is displayed as CPK and coloured in 
grey (starting complexes) and red (calculated complexes). The porphyrin ligands are coloured by atom type (C: green; N: blue, 
and H: white) and displayed as CPK. In the zoomed view the amino acid residues involved in ionic and cation-π interactions are 
coloured in red and yellow, respectively, and displayed as CPK. Figure reproduced from Santoro A. M. et al. (2015) with 
permission from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5sc03312h). 
 
Curiously, ortho-H2T4 make interactions with two negatively charged residues in the groove between α5 and 
α6 subunits, which are known to be engaged in the binding with the positively charged C-terminal tails of  
regulatory proteins (RPs).132-135 Therefore, the different binding modes of  the three isomers appears to 
mirror their different inhibitory potencies. Indeed, as depicted in Figure 29, the in vitro CP inhibition assay 
evidenced the ability of  meta-H2T4 and ortho-H2T4 derivatives to inhibit the three catalytic activities to 
different extents and with lower inhibitory potency with respect to H2T4. According to our docking 
simulation, meta-H2T4 and ortho-H2T4 could modulate the catalytic activity through a more refined tight fit 
with proteasome allosteric regulation compared to H2T4 (which blocks gate access), being the three 
proteasome catalytic activities subordinated to the opening of  the gate by means of  various allosteric 
mechanisms, involving the grooves between adjacent protein subunits.  
On the premise of  these outcomes, it is conceivable to propose that H2T4 binding to the 20S α-subunits 
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could influence the catalytic activities both clogging the entry of  all substrates and modulating the 
conformational equilibrium of  the 20S human proteasome, bringing about a shift in the equilibrium of  the 
“open-to-close” structural transition. These peculiar mechanisms of  action coupled with their versatile 
chemistry, propose cationic porphyrins as a new class of  CP conformational regulators with great 
potentialities as lead pharmacophores. Moreover, the key role played by electrostatics in driving 
porphyrin:proteasome interactions suggested that these highly versatile inhibitors may be fine-tuned by 
conjugating the parent frame with different charged moieties, endowing special properties to the molecule. 
In this view, the negatively charged residues of  the human 20S implicated in ionic interactions with the 
positively charged amino acids of  PA200, PA28α, and 19S RPs have been mapped, discovering putative 
binding sites for cationic porphyrin-based allosteric inhibitors.  
In particular, a bioinformatics and structural analysis was carried out to identify the negatively charged 
residues of  the human 20S CP which are implicated in ionic interactions with positively amino acids of  the 
RPs. In fact, the interaction with such negative residues from small-molecule ligands may have an effect on 
the allosteric mechanism correlating the opening/closing of  the gate with the activation of  proteolytic 
activity.136,137 In this analysis, we took into account the three RPs of  20S human proteasome: PA28α 
(REGα/11S), PA200, and 19S.  
PA28 is an ATP-independent activating complex of  human 20S, which consists of  seven structural 
subunits with three recognised isoforms (PA28α-γ).138 For the purpose of  mapping the interactions of  the 
human 20S with PA28, the X-ray crystallography complex between Saccharomyces cerevisiae 20S with 
Trypanosoma Brucei PA26 (human PA28 homolog)139 was employed as structure of  reference. The residues 
of  the complex that are engaged in electrostatic interactions between the CP (negative) and the RPs 
(positive) were detected. At the end, the information was translated to the relating human homologs 
employing the X-ray structures of  PA28α and 20S human (closed and open states) (Figure 35A and Table 
7). 
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Figure 35. Homology models of  20S human (α-ring) in complex with A PA28 and B PA200. The residues involved in ionic 
interactions are evidenced (CPK render) and coloured in red (negative, 20S) and blue (positive, PA28). Proteins are displayed as 
solid ribbons; PA28 (A) is coloured by subunit type. Figure reproduced from Di Dato A. et al. (2017) with permission from the 
Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
Table 7 | Ionic interactions between 20S human (negative) and PA28α(positive) obtained using as 
reference structure the X-ray complex of  20S yeast proteasome with Trypanosoma Brucei PA26 (PDB ID: 
1ZTQ). 
 
20S yeast 
proteasome 
(negative) 
Trypanosoma 
Brucei  PA26a 
(positive) 
20S human 
proteasome 
(negative) 
human PA28α 
(positive)a 
E22 (α1) K100 
(Subunit 7) 
E19 (α1) R141 
(Subunit 7) 
- - E26 (α1) K245 
(Subunit 7) 
- - E23 (α2) K245 
(Subunit 1) 
E16 (α3) K100 
(Subunit 2) 
E15 (α3) R141 
(Subunit 2) 
- - E22 (α3) K245 
(Subunit 2) 
D14 (α4) K100 
(Subunit 3) 
D13 (α4) R141 
(Subunit 3) 
- - E20 (α4) K245 
(Subunit 3) 
E18 (α5) K100 
(Subunit 4) 
E18 (α5) R141 
(Subunit 4) 
- - E25 (α5) K245 
(Subunit 4) 
- - E23 (α6) K245 
(Subunit 5) 
D17 (α7) K100 
(Subunit 6) 
D18 (α7) R141 
(Subunit 6) 
- - E25 (α7) K245 
(Subunit 6) 
aPA26 and PA28 subunits are numbered according to PDB structures 1ZTQ and 1AVO, respectively. 
Table reproduced from Di Dato A. et al. (2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-
17008-7). 
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Contrary to the prior RP, despite PA200 is an ATP-independent activator protein too, the stimulation of  
proteasomal hydrolysis of  PGPH-L substrates is nearly three times greater compared to the hydrolysis of  
ChT-L and T-L substrates.140 The ionic interactions arising between PA200 and 20S human (open/closed 
states) were recognised making use of  the X-ray complex of  Saccharomyces cerevisiae 20S with the RP 
Blm10139 (human PA200 homolog) as template structure. Acquired results are reported in Figure 35B and 
Table 8. 
 
Table 8 | Ionic interactions between 20S human (negative) and PA200 (positive) obtained using the X-ray 
complex of  20S yeast proteasome with yeast Blm10 (PDB ID: 4V7O) as reference structure. 
 
20S yeast 
proteasome 
(negative) 
yeast  Blm10 
(positive) 
20S human 
proteasome 
(negative) 
human PA200 
(positive) 
- - E175 (α2) K1025 
- - E200 (α2) K711 
K878 
- - E58 (α3) K1069 
- - D202 (α3) R1074 
- - E209 (α3) K1069 
E173 (α4) R1798 E170 (α4) R1502 
E7 (α5) K589 E7 (α5) K411 
D9 (α5) K2112 D9 (α5) R1811 
E18 (α5) K2111 E18 (α5) R1810 
E25 (α5) K2112 E25 (α5) R1811 
E27 (α6) K2111 E27 (α6) R1810 
D203 (α6) R2048 E202 (α6) R1742 
- - D204 (α6) R1740 
Table reproduced from Di Dato A. et al. (2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-
17008-7). 
 
Finally, 19S is an ATP-dependent RP complex that stimulates roughly three-fold all catalytic activities of  
20S human.141 It is composed by various ATPase and non-ATPase subunits that are put in order according 
to a cylindrical-shaped assembly. Using cryo-elctron microscopy (Cryo-EM) techniques, Chen et al.142 
achieved significant information about proteasome 3-D shape by solving four different 20S-19S complexes 
(called SA-D): from the ground state (SA) to the opening of  the 20S gate channel (SD). The four structures 
were employed in our analysis in order to examine the ionic interactions taking place at 20S-19S interface 
(Figure 36 and Table 9). 
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Figure 36. Ionic interactions occurring between human 20S and 19S according to Cryo-EM data Side view of: SA, SB, SC, and SD 
conformational/functional states. The residues involved in ionic interactions between 20S (negative: red) and 19S (positive: blue) 
are displayed as CPK. Proteins are displayed as solid ribbons and coloured as follows: 20S α-ring (grey), 19S Rpt1 (pink), Rpt2 
(orange), Rpt3 (brown), Rpt4 (light green), Rpt5 (cyan), Rpt6 (magenta), Rpn5 (green), and Rpn6 (yellow). Figure reproduced 
from Di Dato A. et al. (2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
 
Table 9 | Ionic interactions between 20S human (negative) and the RP protein complex 19S (positive) in 
the SA-D states (PDB IDs: 5T0G; 5T0H; 5T0I; 5T0J). 
 
20S human 
proteasome 
(negative) 
19S human  
(positive) 
D58 (α1) R372 (Rpt4) 
D155 (α1) K418 (Rpt3) 
E174 (α1) R366 (Rpt3) 
K408 (Rpt3) 
K404 (Rpt3) 
D236 (α1) K36 (Rpn5) 
E244 (α1) K36 (Rpn5) 
E49 (α2) K418 (Rpt3) 
E183 (α2) K121 (Rpn6) 
E185 (α2) R122 (Rpn6) 
D228 (α2) K84 (Rpn6) 
E15 (α3) R333 (Rpt2) 
E24 (α4) K422 (Rpt1) 
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E18 (α5) K430 (Rpt5) 
E29 (α5) R351 (Rpt1) 
E51 (α5) R375 (Rpt1) 
E207 (α5) R375 (Rpt1) 
E173 (α6) R386 (Rpt5) 
D9 (α7) K387 (Rpt4) 
E176 (α7) K369 (Rpt4) 
D203 (α7) K193 (Rpt5) 
Table reproduced from Di Dato A. et al. (2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-
17008-7). 
 
 
The achieved results enabled to map the spatial positioning of  the negatively charged residues of  20S 
human engaged in ionic interactions with the all three RPs. Curiously, it emerged a regular disposition of  
such amino acids on the outer layer of  the α-ring (Figure 37), revealing a structural code which clarifies the 
important role played by ionic interactions in the allosteric regulation of  proteasome catalytic activity.143 
 
 
 
Figure 37. Putative binding sites of  pTMPyPP4 on the α-ring surface of  20S human in the closed A and open B conformation. 
The putative interacting residues are labelled and circled in blue. The ligand is displayed in stick and coloured by atom type; 
hydrogens are omitted for sake of  clarity. The inter-atomic distances among the pyridine nitrogen atoms (evidenced in CPK) are 
reported. The 20S human proteasome (top view) is displayed as Connolly surface and coloured in grey except for negatively 
charged residues involved in ionic interactions with PA28, PA200, and 19S RPs which are displayed as CPK and coloured in red. 
Figure reproduced from Di Dato A. et al. (2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-
17008-7). 
 
 
This structural analysis allowed us to identify the 20S negatively charged residues placed at the rim of  the 
α1-α2 and α4-α5 grooves as supposed binding sites for cationic ligands having a planar conformation of  
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the positively charged groups, similar to 1 (Figure 38).  
 
 
 
 
Figure 38. Chemical structures of  cationic porphyrins H2T4 (1) and pTMPyPP4 (2). Figure reproduced from Di Dato A. et al. 
(2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
Nevertheless, according to the inter-atomic distances, to allow the electrostatic interactions with the 
negatively charged amino acids of  the protein, a greater distance (17 Å) between the protonated pyridine 
nitrogen atoms of  the ligand is necessary with respect to that showed by 1 (11 Å). Consequently, a new 
polycationic porphyrin, having in the meso positions four phenylpyridine moieties (meso-tetrakis(4-N-
methylphenyl pyridyl)-porphyrin pTMPyPP4 (2) has been designed and synthesised (see Figure 38). In fact, 
in 2 a phenyl ring is inserted between the pyridine substituent and the porphyrin planar core, thus leading 
to a distance among the adjacent charged groups of  approximately 17 Å (Figure 37). Albeit additional 
putative binding sites have also been identified at the α1-α2 groove (Figure 37), however, the presence of  a 
large number of  negatively charged residues characterises the α4-α5 groove, thus proposing this as the 
more likely binding site for 2. To corroborate this finding, 2 was subjected to dynamic docking calculations 
in complex with 20S human. 
It should be underlined that the docking calculations have been carried out considering the whole 20S 
human proteasome structure available experimentally, including α-β-β-α rings for closed conformation and 
α-β rings for open conformation. Despite the extensive calculation time and the difficulty to model such a 
system due to the large number of  residues, our approach allowed to explore the intricate mechanism 
underlying the dynamic of  such protein complex. 
To perform docking calculations on both, the closed and the open 20S structure, the molecular model of  
20S human proteasome in the open conformation was built and optimised by MM (see the Experimental 
Section for details). On the other hand, the previously developed model of  20S human129 was used to 
perform docking calculations with 20S human in the closed conformation. Afterward, to reproduce the 
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dynamic of  the ligand-protein recognition event, the previously described docking protocol based on a 
Monte Carlo-Metropolis/simulated annealing (SA) approach was applied.68,69,70  
Calculations were carried out starting from both the closed and the open 20S conformations, giving rise to 
two sets of  results (Figures). The obtained complexes from Monte Carlo and SA were classified according 
to their ligand-protein interaction energies (Group Based non-bonded interactions method)144 (Figures 39 
and 40). Moreover, the quality of  the chosen complexes was then evaluated by using structure evaluator 
software (i.e., Molprobity).72 
Many of   the obtained SA complexes showed the ligand bound to the α4-α5 groove, with only six obtained 
complexes (using as starting structure the closed conformation of  20S human proteasome) exhibiting the 
position of  ligand in the substrate channel at the level of  the first β-ring, or at the interface between the 
two β-rings (Figures 39C).  
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Figure 39. A. Dynamic docking results obtained for 2 using as starting structure the closed conformation of  20S human 
proteasome. B. Top view of  dynamic docking results without the two rings of  β subunits and the second ring of  α subunits. C. 
Top view of  dynamic docking results without the first ring of  α-subunits. The backbone of  the starting complex is displayed as 
solid ribbons and coloured in pink (α1), orange (α2), brown (α3), light green (α4), cyan (α5), magenta (α6), and grey (α7, α- 
subunits of  the second ring and all β-subunits). The backbone of  the calculated complexes is displayed as line ribbons and 
coloured in orange. The porphyrin ligands are coloured by atom type (C: green and N: blue) and displayed as CPK. In B the α 
subunits and the catalytic β-subunits are labelled. In C the catalytic β-subunits are labelled and coloured in pink (β1), violet (β2), 
and cyan (β5). The last six generated complexes (each docked complex is generated from the last accepted structure, see the 
Experimental Section for details) presented the ligand positioned in the substrate channel at the level of  the first β-ring, or at the 
interface between the first and the second β-ring (evidenced in C); however, the binding to the α4- α5 groove (evidenced in B) is 
favoured according to the calculated non-bonded interactions energies. Figure reproduced from Di Dato A. et al. (2017) with 
permission from the Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). 
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Figure 40. A. Dynamic docking results obtained for 2 using as starting structure the open conformation of  20S human 
proteasome. B. Top view of  dynamic docking results without the ring of  β subunits. The backbone of  the starting complex is 
displayed as solid ribbons and coloured in pink (α1), orange (α2), brown (α3), light green (α4), cyan (α5), magenta (α6), and grey 
(α7 and β subunits). The backbone of  the calculated complexes is displayed as line ribbons and coloured in orange. The 
porphyrin ligands are coloured by atom type (C: green and N: blue) and displayed as CPK. In B the α subunits and the catalytic β 
subunits are labelled. Figure reproduced from Di Dato A. et al. (2017) with permission from the Nature 
(http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
Anyway, in accordance with the calculated non-bonded interaction energies (Tables 10 and 11), the 
complex with the best compromise between the non-bonded interaction energies obtained by Monte Carlo 
and SA calculations has been selected. According to the calculated non-bonded interaction energies, not 
only the two selected complexes but also the other favourable resulting SA complexes showed, in any case, 
the ligand placed within the α4-α5 groove. 
 
Table 10 | Non-bonded interaction energies (kcal/mol) of  the 20S-2 complexes obtained by Monte Carlo 
and SA calculations using as starting structure the closed conformation of  20S.   
 
Cplx Non-bonded interaction energies (kcal/mol) 
 
Monte Carlo 
simulation 
Simulated Annealing 
simulation 
1 -42.363 -66.518 
2 -42.948 -81.754 
3a -53.260 -76.404 
4 -50.670 -50.246 
5 -25.029 -60.942 
6 -6.877 -57.008 
7 -6.649 -65.689 
8 -4.466 -21.349 
9 -6.976 -63.463 
10 -17.344 -59.432 
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11 -3.415 -50.117 
aSelected complex 
Table reproduced from Di Dato A. et al. (2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-
17008-7). 
 
Table 11 | Non-bonded interaction energies (kcal/mol) of  the 20S-2 complexes obtained by Monte Carlo 
and SA calculations using as starting structure the open conformation of  20S.   
 
 
Cplx Non-bonded interaction energies (kcal/mol) 
 
Monte Carlo 
simulation 
Simulated Annealing 
simulation 
1 -14.601 -56.056 
2 -6.522 -55.024 
3 -5.914 -0.147 
4 -0.689 -62.805 
5 0.672 -16.006 
6 0.075 -42.347 
7 -0.904 -70.354 
8 -0.234 -60.497 
9a -3.970 -66.822 
10 -1.321 -61.119 
11 -1.646 -13.116 
aSelected complex 
Table reproduced from Di Dato A. et al. (2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-
17008-7). 
 
 
Considering the interactions established by 2 in the best docked complexes, when the 20S closed 
conformation as starting structure was used, the polycationic porphyrin 2 shows interactions with the α4-
α5 groove by establishing (Figure 41A): 
 ionic interactions with six negatively charged residues (i.e., E20(α4), E24(α4), E170(α4), E25(α5), 
E29(α5), and E207(α5); all involved in the binding to RPs), 
 cation-π interactions with three aromatic residues (i.e., F17(α4), Y21(α4), and Y26(α5) ) and one 
positively charged residue (i.e., R53(α5)), 
 a π -π interactions with a histidine residue (i.e., H15(α4)) (Figure A).  
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Figure 41. The 20S-2 docked complexes obtained starting from the closed A or open B conformation of  20S. The α-subunits 
are displayed as ribbons and coloured in grey. 2 is displayed as CPK and coloured by atom type (C: green; N: blue). The amino 
acid residues involved in ionic, cation-π and π-π interactions are displayed as CPK and coloured in red (negatively charged 
residues), yellow (aromatic residues), and blue (positively charged residue). The protein van der Waals volume is displayed as 
transparent surface and coloured by subunit type. Figure reproduced from Di Dato A. et al. (2017) with permission from the 
Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). Figure reproduced from Di Dato A. et al. (2017) with permission 
from the Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
Moreover, the binding of  the ligand at the α4-α5 groove induced conformational changes which are not 
circumscribed to the α-ring, but also affect the interface with the β5-subunit and, in turn, the shape of  the 
S3 catalytic site pocket (Figure 42). 
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Figure 42. α4, α5, and β5 subunits before (left) and after (right) docking calculations in complex with 2. A. Starting from the 
20S closed state. B. Starting from the 20S open state. The protein is displayed as grey ribbons. αH1 and αH2 (α4-subunit; light 
green), αS3, αS4 and αH1 (α5-subunit; cyan), βH1 and βH2 (β5-subunit; pink), the loop region aa102-111 (β5-subunit; blue), and 
the S3 pocket (β5-subunit; red), are evidenced as solid ribbons. Key residues are displayed in ball and sticks. 2 is displayed as stick 
and coloured by atom type (C = green and N = blue).  In (A) the conformational changes at α4-α5 groove caused, in the region 
at the interface among the subunits α4, α5 and β5, the break of  the ionic interaction between E65 (αS3 strand of  α5-subunit) 
and K71 (loop between the helices βH1 and βH2 of  β5-subunit) which moved to interact with E69 (αS3  strand of  α5-subunit). 
In turn, this change moved the helix αH2 (aa104-121) of  the subunit α4 toward both the β5-subunit, determining the formation 
of  a H-bond between R109 (α4) and N70 (β5), and the α5-subunit determining the formation of  an ionic interaction between 
R109 (α4) and D90 (α5). Moreover, this movement modified the positioning of  the βH2 helix with respect the loop region 
(aa102-111) within the β5-subunit. Figure reproduced from Di Dato A. et al. (2017) with permission from the Nature 
(http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
 
Noteworthy, the regions involved in the calculated conformational changes were previously indicated to be 
implicated in the allosteric regulation of  the 20S catalytic activity by NMR studies.136,142  In particular, 2 
provoked conformational changes involving the closing of  the loop which describes the S3 pocket (i.e., 
aa20-30) in proximity to the catalytic threonine (Figure 42). This structural movement is opposite 
compared to that watched in the shift from the closed to the open conformation of  20S, accounting for 
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the ability of  2 to allosterically inhibit proteasome catalytic activity. The binding of  2 at the α4-α5 groove 
influenced the conformation of  the other α-grooves too, by changing the spatial positioning of  the 
negatively charged residues that make interaction with the RPs (Figure 43). 
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Figure 43.  Top view of: A 20S human closed state, B 20S human in complex with 2 (Cplx_3), C) 20S human open state, and 
D) 20S human in complex with 2 (Cplx_9). In B and D 2 is displayed in ball and stick and coloured by atom type (C = green; N 
= blue). The 20S human proteasome is displayed as CPK and coloured in grey. All negatively charged residues are coloured in 
red with the exception of  those present in the groove α3-α4 (A and B) or in the groove α5-α6 (C and D) which are evidenced in 
green and labelled. Hydrogens are omitted for sake of  clarity. Figure reproduced from Di Dato A. et al. (2017) with permission 
from the Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
Thanks to this conformational change, the negatively charged amino acids at the α3-α4 groove, result in a 
spatial arrangement capable to interact with the four positively charged pyridine of  2, enabling the 
supposed binding of  a second ligand molecule (Figure 43B).  
In the second set of  docking results, achieved using 20S open conformation as starting protein structure, 2 
interacts with the α4-α5 groove establishing:  
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 ionic interactions with six residues also found to interact with RPs (i.e., D13(α4), E20(α4), E24(α4), 
E170(α4), E51(α5), and E207(α5)),  
 cation-π interactions with two aromatic residues (i.e., F17(α4) and Y21(α4)) and one positively 
charged residue (i.e., R169 (α4)), 
 a π -π interaction with H15(α4) (Figure 41B).  
 
In this case too, immediately after the binding of  2 to the α4-α5 groove, conformational changes were 
induced to the whole α-ring surface, revealing the formation, also in this case, of  a further putative ligand 
binding site, which, this time, is located at the negatively charged residues identified to interact with RPs at 
the α5-α6 groove (Figure 43-D vs. 43C). Furthermore, the α4 N-terminal tail moved into the substrate gate, 
making interaction with the backbone carbonyl groups of  residues G8 (α1), R3(α6), and N4 (α6) thanks to 
charge assisted H-bonds. This prompts the positioning of  α1, α4, and α6 N-terminal tails at the substrate 
gate, inducing its steric blockage. The docking of  2 with human 20S in the open conformation caused 
lesser conformational changes at the interface with β5-subunit (Figure 42B vs. 42A) compared to the first 
set of  docking results (20S in the closed conformation). In fact, the positioning of  the βH2 helix with 
respect the loop region (aa102-111), as well as the positioning of  the loop region (aa20-30) with respect to 
the catalytic threonine, resulted similar, to the end simulation, to those present in the starting (open) 
structure (Figure 42B).  
Overall, the docking results indicate that 2 may bind at the α4-α5 groove of  20S, not only in the closed but 
also in the open conformation. Moreover, the binding of  2 means conformational changes promoting the 
accommodation of  a second ligand molecule. It have to bear in mind that bioinformatics and structural 
analysis showed another possible binding site at the α1-α2 groove, which involved the negative residues 
implicated to the anchoring of  RPs, thus, three supposed binding site for 2 were identified on each α-ring 
surface of  the 20S human CP.  
Importantly, on the basis of  these results the inhibition mechanism of  20S human proteasome by 2 was 
investigated. Results evidenced that: i) 2 is able to inhibit the three catalytic activities at the same extent, 
with IC50 values very similar to 1 (around 2 μM) (Figure 44) , ii) 2 displays a purely non-competitive 
inhibition mechanism (Figure 45A) contrarily to what observed for 1 which acts as a competitive inhibitor. 
These experimental evidences perfectly matched our computational hypothesis. 
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Figure 44. Comparison of  the IC50 values of  1 and 2 determined for the ChT-L (black), T-L (red) and PGPH-L (blue) peptidase 
activities of  the CP. Figure reproduced from Di Dato A. et al. (2017) with permission from the Nature 
(http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
 
An almost pure non-competitive inhibitory mechanism was also observed when tested against yeast 20S 
proteasome (see Figure 45B), confirming that this porphyrin acts through a similar molecular mechanism 
against both human and yeast 20S proteasome. On the contrary, in the case of  the yeast mutant α-3ΔN, 
where the first nine amino acids of  the α-3 N-terminal tail have been removed, seemingly blocking the 20S 
proteasome in the “open” conformation,145,146 the porphyrin behave as a competitive inhibitor (see Figure 
45C). 
 
 
IC50 (μM) 1 2 
ChT-L 0,393±0,09 1,77±0,07 
T-L 0,64 ±0,11 2,00±0,06 
PGPH-L 
0,140 
±0,10 
1,75±0,36 
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Figure 45.  Double reciprocal Lineweaver-Burk plot of  substrate Suc-LLVY-AMC enzymatic processing in the absence of  
inhibitor (black) and in the presence of  increasing amounts of  2 (as indicated), for various concentrations of  the substrate, by 
20S human proteasome (panel A); by 20S yeast proteasome (panel B); by α-3ΔN 20S yeast mutant (panel C). Figure reproduced 
from Di Dato A. et al. (2017) with permission from the Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
.  
In addition, the analysis of  the kinetic data, obtained from stopped-flow kinetic experiments conducted by 
prof. M. Coletta research group, revealed the cooperative binding of  at least three inhibitor molecules to 
two different clusters of  binding sites on human 20S, envisaging the possibility that this porphyrin is a 
conformational modulator of  the 20S proteasome, likely affecting the open/closed equilibrium, in full 
accordance with in silico results (Figure 46). This experimental evidence confirmed the results obtained by 
computational studies, which indicated the presence of  three potential binding sites on both proteasome 
faces, one of  which formed after the binding of  the first ligand molecule to the first (higher affinity) 
binding site located at the α4-α5 groove. 
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Figure 46. Porphyrin concentration dependence for the binding rate constants to 20S human proteasome at 37°C of  1 (o, fast 
phase, x, slow phase, see ref. 89 and 2 (+, fast phase, *, slow phase). Figure reproduced from Di Dato A. et al. (2017) with 
permission from the Nature (http://dx.doi.org/10.1038/s41598-017-17008-7). 
 
 
In fact, from a broader outlook of  parameters reported in Table 12, it emerges that binding of  
porphyrin(s) to the first cluster provoked a shift of  the conformational equilibrium from the closed (which 
is prevalent in the absence of  substrate) in favour of  the open structure (as displayed by the higher affinity 
for the open state, see Table 12); differently, binding to the second cluster produces the opposite shift (as 
depicted by the higher affinity for the closed state, see Table 12), in a manner that completely porphyrin-
bound proteasome regain to a “closed” conformation, which is not necessarily the same structure of  initial 
one, differentiated by a limited enzymatic activity. 
 
Table 12 | Kinetic parameters for the reaction of  2 and 1 with the human 20S proteasome. 
 
Kinetic parameters 
2 1a 
1kc (M-1s-1)    1.3×102 1kon (M-1s-1)       5.6×104 
1ko (M-1s-1)   2.8×106 2kon (M-1s-1)      1.3×104 
1Kc (M-1)      7×103 3k      (s-1)         3.2×10-3 
1Ko (M-1)       1.8×107  
1koff (s-1)        0.22  
1L                 4×10-6  
2kc (M-1s-1)     6.8×105  
2ko (M-1s-1)     6.75  
2Kc (M-1)       3.1×106  
2Ko (M-1)       2.5×103  
2koff (s-1)         2.7×10-3  
2L                  7.3×104  
                                                                            afrom ref. 133 
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Importantly, the computational hypothesis resulted in agreement with both literature data and our 
biochemical data (including the hypothesis to host three binding sites for each α-ring structure). Moreover, 
our results confirm the hypothesis that gating dynamics are involved in driving conformational movements 
of  the catalytic β-subunits, offering an insight for the design of  increasingly refined porphyrin-based 
allosteric proteasome inhibitors. 
 
4.3 Investigating the Open/Close Conformational Transition of 20S Human Proteasome by 
Molecular Dynamics Simulations 
 
The allosteric connection between α-ring conformational changes (opening/closing of  the gate) and β-ring 
catalytic activities (including substrate access, enzymatic reaction, and product release), is finely tuned by 
inter-related molecular interactions which can be triggered “from the outside” (the α-ring) or “from the 
inside” (catalytic β-subunits).147 An augmenting number of  alternative 20S conformational states, 
depending on external factors (i.e., the experimental technique, changes in solvent environment, presence 
of  ligands, etc.), have been now characterised. These evidences prove the existence of  large-scale 
conformational transitions regulating 20S functions; however, no information on how such transitions 
occur at the molecular level is actually available. Affecting the 20S human proteasome conformational 
equilibrium is the key molecular mechanism of  our allosteric porphyrin inhibitors, as well as of  other 
modulators, including 20S RPs, thus, the availability of  a molecular model of  such a transition could have a 
dramatic impact on future researches. Regrettably, the gap between the transition and the currently 
accessible simulation times prevents the employ of  direct-unbiased MD approaches to investigate large-
scale protein conformational changes. Therefore, a simplification of  the system and/or of  the performed 
calculations is necessary, so that less computer time is needed for each simulation step, leading to an 
artificial increase of  the available computational power and a greater sampling of  the studied system.  On 
these bases, discrete molecular dynamics (dMD),41,42 which employs discrete step function potentials in 
place of  the continuous potential used in traditional MD, has emerged as a simplification of  traditional 
MD. During dDM, the simulation engine solves the ballistic equations of  motion for only those particles 
participating in a collision, instead of  solving Newton’s equations of  motion for every particle in the 
system. Because fewer calculations are performed per time step, the dMD technique allows longer time and 
length scales to become accessible in the simulation of  large biomolecules. Moreover, the use of  coarse-
grained (CG) protein models148 extends the computational advantage of  dMD, as the simulation of  a CG 
system requires fewer resources and goes faster than that for the same system in all-atom representation. 
As a result, an increase of  orders of  magnitude in the simulated time and length scales can be achieved. On 
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these bases, in order to simulate the opening/closing of  20S human proteasome, I spent eight-months at 
the Molecular Modelling and Bioinformatics laboratory (Institute for Research in Biomedicine; IRB 
Barcelona) coordinated by prof. Modesto Orozco, where I applied an innovative dMD approach. In 
particular, dMD was used in the framework of  the GOdMD software 
(http://mmb.irbbarcelona.org/GOdMD), a new algorithm to trace conformational transitions in 
macromolecules that was developed by the research group of  prof. Orozco.149  
GOdMD is based on the use of  discrete Molecular Dynamics (dMD)41,42 and biasing techniques based on a 
combination of  essential dynamics and Maxwell-Demon sampling techniques.150 The whole procedure 
applied by GOdMD is depicted in the flowchart in Figure 47. 
 
 
Figure 47. Flowchart of  the basic GOdMD algorithm.  
 
In particular, the dMD approach uses two paths to simplification: the first through variation of  the 
interaction potential and the second by a search algorithm. The interactions between atoms are computed 
by the simplest possible potential function, a square-well potential. This facilitated  method represents a CG 
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model of  the potential function itself, and quite curtails the number of  calculations required. Unlike MM 
and MD simulations, which are driven by physical forces, dMD simulations are led by collision events. 
Indeed, the basic dMD formalism supposes that particles move to constant-velocity regime until they 
collide with another atom. Consequently, the interaction potential between the two atoms differs and, 
accordingly, the velocities of  the two interacting atoms vary immediately. These changes of  velocity must 
be in accordance with the energy and momentum conservation laws. Then, the potential energy is rough 
out with progressive discontinuous functions of  the particle-particle distance instead of  continuous 
functions employed in standard MD. The searching of  these collision events gives rise to the second major 
simplification present in dMD. Instead of  searching every possible collisions, the tracking algorithm is 
circumscribed to a local search; only those atoms inside the same local area are taken into account as 
having possible collisions. Once collisions are recognised, only the atoms taking part in collision are 
required to be updated after every event, thereby fewer calculations required per time-step and significantly 
improving ability of  sampling. 
GOdMD adopt a CG representation of  the protein, in accordance with an one-bead model, where only Cαs 
of  the protein are explicitly represented as single spheres and with the entire protein represented by beads-
on-a-string polymer. The potentials make use of  a single square well with infinite walls to define the bonded 
interactions between consecutive beads. The non-bonded interactions, instead, are characterised by a 
multiple well Go-like model,151,152 dependent on the experimental inter-particle distance and classified in 
two categories based in presenting or not a different inter-particle distance between the initial (A) and final 
(B) conformation. Indeed, when both structures shows a distinct inter-particle distance, a double well 
potential is defined (Figure 47A), centred in the related experimental values (rA and rB). When, on the 
contrary, the distances are similar in both conformations, a single and ample well (50% larger) is defined, 
centred at ½ (rA + rB) (Figure 47A). This scheme allows completing transition paths since target minimum 
behaves as attractor and makes possible to use softer biasing schemes. To avoid the over-restraining of  the 
system with physically irrelevant interactions, the potential energy was defined only for those particles 
within a cutoff  (rA, rB > radii of  gyration/2).  Moreover, the height of  the wells for all non-bonded 
interactions is 0.5 kcal/mol, permitting the particles to dash off  from the wells if  necessary.  
In order to guarantee an enrichment of  sampling along the transition path, two biasing schemes are used 
by GOdMD algorithm. In particular, the first level of  biasing is delineated to move the protein far away 
from the starting conformation (Figure 47B), by combining metadynamics38 with Elastic Network Model 
(ENM),153,154 in such a way that: 
 the wells associated to inter-particle distances showing large changes along the first five essential 
deformation modes are filled faster; 
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 the wells associated to inter-particle distances that are not coupled to the essential deformation 
modes of the protein are filled slowly. 
The ENM analysis is performed only on the initial structure irrespective of the target structure, avoiding 
the production of too linear pathways. Moreover, the ENM-metadynamics guarantees to explore 
alternative ways to run away from the original structure minima, expanding the possibility to sample 
favoured pathways as described by the essential deformation modes. 
The second level of  biasing is designed, instead, to address the trajectory toward the final structure, 
without inserting energy restraints (Figure 47C). For this purpose, a Maxwell Demon biasing algorithm was 
used, which increases the sampling in the transition direction and along the essential deformation modes. 
Following the Maxwell-Demon approach, the bias toward the target structure is defined by the calculation 
of  a progress variable correlated to RMSd value. Accordingly, after at a certain simulation step (t), a 
progress variable Г (dependent on the total number of  residues, target structure, the sampled 
conformation and a weight function dependent on the inter-particle distance and the size of  protein) is 
calculated and compared with that obtained in a previous accepted movement (t + Δt). The simulation 
frame (t + Δt → t) is then accepted or rejected based on a Metropolis test, where acceptance probability is 
a function of  the RMSd between the structure sampled at time X(t) and the target structure, including also 
a variable that is adjusted to guarantee an acceptation rate of  70% and the time frame (Δt) is typically 100 
time steps. These large acceptance rates, combined with a weight function having a maximum at ~15Å, 
enables the system not to explore direct pathways that could lead to stressed structures and provides the 
best local geometries.  
If  the simulation frame is rejected, the structure sampled at time X(t) continues the simulation and it is 
redirected to the Metropolis test again. If  the simulation frame is accepted, the convergence value is 
verified. Considering that the protein structures are in constant moving by thermal noise, it would be 
unrealistic to obtain a zero RMSd value when a protein structure is intrinsically oscillating at room 
temperature. On this basis, a convergence principle based on the slope of RMSd to target structure respect 
to time has been adopted. This criterion averts to obtain stressed structures that would be only an untrue 
minimum as a result of the strong bias necessary to reach close to zero RMSd values. On the other hand, if 
this criterion is not met, the algorithm reassess the potential energy and add or not energy based on Go-
like scheme described above, subjecting the structure sampled at simulation steps and, then, at Metropolis 
test. 
In order to trace the transition between known equilibrium conformations of  20S human proteasome, our 
previously developed129,155 molecular models of  human 20S proteasome, in the closed and in the open state, 
were taken as starting and target structures. To perform the GOdMD calculation both structures should 
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contain the same number of  residues and ordering should match the appropriate sequence alignment, thus, 
only two packed rings (i.e., one α-ring and one β-ring) were considered for each structure of  20S human 
proteasome (it has to be herein recalled that, being 20S structured as a dimer, the other two missing rings 
are identical). All trajectories were generated with random seed number, applying a temperature of  300 K 
and a simulation time of  5000,000 ps.  
Overall, 80 trajectories were obtained, considering the open → closed and closed → open transitions for 
both 20S wild type and the α-3ΔN mutant (lacking the first N-terminal residues of  the α3-subunit). The 
most representative structures have been selected by evaluating the RMSd value. The conformational 
changes spanned by these simulations was analysed using Root-Mean-Square Fluctuations (RMSF). 
Firstly, the closed → open transition of  20S human proteasome was simulated and twenty trajectories were 
generated. At the end of  the simulation the trajectory with the lowest overall RMSd value was selected as 
the best simulated transition (FigureV). Interestingly, according to the selected trajectory, all the generated 
complexes presented a linear decrease of  the RMSd value to the target structure (Figure 48).  
 
 
Figura 48. RMSd values of  twenty generated trajectories with random seed numbers and Plot of  RMSd for selected trajectory 
(highlighted in red).  
 
The dMD simulation shows a concerted opening movement involving α and β subunits, allowing α3 N-
terminal tail, which deletion leads to an opening of  the channel, to get out of  the gate channel. On the 
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other hand, since α2, α3, and α4 N-terminal tails are involved in molecular interactions with each other, 
then, the conformational change of  α3 N-terminal tail affects also the position of  α2 N-terminal tail. This 
latter shows a marked readiness to switch spatial positioning in absence of  α3 N-terminal tail and, in 
accordance with the intimate connection among the N-terminal portions at the access of  gate, the α2 N-
terminal tail residues (aa1-8) show a partial (not complete) movement in adopting the positioning towards 
open conformation as well as α4 N-terminal tail residues (aa1-7) (Figure 49A). Moreover, the RMSd values 
between the last frame of  the considered trajectory and the target structure (open conformation of  the 20S 
human proteasome) showed that also some residues at the β2-β3 interface (T-like catalytic activity) are not 
able to reach their target position (aa136-146 β3) (Figure 49B).  
 
 
Figure 49. Overall view of  the 20S human proteasome structure (α and β rings). The Cαs are explicitly represented as single 
spheres and coloured by RMSF. Red values indicate areas of  less fluctuation (RMSF < 1 Å), white indicate areas of  medium 
fluctuation (1 Å < RMSF < 7 Å),  and blue values indicate areas of  more fluctuation (> 7 Å). 
 
This aspect highlights the existing connection between α and β rings, accounting for the experimental 
evidences about 20S allostery.155,136,147  
In addition, Root-Mean-Square Fluctuations (RMSF) were calculated in order to obtain a measure of  the 
average atomic mobility of  Cαs atoms during the simulation and identify structure local changes (Figure 
50). 
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Figure 50.  Plot of  RMSF for selected trajectorie vs. 20S human proteasome target structure (open conformation). 
 
Excluding some C-terminal tails (reported with green asterisks), which  correspond to disordered and 
flexible protein regions, the graph evidenced as the most pronounced local changes those occurring at α5-
subunit and β2-β3 interface (S3 catalytic site pocket). In particular, regarding the affected α5 structural 
region, it matches to loop forming part of  the so called α-annulus, that is, a narrow channel that is located 
slightly below the surface of  the α ring. Substrates enter the proteasome through a gated pore in the centre 
of  α-ring156 and their passage is restricted by the α-annulus, which is in direct connection with the β-ring and 
ensures that substrates are substantially unfolded before they can enter the catalytic site. Accordingly, our 
results showed conformational changes transmitted from the α-ring (α5) to the interface with the β-ring, 
and extending to the S3 active site pocket of  the T-like catalytic activity (β2-β3 subunits). Importantly, 
NMR studies evidenced that the same 20S structural regions are involved in the regulation of  proteasome 
activation.136,142 
 
Then, the opposite conformational transition, i.e., open → closed state, was investigated applying the same 
simulation procedure. Obtained results have showed a value of  1.49 Å for the trajectories with the lowest 
RMSd and the trajectory 20 was selected as the most representative.(Figure 51) 
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Figura 51. RMSd values of  twenty generated trajectories with random seed numbers and Plot of  RMSd for selected trajectory 
(highlighted in red).  
 
 
The selected transition confirms the coordinated conformational changes of  the α and β rings, as well as, a 
trend toward the fitting to the target structure of  α2 and α4 N-terminal tails (Figures 52 and 53). 
Differently, the α3 N-terminal tail appears more constrained, underlining its structural role as clog of  the 
proteasome central pore. 
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Figure 52. Top vision of  the 20S human proteasome structure (α and β rings); The Cαs are explicitly represented as single 
spheres and coloured by RMSF. Red values indicate areas of  less fluctuation (RMSF < 1 Å), white indicate areas of  medium 
fluctuation (1 Å < RMSF < 7 Å),,  and blue values indicate areas of  more fluctuation (> 7 Å). 
 
 
 
Figure 53.  Plot of  RMSF for selected trajectorie vs. 20S human proteasome target structure (closed conformation). 
 
 
Our results indicate that 20S catalytic activities are auto-inhibited by the outer α-ring subunits, with a key 
role played by the N-terminal tail of  the α3-subunit. In the latent state, it prevents substrate entry by 
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imposing topological closure. Importantly, biochemical and structural analysis showed that deletion of  the 
N-terminal tail of  the α3-subunit (α-3ΔN mutant) leaves the channel permanently open to the 
proteolytically active interior chambers.145 On the other hand, the correct repositioning of  the α3-subunit 
N-terminal tail in to the gate is not achieved in the open → closed transition simulation, suggesting that an 
additional intermediate conformational state is probably involved, which may explain as the mechanism of  
the gate opening is finely regulated by a sequence of  perfectly coordinated events. 
Thus, to further investigate the structural role of  the N-terminal tail of  the α3-subunit on 20S closed/open 
equilibrium, the structure of  the α-3ΔN mutant was built by the deletion of  nine residue (1MSRRYDSRT9) 
from the N-terminal tail in the two 20S human proteasome structures (closed and open states). The 
resulting models were subjected to the same dMD procedure previously applied to the wild type structure. 
The best trajectory obtained for the α-3ΔN mutant in the simulation of  the closed → open transition show 
an RMSd value of  1.37 Å (Figure 54).  
 
 
Figura 54. RMSd values of  twenty generated trajectories with random seed numbers and Plot of  RMSd for selected trajectory 
(highlighted in red).  
 
According to this simulation, the α4 N-terminal tail of  the mutant gets out of  the proteasome gate in place 
of  the α2 N-terminal tail, which instead remain deeply into the central pore. This behaviour, once again, 
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emphasises the close relationship between α2 and α3 N-terminal tails. Indeed, the lack of  α3 N-terminal 
tail does not allow α2 N-terminal tail to detach from central gate (Figures 55 and 56). 
 
 
Figure 55. Top vision of  the 20S human proteasome structure (α and β rings); The Cαs are explicitly represented as single 
spheres and coloured by RMSF. Red values indicate areas of  less fluctuation (RMSF < 1 Å), white indicate areas of  medium 
fluctuation (1 Å < RMSF < 7 Å),  and blue values indicate areas of  more fluctuation (> 7 Å). 
 
 
 
Figure 56. Plot of  RMSF for selected trajectorie vs. 20S human proteasome target structure of  α-3ΔN mutant (open 
conformation). 
85 | P a g e  
 
 
On the other hand, the best trajectory obtained during the simulation of  the open → closed transition 
exhibits a RMSd value of  1.34 Å (Figure 57) and the same tendency for the α2 and α4 N-terminal tails to 
correctly adopt the positioning of  the target (closed) conformation, as observed for the wild type structure 
(Figures 58 and 59) 
 
 
Figura 57. RMSd values of  twenty generated trajectories with random seed numbers and Plot of  RMSd for selected trajectory 
(highlighted in red).  
 
 
Figure 58. Top vision of  the 20S human proteasome structure (α and β rings); The Cαs are explicitly represented as single 
spheres and coloured by RMSF. Red values indicate areas of  less fluctuation (RMSF < 1 Å), white indicate areas of  medium 
fluctuation (1 Å < RMSF < 7 Å),  and blue values indicate areas of  more fluctuation (> 7 Å). 
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Figure 59. Plot of  RMSF for selected trajectorie vs. 20S human proteasome target structure of  α-3ΔN mutant (closed 
conformation). 
 
These studies provided the first molecular model accounting for the key role played by the α3 N-terminal 
tail in the regulation of  the 20S conformational equilibrium.  
 
4.3.1 Full atom simulation 
 
MD simulations on full atom structures of  20S human proteasome, either in the closed and in the open 
state, have been also performed in order to explore essential structure fluctuations in both conformational 
states. All simulations were performed with the GROMACS 5.0 software package.157 The flowchart below 
describes the general procedure for setting up an MD run. (Figure 60). 
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Figure 60. Flowchart of  Gromacs procedure. 
 
The Amber ff99SB-ILDN force field158 was used, in which side chain torsion parameters of  four residues 
(isoleucine, leucine, aspartate, and asparagine) have been improved. The LINCS159 algorithm was used to 
constrain bond lengths, allowing a time step of  2 fs.  
Following the flowchart in Figure T, the initial structure coordinate file is converted into a GROMACS 
readable format (pdb2gmx), generating two files that contain the molecular structure and the topology file 
(i.e., molecular parameters, force field and charges). Then, a dodecahedron box is generated around the protein 
with a buffer of  1.4 nm between the outside of  the protein and the edge of  the box (editconf). Moreover, 
a water box, based upon the dimensions/box type, is created and the number of  water molecules needed 
to solvate the box of  the given dimensions (genbox) have been added with the TIP3P (transferable 
intermolecular potential 3P) model.160 Subsequently, it was necessary to neutralize the system prior to 
simulations and, for this reason, counter ions have been added according to the total charge of  the system 
(genion). At this point, the protein has been subjected to energy minimisation using the Steepest Descent 
algorithm (etmol = 1 and emstep = 0.01).  In order to rearrange the water molecules towards protein, 
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before the starting of  MD simulation, the backbone restraints on whole protein (except for the modelled 
N- and C-terminal portions) were applied using the 'define = -DPOSRES' line command. The MD 
simulation procedure starts with equilibration, carried out in two steps. First, an NVT (constant Number 
of  atoms, Volume, and Temperature) simulation is performed in order to bring the system to the final 
temperature of  300K. The parameter file for the NVT simulation calls for an MD run of  1000000 steps 
with a 0.02 ps time-step (a total of  2000 ps = 2 ns). Temperature coupling has been performed using the 
V-rescale method and simulated annealing procedure. In order to be sure velocities (and therefore 
temperature) are evenly distributed across water and protein, protein and water atoms are coupled to 
separate baths (separate coupling).  
After the equilibration to a target temperature, the system is next relaxed into a constant pressure 
ensemble. Indeed, a NPT (constant Number of  atoms, Pressure, and Temperature) simulation is carried 
out to allow the system to find the correct density. In particular, five NPT equilibration steps each of  0.5 ns 
have been performed (a total of  2.5 ns), decreasing  gradually the constant forces of  position restraints as 
follows: step1/9000 kJ mol-1 nm-2, step2/1000 kJ mol-1 nm-2, step3/100 kJ mol-1 nm-2, step4/10 kJ mol-1 
nm-2, and step5 without restraints. The V-rescale thermostat has been preserved and the Berendsen 
barostat161 has been used to couple pressure isotropically (the same in all directions) to a value of  1.0 bar 
(from step1 to step3). Then, a Parrinello-Rahman barostat162 allowed a variable cell shape during the 
simulation (from step4 to step5). Finally, being this run a continuation of  the previous run, “gen_vel” has 
been set to “no” and “continuation” has been set to “yes”. Once the system was properly equilibrated, the 
parameter file for MD production looks almost exactly like that of  the last NPT equilibration step (step5) 
for a 10,000,000 MD steps with a 2 fs time-step, totaling 20,000 ps (or 20 ns) of  sampling. Subsequently, 
such MD run was extended for further 25,000,000 MD steps (50,000 ps = 50 ns) for a total time of  70 ns. 
It should be underlined that a very large number of  amino acid residue composes the 20S human 
proteasome structures, by consequence, the MD calculations requested an extensive computational time 
despite a multiple parallelization scheme (i.e, 96 processors used).  
The Principal Component analysis (PCA) has been used in order to extract the most important elements in 
the obtained data, using a covariance matrix constructed from atomic coordinates that describe the 
accessible number of  degrees of  freedom of  the protein, such as the cartesian coordinates that define 
atomic displacements in each conformation comprising a trajectory.163 Thus, the “essential” motions were 
extracted from the set of  sampled conformations and the obtained eigenvectors of  a covariance matrix has 
been analysed. RMSF values were calculated in order to quantify the essential dynamics of the 20S human 
proteasome. The obtained results showed interesting details. Both the α-ring and β-ring appear to be more 
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susceptible to structural fluctuations when the 20S human proteasome is in the closed conformation 
(Figure 61).   
 
 
Figure 61.  Top vision of  the 20S human proteasome structure (α and β rings); the Cαs are explicitly represented as single 
spheres and coloured by PCA RMSF. Red values indicate areas of  less fluctuation (RMSF < 1 Å), white indicate areas of  
medium fluctuation (1 Å < RMSF < 7 Å),  and blue values indicate areas of  more fluctuation (> 7 Å). Plot of  PCA RMSF for 
20S human proteasome (α and β rings) for 70 ns of  simulation. 
 
In particular, the α-ring showed most conformational changes at the grooves (and C-terminal tails) level 
while the N-terminal tails kept their initial positions, confirming their role as gate blocker. On the other 
hand, the β-ring showed conformational changes at catalytic subunits level and more precisely at the β5-β6 
subunit interface. Indeed, the β6-loop looks as if  it opens up in order to allow the entrance and/or  release 
of  the substrate. Moreover, the β2 C-terminal tail was the only to show a significant RMSF value, 
confirming highly dynamic and eager to act as structural communication between the α and β rings. 
Indeed, during the simulation, the long β2 C-terminal tail makes contacts with the α2 and α3 subunits, 
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notably, its positioning has never been experimentally determined and these results suggest that it could 
represent the structural portion designated to the allosteric communication between α and β rings. 
The same study has been performed also considering the 20S human proteasome in the open 
conformation (Figure 62). 
 
 
Figure 62.  Top vision of  the 20S human proteasome structure (α and β rings); The Cαs are explicitly represented as single 
spheres and coloured by PCA RMSF. Red values indicate areas of  less fluctuation (RMSF < 1 Å), white indicate areas of  
medium fluctuation (1 Å < RMSF < 7 Å),  and blue values indicate areas of  more fluctuation (> 7 Å). Plot of  PCA RMSF for 
20S human proteasome (α and β rings) for 70 ns of  simulation. 
 
 
Differently from the previous results, the α-ring showed large conformational fluctuations in several 
protein regions; in fact, the α1-α2 and α3-α4 grooves showed a higher RMSF value with respect to other α-
subunit interfaces. Moreover, the α1 and α5-α7 N-terminal tails tend to adopt the closed conformation 
while those of  α2, α3, and α4 are consistently in the open conformation, in accordance with their intimate 
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structural relationship, as described above. In addition, two peculiar aspects that could be of  interest for 
the mechanism of  gate closing/opening, also emerged from these results. In particular: i) the N-terminal 
tails showed a co-operative movement with the α-annulus and groove regions, ii) the α3 and α5 N-terminal 
tails are involved in molecular interactions with the α3 and α7 C-terminal tails, respectively. This could 
account for the auto-regulation of  20S, which it is capable to adopt a closed/open conformation also in 
the absence of  RPs. Unfortunately, the lack of  accurate information about the biological and structural 
role of  the 20S C-terminal tails allows only to formulate hypotheses, so far.  
Regarding the β-ring, the results show that conformational changes occur at β2 C-terminal tail and β5-β6 
interface, congruent with those observed in the closed conformation, although highlighting a more marked 
movement of  the β2-subunit.  
Finally, by comparing the RMSF values of  the closed and open conformation, significant differences in 
local fluctuations can be observed (Figure 63). 
  
 
Figure 63. PCA RMSF plot of  the backbone atoms of  20S human proteasome vs. amino acids number. The closed 
conformation is shown in cyan; the open conformation is shown in red.  
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In fact, the closed conformation of  20S human proteasome showed greater fluctuations during the MD 
simulation at the β-ring and other specific regions, such as: 
- α3-subunit: structural region belonging to α3-α4 groove; 
- α4-subunit: α-helix in connection with β5-subunit; 
- α7-subunit: structural region belonging to α6-α7 groove. 
 
Differently, the open conformation of  20S human proteasome showed major conformation changes at α-
ring level, such as: 
- α2-subunit: structural loop belonging to annulus region and structural region belonging to α1-α2 
groove. 
- α3-subunit: structural loop belonging to annulus region and structural loop belonging to α3-α4 
groove; 
- α5-subunit: structural loop belonging to annulus region. 
 
In conclusion, conventional molecular dynamics simulations and discrete molecular dynamics simulations 
were  performed to investigate the structural characteristics for the open and closed 20S CP states and the  
dynamic transition mechanism of  the two states, respectively. The results of  this study show that the  
predominant structural differences between the open and closed 20S states were localised at gate, grooves 
and α-β interface, underlining the allosteric network occurs from α-ring to the β-ring via the N-terminal 
tails and annulus region. In fact, the structural regions involved in the conformational changes were 
previously proved136 to be involved in the allosteric regulation of  the 20S catalytic activity. Taken together, 
this observations represent a further confirmation of  obtained dynamic docking results and  provides 
useful insights into understanding the dynamics of  the transition mechanism of  the closed 20S CP state to 
the open 20S state. In all these contexts, the availability of  chemical tools that allow the control and 
modulation of  the functional dynamics of  proteins (and their networks) can have fundamental impact on 
physiology studies and the development of  novel mechanism-based therapeutics. 
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Chapter 5 
 
5.1 Design of Redox-active Chemotherapeutics 
 
Natural compounds including redox-active chemical function(s) are frequently cytotoxic and only some of  
them show a profile of  selectivity appropriate to become structural leads for the development of  new 
chemotherapeutic agents. A perfect redox-active cytotoxic agent should behave as a “sleeping bomb” 
which is activated only in a precise cellular environment (e.g., cancer, microbial, or infected cells).164,165 
However, the molecular mechanisms of  such selective cytotoxicity are even now not well-know. This is 
caused by the intricacy of  the chemical reactions taking place in biological systems165 and by the difficulty 
to precisely predict the molecular reactivity of  the ligands in such environments.166-168 In addition, in many 
cases, these compounds do not present a well-defined protein target.164 Therefore, the chemical reaction 
driving to their bio-activation represents the key molecular interaction to be examined. When a series of  
active analogues is available but the protein target is unknown or not specific, only ligand-based approaches 
can be used to address hit identification/optimisation. One of  the most common application is the 
development of  a pharmacophore model based on the SARs of  available ligands.169 Considering all putative 
mechanism of  action, the in-depth analysis of  the conformational behaviour of  the considered ligands is a 
key point for the identification of  the features responsible for the identified biological activity. Indeed, the 
molecular recognition is driven by the conformational equilibria of  the interacting species present in 
solution. Obviously, this is true also when the mechanism of  action pertains to a redox reaction. The 
majority of  the conformations that a ligand can hypothetically acquire are energetically not allowed and are 
not observed experimentally. The difficult task for a computational chemist is to comprehend the 
structural and energetic dissimilarity among these conformations, recognising the prevalent and the 
bioactive ones (which may show a higher energy with respect to their global minima).170,171 In the case of  
redox-active ligands, the bioactive conformations are those capable to interact with the redox counterpart 
(e.g., radical species, metal ions, etc.) accountable for the bio-activation reaction  permitting simultaneously 
the appropriate spatial orientation of  all reaction partners. In this context, in order to enhance the 
biological activity by inserting rational structural modifications capable to regulate the redox behaviour, the 
identification of  the bioactive conformation must be combined with the capability to accurately calculate 
the electronic parameters. Accordingly, the computational approach (summarised in Figure 5 Chapter 2) 
was applied to design new antimalarial agents and to the investigate their redox mechanism of  action.  
Malaria is a disease of  worldwide involvements and eradicating malaria is one of  the biggest programs of  
the World Health Organization (WHO).172 An alarming rise in the number of  lethal cases has been taken 
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note in recent years and it is especially due to the propagation of  multi-drug resistant strains of  Plasmodium 
falciparum (Pf), making less effective the available drugs.173 Malaria parasite is a micro-organism highly 
sensitive to oxidative stress forced to live in a pro-oxidant environment including oxygen and iron, which 
elicit a large quantity of  reactive oxygen species (ROS). This imposes a serious threat to the parasite,165,174 
which developed adaptation and survival strategies to live under these pro-oxidant conditions. Therefore, 
identification of  redox-active cytotoxic molecules which can be activated in the parasite environment 
represents a rational approach to design new antimalarial drugs. 
The lead compound in the family of  antimalarial endoperoxides is Artemisinin (Figure 64), a natural 
compound isolated from the plant Artemisia annua. 
 
 
Figure 64. Structure of  Artemisinin , Plakortin (1), Dihydroplakortin (2) and the scaffold of  the new synthetic 3-methoxy-1,2-
dioxanes (4-7). R1, R2, and R3 are hydrogens or alkyl chains. Figure adapted from Persico M. et al. (2016) with permission of  
WILEY-VCH Verlag GmbH & Co. KGaA (http://dx.doi.org/10.1002/minf.201501028). 
 
Artemisinin and its semi-synthetic derivatives are the principal components of  Artemisinin-based 
Combination Therapies (ACTs), the first-line treatment for Pf malaria in disease-endemic countries. The 
neurotoxicity and the known cases of  clinical resistance related to the use of  artemisinins175,176 strongly 
incite the discovery, as soon as possible, of  feasible alternatives to the existing therapeutic options. 
Therefore, there is an impelling need for novel and affordable antimalarial drugs with high effectiveness 
against resistant strains and action broad stage mode.  
In this regard, the research group of  my tutor C. Fattorusso investigated the molecular mechanism of  
action of  plakortin (1, Figure 64) and dihydroplakortin (2, Figure 64), simple endoperoxide-containing 
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polyketides isolated from the Caribbean sponge Plakortis simplex,177 possess an interesting in vitro 
antimalarial activity on CQ-Resistant strains (CQ-R) of  Pf.178,179 The synthesis of  several plakortin semi-
synthetic derivatives, in order to gain insight into the structural requirements of  these simple 1,2-dioxanes 
for exhibiting antimalarial activity, showed the crucial role both of  the endoperoxide function and of  1,2-
dioxane ring conformation, together with the absence of  stereoselectivity in the antimalarial mechanism of  
action.180 These data strongly revealed that 1, similarly to artemisinin, does not interact with a specific 
protein target, but rather impedes heme detoxification which occurs in the food vacuole (FV), 
compromising the plasmodium antioxidant defences. On these bases, in a recently reported investigation181-
183 based on an exhaustive computational and experimental study, it was proposed that molecules belonging 
to the plakortin family, immediately after interaction with Fe(II), undergo a dissociative electron transfer 
(DET) of  the endoperoxide bond, generating an oxygen-centered radical. Then, a fast “through space” 1,4- 
or 1,5- intramolecular radical shift to an alkyl side chain carbon atom occurs through a radical cascade that 
leads to the putative toxic species for the Plasmodium environment (Figure 65). 
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Figure 65. Proposed antimalarial mechanism of  action of  plakortin (1) and di-hydroplakortin (2). Figure reproduced from 
reference Chianese et al. (2014), Bioorg. Med. Chem. (http://dx.doi.org/10.1016/j.bmc.2014.07.034). 
 
This putative antimalarial mechanism of  action was confimed by SARs studies carried out on further 
plakortin analogues and the obtained information allowed to develop a pharmacophoric model of  
plakortins (Figure 66).180,184-186 
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Figure 66. 3-D pharmacophore model of  plakortin analogues. Figure reproduced from Taglialatela-Scafati O. (2010), Org. 
Biomol. Chem. (http://dx.doi.org/10.1039/b918600j). 
 
Starting from these results, a new series of  antimalarial endoperoxides was developed, characterised by a 3-
methoxy-1,2-dioxane scaffold (Figure 67), a low cost synthesis and an in vitro antimalarial activity on Pf  
CQ-resistant strains similar to that of  the lead compound plakortin.187-189 
 
Computational and SAR studies performed on these new synthetic 1,2-dioxane derivatives showed that, as 
in the case of  plakortins, the antimalarial activity is related to their capability to react with Fe(II) and to 
develop a carbon centered radical on the alkyl chain located on C3 and/or C6 by means of  an intra-
molecular hydrogen shift. Furthermore, the 3-D-dimensional-SAR study demonstrated the active role of  
the C4 substituent to determine the antimalarial activity, allowing to achieve IC50 on CQ-R strain in the low 
micromolar range and, at the same time, very low toxicity against human cells. 
5.2 Optimisation of Cellular Pharmacokinetic and Pharmacodynamic Properties of New 
Antimalarial 3-methoxy-1,2-dioxanes 
 
Starting from the results described in the previous paragraph and since the amine chains are known to play 
a decisive role both on cellular pharmacokinetic and pharmacodynamic properties of  different 
antimalarials,190-192 a new series of  compounds with general structure 9193,194 (Figure 67) were designed and 
synthesised, inserting a substituted amine chain at C4 of  3-methoxy-1,2-dioxane scaffold.193  
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Figure 67. General structure of  4-methylamino-1,2-dioxanes 9 (R3 = amino group containing molecular scaffold or N-
heterocyclic moiety). Figure reproduced from Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
In particular, a methylamino group, which, by means of  a flexible spacer, binds a second amino-including 
scaffold or a N-heterocyclic moiety was introduced. Among the polyamine chains inserted at C4, also the 
aromatic substructure of  chloroquine or primaquine was considered, leading to the production of  new 
endoperoxide-quinoline hybrids. The antimalarial activity and the structures of  the new compounds, 
modified at C4 side chain, are reported in Tables 13 and 14. 
 
Table 13 | Structure, yield, c Log D values, antimalarial activity against CQ-S (D10) and CQ-R (W2) Pf  
strains, and cytotoxicity against HMEC-1 of  3,4-cis-3-methoxy-4-aminomethyl-1,2-dioxanes 9a-j.  
 
 
          c Log Da 
3,4-cis-9 
(Y %)b 
R1 R2 R3 D10 IC50 
(µM)c 
W2 IC50 
(µM)c 
RId HMEC-1 IC50 
(µM)c 
D10 
SIe 
W2 
SIe 
pH 
7.4 
pH 
7.2 
pH 
5.5 
9a (91) n-Bu Me 
N
N
 
0.42 ± 0.09 0.21 ± 0.04 0.5 > 59 > 140 > 280 0.5 0.3 -1.3 
9b (83) Me n-Bu 
N
N
 
0.37 ± 0.05 0.4 ± 0.1 1.1 - - - 1.9 1.7 0.1 
9c (83) n-Bu n-Bu 
N
N
 
0.24 ± 0.06 0.2 ± 0.1 0.8 5.14 ± 0.08 21.4 25.7 3.2 3.0 1.4 
9d (85) n-Bu Me NMe2 0.6 ± 0.1 0.39 ± 0.02 0.7 - - - -0.3 -0.6 -1.9 
9e (88) Me n-Bu NMe2 0.54 ± 0.09 0.33 ± 0.05 0.6 3.624 ± 0.001 6.7 11.0 1 0.8 -0.3 
9f (85) n-Bu n-Bu NMe2 0.8 ± 0.1 0.6 ± 0.3 0.8 - - - 2.4 2.1 0.8 
9g (86) n-Bu Me 
N O
 
1.4 ± 0.4 0.55 ± 0.06 0.4 - - - 0.2 0.0 -0.6 
9h (85) Me n-Bu - 0.6 ± 0.1 0.4 ± 0.2 0.7 - - - 5.4 5.3 4.0 
9i (86) Me - 
N
N
 
2.1 ± 0.8 0.7± 0.1 0.3 - - - 0.4 0.2 -1.3 
9j (65) Me Me 
N
N
 
>10 >10 - - - - -0.9 -1.1 -2.6 
CQf - - - 0.05 ± 0.02 0.7 ± 0.2 14 > 38 > 760 > 54 - - - 
DHAg - - - 0.005 ± 0.001 0.0024 ± 0.0004 0.5 3.1 ± 0.3 620 1292 - - - 
aACD/Percepta software (version 14.0.0, Advanced Chemistry Development, Inc., Toronto, ON, Canada) bIsolated yields. cData 
are the mean ± SD of  three different experiments in duplicate. dRI = Resistance Index: IC50 ratio for CQ-R/CQ-S strains of  Pf. 
eSI = Selectivity Index: IC50 ratio for HMEC-1/CQ-R or CQ-S strains of  Pf. fCQ: chloroquine. fDHQ: di-hydroartemisinin. 
Table adapted from Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
98 | P a g e  
 
 
Table 14 | Structure, yield, c Log D values, antimalarial activity against CQ-S (D10) and CQ-R (W2) Pf 
strains, and cytotoxicity against HMEC-1 of  3,4-cis-3-methoxy-4-aminomethyl-1,2-dioxanes 9k-s.  
 
 
          c Log Da 
3,4-cis-9 
(Y %)b 
R1 R2 n D10 IC50 
(µM)c 
W2 IC50 
(µM)c 
RId HMEC-1 IC50 
(µM)c 
D10 
SIe 
W2 
SIe 
pH 
7.4 
pH 
7.2 
pH 
5.5 
9k (65) n-Bu Me 1 0.050 ± 0.002 0.11 ± 0.04 2.2 5.5 ± 0.7 110 50 1.9 1.6 0.4 
9l (62) Me n-Bu 1 0.072 ± 0.004 0.11 ± 0.03 1.5 3.31 ± 0.08 46 30 3.1 2.9 1.7 
9m (65) n-Bu n-Bu 1 0.09 ± 0.01 0.13 ± 0.02 1.4 5.49 ± 0.05 61 42 4.6 4.4 3.1 
9n (61) n-Bu Me 2 0.05 ± 0.01 0.13 ± 0.02 2.6 2.5 ± 0.2 50 19 2.1 1.9 0.7 
9o (60) Me n-Bu 2 0.074 ± 0.003 0.13 ± 0.01 1.8 2.24 ± 0.01 30 17 3.3 3.1 2.0 
9p (64) n-Bu n-Bu 2 0.09 ± 0.01 0.11 ± 0.03 1.2 - - - 4.8 4.5 3.4 
9q (63) Me Me 2 0.048 ± 0.006 0.34 ± 0.09 7.1 25 ± 2 521 74 0.8 0.5 -0.6 
9r (60) n-Bu Me - 0.5 ± 0.1 0.31 ± 0.07 0.6 - - - 2.8 2.7 2.5 
9s (62) Me n-Bu - 0.94 ± 0.04 0.5 ± 0.1 0.5 - - - 4.1 4.0 3.7 
CQf - - - 0.05 ± 0.02 0.7 ± 0.2 14 > 38 > 760 > 54 - - - 
DHAg - - - 0.005 ± 0.001 0.0024 ± 0.0004 0.5 3.1 ± 0.3 620 1292 - - - 
aACD/Percepta software (version 14.0.0, Advanced Chemistry Development, Inc., Toronto, ON, Canada) bIsolated yields. cData 
are the mean ± SD of  three different experiments in duplicate. dRI = Resistance Index: IC50 ratio for CQ-R/CQ-S strains of  Pf. 
eSI = Selectivity Index: IC50 ratio for HMEC-1/CQ-R or CQ-S strains of  Pf. fCQ: chloroquine. fDHQ: di-hydroartemisinin 
Table adapted from Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
The results presented in Tables 13 and 14 evidenced that imidazol-1-yl derivatives 9a-c exhibited IC50 
values in the high nanomolar range (200-400 nM) against both parasite strains, an activity greater than the 
whole library of  endoperoxides previously reported. The need of  butyl chain(s) either at position C3 or C6 
of  the 1,2-dioxane ring is confirmed by the absence of  activity showed by 9j. Moreover, the substitution of  
the butyl chains at C6 with a spiro-cycloheptane ring (9i) reduced the antimalarial activity (Table 13). In 
fact, the corresponding spiro-derivatives 4i and 7i, owning a methyl ester and a methyl amide substituent at 
C4, respectively, were both completely inactive (Table 15). 
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Table 15 | Structure, c log D values, and antimalarial activity of  4i, 7i and 9i against CQ-S (D10) and CQ-
R (W2) Pf strains.  
 
   c Log Db 
 D10 IC50 
(µM)a 
W2 IC50 
(µM)a 
pH 
7.4 
pH 
7.2 
pH 
5.5 
4i  > 10 > 10 3 3 3 
7i > 10 > 10 2.1 2.0 0.6 
9i 2.1 ± 0.8 0.7 ± 0.1 0.4 0.2 -1.3 
aData are the mean ± SD of  three different experiments in duplicate. 
bACD/Percepta software (version 14.0.0, Advanced Chemistry Development, Inc., Toronto, ON, Canada).  
Table adapted from Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
A small but important loss of  antimalarial activity is linked to the substitution of  the imidazole ring with 
simple aliphatic tertiary amines (9d-h), especially when the tertiary amine is inserted into a morpholine ring 
(9g). Generally, all the compounds showed in Table 13 were most active against W2 (CQ-R) compared to 
D10 (CQ-S) Pf strains (RI ≤ 1; Table 13) and exhibited variable cytotoxicity against human cells HMEC-1. 
In particular, compound 9a, as CQ, was very safe when tested for cytotoxicity against the human cell line. 
The hybridisation of  the 1,2-dioxane scaffold with 4-amino-7-chloroquinoline (9k-q) generated a series of  
molecules with significantly higher activity against both Pf  strains (Table 14). It should be noted that, as in 
the case of  the derivatives reported in Table 13, the compound that did not exhibit any significant toxicity 
against HMEC-1 cells (9q, Table 14) was the one described by the lowest c Log D value at physiological 
pH. Concerning the antimalarial activity, although it is complicated to discern the role of  the two 
pharmacophoric moieties (i.e., 1,2-dioxane and 4-amino-quinoline); the low IC50 values of  this series of  
compounds against the D10 strain (CQ-S) appear to be caused by quinoline moiety. This hypothesis is 
firstly confirmed by compound 9q. In fact, having only methyl substituents at C3 and C6, the 1,2-dioxane 
moiety of  9q cannot take part to the antimalarial activity; however, this compound was active as CQ on 
D10 (CQ-S) strain (Table 14). Moreover, 9q, due to its lower activity against W2 (CQ-R) strain, showed an 
extended resistance index (RI) than to 9k-p (Table 14). Compounds 9k-p were indeed significantly more 
active than CQ against the W2 (CQ-R) strain with a levelling effect of  IC50 at the 100 nM, which could 
denote the participation of  the endoperoxide pharmacophore to the studied antimalarial activity. 
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Therefore, a synergic and/or a resistance reverting effect of  the two pharmacophores appears to take place 
in the case of  the W2 (CQ-R) Pf strain. The 8-Aminoquinoline including hybrids 9r,s are intriguing, too, 
for the known potential activity against the Pf hepatic stage and as transmission blocking agents. The 
compounds 9r,s exhibited increased IC50 with respect to 9k-p (Table 14) against both CQ-R and CQ-S Pf 
strains.  
In order to investigate the SARs of  this new series of  antimalarial endoperoxides and to identify their 3-D 
structural features accountable for the antimalarial activity, all the compounds reported in Tables 13 and 14 
(9a-j and 9k-s, respectively) were subjected to computational studies. These studies started with the 
estimation of  the ionic forms at pH 7.4, 7.2, and 5.5 (blood, cytoplasm, and Pf  FV) (Table 16). 
Subsequently, in order to investigate the role on antimalarial activity of  a probable accumulation in the FV, 
the distribution coefficient (Log D) values at blood, cytoplasm, and FV pH, were calculated using the 
ACD/Percepta software (version 14.0.0, Advanced Chemistry Development, Inc., Toronto, ON, Canada). 
Results are reported in Tables 17 and 18. Log D is an expression of  the lipophilicity of  the compounds 
which reveals the equilibrium concentration of  ionic forms at a given pH. It is usually accepted195,196 that 
molecules with reasonable lipophilicity (Log D 0-3) show a good balance between permeability and 
solubility and are ideal for cell membrane permeation. When the Log D is included among a 3-5 value, the 
compounds still show a good membrane permeability, but absorption is lower owing to their lower 
solubility. 
 
Table 16 | Calculated ionic forms of  3-methoxy-4-aminomethyl-1,2-dioxanes 9a-s.  
 
Compound Ionic form (%)a 
 pH7.4 pH 7.2 pH 5.5 
9a 
DP(15) 
P(85) 
DP(22) 
P(78) 
DP(93) 
P(7) 
9b 
DP(15) 
P(85) 
DP(22) 
P(78) 
DP(93) 
P(7) 
9c 
DP(15) 
P(85) 
DP(22) 
P(78) 
DP(93) 
P(7) 
9d 
DP(80) 
P(20) 
DP(86) 
P(14) 
DP(100) 
9e 
DP(80) 
P(20) 
DP(86) 
P(14) 
DP(100) 
9f DP(80) DP(86) DP(100) 
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P(20) P(14) 
9g 
DP(2) 
P(98) 
DP(3) 
P(97) 
DP(56) 
P(44) 
9h 
P(68) 
N(32) 
P(77) 
N(23) 
P(99) 
N(1) 
9i 
DP(15) 
P(85) 
DP(22) 
P(78) 
DP(93) 
P(7) 
9j 
DP(15) 
P(85) 
DP(22) 
P(78) 
DP(93) 
P(7) 
9k 
DP(14) 
P(86) 
DP(21) 
P(79) 
DP(100) 
9l 
DP(14) 
P(86) 
DP(21) 
P(79) 
DP(100) 
9m 
DP(14) 
P(86) 
DP(21) 
P(79) 
DP(100) 
9n 
DP(11) 
P(89) 
DP(16) 
P(84) 
DP(100) 
9o 
DP(11) 
P(89) 
DP(16) 
P(84) 
DP(100) 
9p 
DP(11) 
P(89) 
DP(16) 
P(84) 
DP(100) 
9q 
DP(11) 
P(89) 
DP(16) 
P(84) 
DP(100) 
9r P(100) P(100) P(100) 
9s P(100) P(100) P(100) 
aPercentage of  ionic form in brackets. P protonated form; DP di-protonated form (ACD/Percepta software, version 14.0.0, 
Advanced Chemistry Development, Inc., Toronto, ON, Canada).  
Table adapted from Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
 
Table 17 | c Log D values of  3-methoxy-4-aminomethyl-1,2-dioxanes 9a-j.  
 
Compound c Log D 
 pH7.4 pH 7.2 pH 5.5 
9a 0.5 0.3 -1.3 
9b 1.9 1.7 0.1 
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9c 3.2 3.0 1.4 
9d -0.3 -0.6 -1.9 
9e 1 0.8 -0.3 
9f 2.4 2.1 0.8 
9g 0.2 0.0 -0.6 
9h 5.4 5.3 4.0 
9i 0.4 0.2 -1.3 
9j -0.9 -1.1 -2.6 
Table adapted from Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
Table 18 | c Log D values of  3,4-cis-3-methoxy-4-aminomethyl-1,2-dioxanes 9k-s.  
 
Compound c Log D 
 pH7.4 pH 7.2 pH 5.5 
9k 1.9 1.6 0.4 
9l 3.1 2.9 1.7 
9m 4.6 4.4 3.1 
9n 2.1 1.9 0.7 
9o 3.3 3.1 2.0 
9p 4.8 4.5 3.4 
9q 0.8 0.5 -0.6 
9r 2.8 2.7 2.5 
9s 4.1 4.0 3.7 
Table adapted from Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
On the other hand, hydrophilic compounds (Log D < 0) show good solubility but inadequate membrane 
permeability.195,196 Therefore, in conformity with the data reported in Tables 17 and 18, an indisputable 
degree of  accumulation in the FV of  the parasite is expected for all compounds, there is no precise 
correlation between the calculated Log D (c Log D) values and the antimalarial activity. A similar 
observation has been reported for 1,2,4-trioxaquines, molecular hybrids including both a quinoline and 
1,2,4-trioxane pharmacophore moieties. In the new series of  antimalarial endoperoxides, it was true for the 
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endoperoxide derivatives 9a-j but not for the quinoline-hybrids 9k-s (Table 13). The c Log D values did not 
give reasons for the activity trend observed with the insertion of  the amino chain at C4, such as, 3-(1H-
imidazol-1-yl)-N-methylpropan-1-amine (9a-c) > N1,N1,N3-trimethylpropane-1,3-diamine (9d-f) ≈ 
octahydro-1-methyl-1H-pyrido[1,2-a] pyrimidine (9h) > N-methyl-3-morpholinopropan-1-amine (9g). 
Furthermore, compound 9c, conversely from 9a and 9b, should be capable to diffuse back to the parasite 
cytoplasm across the FV membrane. This characteristic did not interfere with the antimalarial activity of  
9a-c, which is almost identical (Table 13). To investigate the role of  the C4 amino-imidazole chain in the 
antimalarial activity of  compounds 9a-c (the amido-imidazole analogue of  9a was inactive),189 compound 
9j was synthesised. Its complete absence of  activity proved that the presence of  at least one butyl chain at 
C3 is essential for antimalarial activity (9j vs. 9a, Table 13). However, due to the unfavourable c Log D value 
at physiological pH (i.e., -0.9, Table 17), the observed inactivity of  9j could be attributed to cellular 
pharmacokinetics. To get an amino-imidazole analogue with increased c Log D without affecting the 
pharmacodynamic features, was used the 3-methoxy-1,2-dioxaspiro[5.6]dodecane moiety. Indeed, in the 
ester series (Table 15), the spiro derivative resulted inactive despite its favourable c Log D, proving that the 
spiro-cycloheptane substituent at C6 do not possess the pharmacodynamic requirements for antimalarial 
activity. Thus, the C4 substituent of  the inactive analogues 4i and 7i was replaced with the amino-imidazole 
chain, synthesising the analogue 9i (Tables 13 and 17). The amino-imidazole derivative 9i showed that, 
when there is a sufficient lipophilicity, just the introduction of  the amino-imidazole chain at C4 is sufficient 
to restore some antimalarial activity (Table 13). In the end, in agreement with the data reported in Tables 
17 and 18, the minimum c Log D7.4 value for activity against human HMEC-1 cell line seems to be +1. 
Indeed, the compounds 9a and 9q, with a c Log D7.4 value < 1, did not have any significant activity. In 
order to continue to rationalise the SARs of  these new antimalarial endoperoxides their conformational 
and electronic properties were investigated. Prevalent ionic forms at cytoplasm and Pf FV pH were 
subjected to an in depth conformational analysis, which included a molecular dynamics (simulated 
annealing, SA) procedure followed by molecular-mechanics (MM) energy minimisation, and the subsequent 
quantum mechanics (QM) full geometry optimisation (MOPAC, PM7) of  the resulting MM minima (see 
Experimental Section for details). The resulting conformers were ranked by their potential energy values 
and grouped into families on the basis of  their 1,2-dioxane ring conformation (Table 19). 
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Table 19 | Occurrence rate (%) of  1,2-dioxane ring conformations considering PM7 conformers within 5 
kcal mol-1 from the GM. 
 
Compound Ionic forma Chair A Chair B Skew boat A Skew boat B 
9a 
P 
DP 
68 
17 
0 
0 
0 
0 
32 
83 
9b 
P 
DP 
17 
0 
0 
0 
0 
0 
83 
100 
9c 
P 
DP 
0 
0 
0 
0 
0 
0 
100 
100 
9d 
P 
DP 
65 
0 
0 
0 
0 
0 
35 
100 
9e 
P 
DP 
71 
0 
0 
0 
0 
0 
29 
100 
9f 
P 
DP 
78 
0 
0 
0 
0 
0 
22 
100 
9g 
P 
DP 
49 
0 
0 
0 
7 
0 
45 
100 
9hb P 9 0 9 82 
9hc P 23 6 0 71 
9i 
P 
DP 
63 
0 
5 
0 
0 
0 
32 
100 
9j 
P 
DP 
41 
0 
0 
0 
0 
0 
59 
100 
9k 
P 
DP 
36 
50 
15 
0 
12 
0 
36 
50 
9l 
P 
DP 
50 
0 
0 
0 
20 
0 
30 
100 
9m 
P 
DP 
29 
0 
13 
0 
29 
0 
29 
100 
9n 
P 
DP 
50 
33 
6 
17 
19 
0 
25 
50 
9o 
P 
DP 
25 
0 
0 
50 
12.5 
0 
62.5 
50 
9p P 25 0 0 75 
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DP 0 0 0 100 
9q 
P 
DP 
45 
20 
7 
0 
13 
0 
35 
80 
9rb P 64 12 3 21 
9rc P 55 17 0 28 
9sb P 50 0 0 50 
9sc P 56 0 0 44 
aDP = di-protonated form, P = protonated form. bDiastereomer with (R)-configured stereocenter in the side-chain. 
cDiastereomer with (S)-configured stereocenter in the side-chain. 
Table adapted from Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
These computational studies evidenced that the series of  derivatives 9 presents particular conformational 
parameters than to the plakortin and the previous synthetic analogues184-189 Indeed, the presence of  the 
amino chain at C4 stabilises the Skew Boat B conformation of  the 1,2-dioxane ring, which becomes by far 
the most populated conformer at the FV pH (Table 19). This boat-like conformation of  the 1,2-dioxane 
ring facilitates accessibility of  endoperoxide oxygens, reproducing the artemisinin endoperoxide ring 
conformation (Figure 68). 
 
 
Figure 68. Superimposition of  PM7 GM of  9b (cyan) in protonated form on artemisinin X-ray structure (pink; CSDS code: 
QNGHSU). The molecules are coloured by atom type (O = red, N = blue, and H = white). Hydrogens are omitted for sake of  
clarity, with the exception of  those involved in the H-bonds (highlighted by a black dashed line). Figure adapted from reference 
Sonawane et al. (2015) with permission from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5ra10785g). 
 
The structural analysis of  all conformers within 5 kcal/mol from the global minimun (GM) pointed out 
that the di-amino derivatives 9d-f and the amino-imidazole derivatives 9a-c, 9j (Table 13), present GM 
conformers displaying comparable conformational characteristics, not only in the protonated (N′) but also 
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in di-protonated (N′ and N″) forms. These conformers resulted to be characterised by the Skew Boat B 
conformation of  the 1,2-dioxane ring which favours the formation of  a network of  intra-molecular H-
bonds, engaging both O1 and the secondary amine N′ (Figure 69).   
 
 
Figure 69. Superimposition of  GM conformers of: (a) 9a (light blue), 9b (light green), 9c (yellow), 9d (pink), 9e (orange), and 
9f (violet); all protonated on N′; (b) 9a (light blue), 9b (light green), and 9c (pink) in di-protonated form; (c) 9d (pink), 9e 
(orange), and 9f (violet); protonated on N′ and N″. The molecules are coloured by atom type (O = red, N = blue, and H = 
white). The heteroatoms involved in H-bonds (highlighted by a black dashed line) are displayed in ball. Hydrogens are omitted 
for sake of  clarity, with the exception of  those involved in H-bonds. Figure adapted from reference Sonawane et al. (2015) with 
permission from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5ra10785g). 
 
Additionally, these low-energy conformers presented, with the exception of  9j, appropriate intra-molecular 
distances for a H-shift from a butyl chain to the putative oxygen radical, in agreement with the developed 
pharmacophoric model (Figures 69 and 70).  
 
 
Figure 70. PM7 GM of  9c presenting intra-molecular distances suitable for the 1,5-H shift in protonated (cyan; a) and di-
protonated (pink; b) form. Atoms are coloured by atom type (O = red, N = blue, and H = white). Hydrogens are omitted for 
sake of  clarity, with the exception of  those involved as possible partners in a “through-space” intra-molecular radical shift and in 
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the H-bonds (highlighted by a black dashed line). Figure adapted from reference Sonawane et al. (2015) with permission from 
the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5ra10785g). 
In order to clarify the effect of  this conformational behaviour on antimalarial activity, a dynamic docking 
study of  9c-heme complex was performed. The protonation state both of  9c and heme has been evaluated 
taking into consideration the FV pH, where heme digestion predominantly occurs.197 Both heme 
parameters and atomic partial charges were attributed employing the QM method (PM7). Throughout the 
dynamic docking calculation, which combines Monte Carlo and SA methods, all rotatable bonds of  9c and 
heme are let completely free to move. The docking results showed only one possible complex structure 
(Figure 71). The resulting docked complex was then subjected to a full geometry optimisation by the semi-
empirical QM method PM7 (for details see Experimental Section). 
 
 
 
Figure 71. Docking results of  9c (protonated on N′ and N″) in complex with heme. The molecules are coloured by atom type 
(C = cyan; O = red; N = blue; Fe = orange and H = white). Iron atom vdW volume is shown (scaled by 50% for clarity of  
presentation). Hydrogens are omitted for sake of  clarity, with the exception of  those involved in H-bonds (highlighted by a 
black dashed line). Figure adapted from reference Sonawane et al. (2015) with permission from the Royal Society of  Chemistry 
(http://dx.doi.org/10.1039/c5ra10785g). 
 
The obtained conformation of  9c exhibited the key characteristics (i.e., Skew Boat B and O1-N′ 
interaction) of  the GM conformer identified by the conformational search (Figure 69b). In addition, the 
both protonated nitrogens N′ and N″ set up charge-assisted H-bonds with the ionised and neutral 
propionic groups of  heme, analogously to what mentioned for the protonated amine chain of  CQ.198 As 
stated above, at Pf  FV pH, when the two basic centers are protonated, compounds 9a-f exhibited a higher 
propensity for the Skew Boat B conformation and the H-bond between N′ and O1 (Table 17 and Figure 
69). For the compounds 9a-c, this is caused by a shortage of  an additional electron donating group (i.e., 
not protonated imidazole) contending with the endoperoxide oxygen O1 the favourable interactions (i.e., 
cation-π) with the protonated secondary amine N′ (Figures 70a vs. 70b). On the contrary, the compounds 
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9d-f resulted to be characterised by an additional stabilisation of  the Skew Boat B conformation, due to the 
interaction of  the distal and protonated tertiary amine group (N″) with O1, O2, and O7 (Figures 69a vs. 
69c). Consequently, the only thing different between the amino-imidazole and the di-amino derivatives (9a-
c and 9d-f, respectively) is that, in the di-protonated form, the GM conformers assume a lying 
conformation of  the substituent at C4, with the protonated imidazole ring orienting far away from the 
remaining molecule portion. Therefore, the 9a-c GM conformers reflect the heme interacting 
conformation obtaining from docking simulations (Figure 71). On the other hand, in the 9d-f GM 
conformers the protonated tertiary amine N″ is bonded through a H-bond to O1, O2, and O7 (Figures 69a 
vs. 69b). As a consequence, when the di-amino derivatives (9d-f) approach heme, the distal protonated 
amine N″ should first of  all disrupt the intra-molecular H-bonds to form ionic interactions with the 
propionate groups. This could explain the total greater antimalarial activity of  9a-c with respect to 9d-f 
(Table 13). In agreement with the apparent pKa values (Table 16), differently from compounds 9a-f, the less 
active morpholine analogue 9g results even mono-protonated at the acidic FV pH (44%). In this form, the 
9g GM conformer does not adopt either the Skew Boat B conformation or the O1-N′ interaction, and the 
first conformer having such characteristics is at ≈ 1 kcal/mol from the GM. On the contrary, in the di-
protonated form, 9g showed the same conformational features of  9d-f (Figure 69c), with the protonated 
tertiary amine (N″) establishing H-bonds with O7. For this reason, even in the case of  di-protonated 9g, 
the morpholine nitrogen could be involved in an extra-interaction with heme propionate after dsirupting its 
intra-molecular H-bond. A specific case is constituted by compound 9h (W2 IC50 = 400 nM, Table 13), 
analysed as a mixture of  two different diastereomers due to the stereogenic carbon of  the bi-cyclic ring. In 
this analogue, the two basic nitrogens (single pKa1: 7.56 ± 0.20 and single pKa2: 7.24 ± 0.20) are forced into 
a bi-cyclic structure and, in agreement with the calculated apparent pKa value, only the mono-protonated 
form is available at cytoplasm and FV pHs (Table 16).  In order to investigate the role of  the bicyclic ring 
on the antimalarial activity, 9h diastereomers were subjected to the same docking procedure applied to 9c 
(see for details Experimental Section). These studies evidenced, also in this case, only one possible complex 
structure for each 9h diastereomer. According to the conformational analysis results, even though not 
exhibiting the H-bond between N′ and O1, the two diastereomers still showed the Skew Boat B of  the 1,2-
dioxane ring as bioactive conformation with the two conformationally restricted amine nitrogens 
appropriately well-positioned to interact with the negatively charged heme propionate group (Figure 72).  
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Figure 72. Superimposition of  the putative bioactive conformer of  9h (a) (pink): (R)-configured stereocenter in the side-chain; 
(b) (yellow): (S)-configured stereocenter in the side-chain) on the docking results of  9c in complex with heme (cyan). The 
molecules are coloured by atom type (O = red; N = blue; Fe = orange; H = white). Iron atom vdW volume is shown (scaled by 
50% for clarity of  presentation). Hydrogens are omitted for sake of  clarity, with the exception of  those involved in H-bonds 
(highlighted by a black dashed line). Figure adapted from reference Sonawane et al. (2015) with permission from the Royal 
Society of  Chemistry (http://dx.doi.org/10.1039/c5ra10785g). 
 
Lastly, also the amino-imidazole spiro derivative (9i; Table 13) present the di-protonated form at FV pH 
(Table 16). The GM conformer of  this form shows the Skew Boat B and the O1-N′ interaction, but, in 
agreement with experimental peroxide oxygen-heme iron distances collected from the Cambridge 
Structural Database,199 the presence of  the stiff  spiro-cycloheptane at C6 compromises the endoperoxide 
approach to heme (Figure 73).  
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Figure 73. Di-protonated form of  9i in complex wih heme superimposed (coordination O2/O7) on the X-ray structure of  
peroxo-bridged heme complex (CSD code: UKACIS). The molecules are coloured by atom type (C = pink and cyan for PM7 
conformer and heme, respectively; O = red; N = blue; Fe = orange; H = white). The solvent accessible surface of  atoms 
responsible for steric hindrance between 9i and heme is shown (transparency = 50%). Iron atom vdW volume is shown (scaled 
by 50% for clarity of  presentation). Hydrogens are omitted for sake of  clarity, with the exception of  those involved in the intra-
molecular H-bonds (highlighted by a black dashed line). Figure adapted from reference Sonawane et al. (2015) with permission 
from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5ra10785g). 
 
The conformational behaviour of  the endoperoxide-aminoquinoline hybrids (9k-s; Table 14) was 
examined by employing the same computational procedure used for 9a-j. In these compounds, the bulky 
quinoline moiety produced a less homogenous conformational behaviour of  the low energy conformers of  
9k-s. In fact, because of  hydrophobic interaction between the quinoline system and the butyl chain(s), the 
conformational properties are affected by the substitution at C6 (Table 19). However, the 9k-s GM 
conformers are still characterised by the Skew Boat B, in the mono-protonated and di-protonated forms. 
The endoperoxide-7-chloroquinoline hybrids (9k-q; Table 14) are completely present in the di-protonated 
form at FV pH, while they are mainly (≈ 80%) mono-protonated at cytoplasm pH (Table 16). Taking into 
account the mono-protonated form, N′ presents a H-bonded with O1 and O7 in 9k, 9n, and 9q (Figure 
74a), and only with O1 in 9l, 9m, 9o, and 9p (Figure 74b).   
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Figure 74. GM conformers of: (a) 9k (green) and 9n (pink) (protonated on N′); (b) 9m (green) and 9p (pink) (protonated on 
N′); (c) 9m (green) and 9q (pink) (protonated on N′ and N″). The molecules are coloured by atom type (O = red, N = blue, and 
H = white). The heteroatoms involved in H-bonds (highlighted by a black dashed line) are displayed in ball. Hydrogens are 
omitted for sake of  clarity, with the exception of  those involved in H-bonds. Figure adapted from reference Sonawane et al. 
(2015) with permission from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5ra10785g). 
 
Differently, in the di-protonated form N′ presents a H-bonded with O1 (9k-m) or O7 (9n-q), while N‴ 
continues to interact with O1, O2, and O7 (Figure 74c). Therefore, the precise pattern of  intra-molecular 
H-bonds is induced by the butyl chains at C6 in the protonated forms (Figures 74a and 74b), and by the 
length of  the alkyl chain that connects the two protonated amino groups in the di-protonated forms 
(Figure 74c). It should be noted that, the 9k-q GM conformers exhibit the quinoline nitrogen (N″) 
accessible to heme iron interaction, while the endoperoxide function is sterically obstructed by the 
quinoline ring (Figure 74). The primaquine-type hybrids (9r and 9s) only appear in the mono-protonated 
form at FV and cytoplasm pH (Table 16); moreover, as showed for the mono-protonated GM conformers 
(9k-q), due to the presence of  the butyl chains at C6 N′ is H-bonded with only O1, or O1 and O7 (Figure 
75). 
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Figure 75. GM conformers of: (a) 9r diastereomer with (S)-configured stereocenter in the side-chain (green) and diastereomer 
with (R)-configured stereocenter in the side-chain (pink); (b) 9s diastereomer with (R)-configured stereocenter in the side-chain 
(green) and diastereomer with (S)- configured stereocenter in the side-chain (pink). The molecules are coloured by atom type (O 
= red, N = blue, and H = white). The heteroatoms involved in H-bonds (highlighted by a black dashed line) are displayed in 
ball. Hydrogens are omitted for sake of  clarity, with the exception of  those involved in H-bonds. Figure adapted from reference 
Sonawane et al. (2015) with permission from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5ra10785g). 
 
In opposite way to 9k-q, in 9r-s hybrids the quinoline ring does not hamper the endoperoxide group 
(Figures 74a and 74b vs. Figures 75a and 75b).  
Taken all together, these results evidenced the key role played by the amine chain at C4 on the antimalarial 
activity. In this view, the SARs of  our new compounds was examined. Some amines are well-known to be 
efficient as antimalarials200,201 or to be present as additional pharmacophoric features in different 
antimalarial compounds.190-192 Accordingly, the new series of  endoperoxides 9a-s showed an improved 
antimalarial activity with respect to the previous analogues, thanks to the amine substituent at C4. This 
enhancement in the activity can be assigned to cellular pharmacokinetics and/or pharmacodynamics. 
Polyamines play a key role as radical scavengers in biological environments202 and their capability to shuttle 
a free-radical from oxygen to carbon atoms has been extensively studied.203-207 Thus, the polyamine 
substituent could promote the activity of  molecular scaffolds, the activity of  which is rigorously connected 
to their redox potential by playing a critical role in the formation/propagation of  toxic radical species. 
Additionally, for compounds presumed to interact with heme in free form, a basic chain could be 
implicated in favourable interactions with heme propionate groups. In this respect, the conformational 
analysis carried out on molecules of  the series 9 unveiled a strong penchant of  the protonated secondary 
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amine to form H-bond with O1, stabilising a 1,2-dioxane ring conformation which facilitates peroxide 
oxygen accessibility. This was proved by dynamic docking calculation on 9c-heme complex, pointing out 
favourable interactions between the polyamine chain and the heme propionate groups. Once this pre-
reactive complex was formed, a potential scenario is that, after the Fe(II) catalysed production of  the 
distonic radical anion, the secondary amine could, at the same time, protonate the oxygen anion and shuttle 
the oxygen radical to an adjacent carbon through a hydrogen radical shift.203-207 Additionally, the presence 
of  such multiple basic functionalities may favour the accumulation of  compounds 9a-s in the acidic FV of  
the parasites. More than be reached thanks to a polyamine transporter,208,209 most probably this could be 
achieved to an insufficiency of  the back diffusion across the membrane of  a single or double protonated 
derivative. Calculated pKa and Log D values at cytoplasm and FV pH suggested that compounds 9a-s can 
accumulate in the parasite FV but no linear correlation was observed between the antimalarial activity and 
the c Log D values, pointing out that additional parameters also influence the antimalarial activity. It is 
important to underline that most of  the low energy conformers (i.e., within 5 kcal/mol from the GM) of  
compounds 9a-s show an intra-molecular H-bond between the two amine functions. The formation of  
intra-molecular H-bonds taking part in ionised groups, can “mask” the molecule charge and influence its 
passage across cellular membranes. The subgroup of  1,2-dioxanes 9k-s hybridises two biologically active 
entities, the 1,2-dioxane scaffold and a quinoline-based pharmacophore. In the recent years examples of  
artemisinin-quinolines hybrids have been reported.210-212 A recent study shows the most intriguing results 
achieved with hybrid molecules including fully synthetic 1,2,4-trioxanes or 1,2,4-trioxolane and an 
aminoquinoline derivative.213,214 These hybrid molecules show a double mode of  action, a concept 
concerned to as “covalent biotherapy”, thus they favour heme alkylation with the peroxy entity, and heme 
stacking with the aminoquinoline moiety resulting in a strengthened inhibition of  haemozoin 
formation.215,216 Killing the parasite by two different mechanisms has also the advantage of  reducing the 
development of  resistance.217 For the hybrids 9k-p, the increased activity of  CQ compared to the peroxide 
moiety is probable to play an important role in the antimalarial activity against Pf CQ-S strains. Contrarily, 
9k-p are more active compared to chloroquine against Pf CQ-R strains and resulting SARs suggest that the 
peroxide pharmacophore is responsible for this increased antimalarial activity. It cannot be ruled out the 
possibility that the improved activity against CQ-R strains is ascribable to the modification of  the basic side 
chain of  CQ, which would not to be recognised by the mutated CQ-transporter. With respect to CQ, 
primaquine is well-known to be poorly active in vitro against Pf  infected erythrocytes, not only on CQ-S but 
also on CQ-R strains (W2 IC50 = 3.3 µM).
212 Accordingly, the antimalarial activity showed by the hybrids 9r 
and 9s has to be ascribed to the mechanism of  action of  the peroxide group, while the primaquine moiety 
acts, in this specific case, as an amine-containing C4 substituent. In summary, optimisation of  the cellular 
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pharmacokinetics of  this series of  antimalarial peroxides by means of  the introduction of  a substituted 
amino side-chain at C4, appears not to be the only factor accountable for their improved antimalarial 
activity (Figure 76). 
 
 
Figure 76. Drawings of  the SARs of  the 4-methylamino-1,2-dioxanes 9a-s. Figure adapted from reference Sonawane et al. 
(2015) with permission from the Royal Society of  Chemistry (http://dx.doi.org/10.1039/c5ra10785g). 
 
As previously discussed,187-189 the substituent at C4 could also affect the pharmacodynamic properties, 
having an effect on the ability of  the peroxide bridge to undergo reductive cleavage and to generate and/or 
to propagate the putative toxic radical chain. Molecular modelling studies put forward that the increased 
antimalarial activity is correlated to the stabilisation of  a conformation which promotes the assumed 
reductive cleavage of  the endoperoxide bridge with a probable participation of  the inserted amine 
functions in toxic radical formation and/or propagation. This is well-supported by the fact that 
substituting the amide group with an amino group increased the antimalarial activity and determined 
distinct SARs. Indeed, the 9a amido-imidazole analogue (which presents one butyl chain at C3; W2 (CQ-R) 
IC50 = 0.21 μM) resulted to be inactive as antimalarial, while the 9b amido-imidazole analogue (which 
presents two butyl chains at C6, W2 (CQ-R) IC50 = 0.4 μM) was one of  the most active derivative (W2 
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(CQ-R) IC50 = 0.5 μM).
188 Therefore, substituting the amide with an amino group increased the antimalarial 
activity in an independent manner from the position of  the butyl chain(s). However, the lack activity of  9j 
proved the necessity of  at least one butyl chain at C3 (9j vs. 9c), the activity of  9i compared to its analogues 
4i and 7i pointed out that the secondary amine function at C4 is enough to restore some antimalarial 
activity and that the inactivity of  9j is probably due to an unfavourable Log D. In this respect, it has to be 
underlined that, in agreement with c Log D7.4 values, the minimum threshold of  lipophilicity to be active 
against infected erythrocytes and normal human cells, is ~ -1 and ~ +1, respectively. Accordingly, 
compound 9a, which has a c Log D7.4 = 0.5, presents a IC50 of  210 nM against Pf W2 strain (CQ-R) and is 
inactive on human HMEC-1 cells, showing an optimal SI. 
In conclusion, the introduction of  a substituted amine chain on easily accessible 3-methoxy-1,2-dioxane 
scaffold led to a significant improvement of  the antimalarial activity as result of  a combination of  
pharmacokinetic and pharmacodynamics effects that, rationalised in the light of  the developed 
pharmacophoric model, can steer the development of  further optimised 1,2-dioxane antimalarials. 
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Chapter 6 
 
EXPERIMENTAL SECTION: MOLECULAR MODELLING STUDIES 
 
Molecular modelling calculations were performed on SGI Origin 200 8XR12000 and E4 Server Twin 2 x 
Dual Xeon 5520, equipped with two nodes. Each node: 2 x Intel Xeon QuadCore E5520, 2,26Ghz, 36 GB 
RAM. The molecular modelling graphics were carried out on a personal computer equipped with Intel(R) 
Core (TM) i7-4790 processor and SGI Octane 2 workstations. 
 
6.1 Sampling procedure of the conformational space of the ligands  
 
6.1.1 Theoretical Background 
 
The detailed analysis of  the ligand conformational behaviour is a central task for the identification of  the 
structural features responsible for the observed biological activity and, then, for the molecular design of  
new optimised analogues.170 At this aim, several conformational sampling methods were developed. These 
sampling methods fall into two broad categories: systematic search and stochastic methods.171 The choice 
of  the most suitable method depends on the flexibility of  the ligands under study (i.e., number of  torsional 
angles). Indeed, although the systematic search can be very effective for molecules with limited 
conformational flexibility, the exponential growth of  the search space with the number of  rotatable bonds 
limits its utility as a general conformational sampling technique. Then, for flexible molecules, it is necessary 
to use stochastic methods, such as simulated annealing (SA),40,218 which rely on probabilistic descriptions to 
generate conformations of  a molecule and to aid in locating the global minimum. Accordingly, in order to 
exhaustively sample the conformational space of  the ligands considered in my research projects, a 
computational protocol which combines SA method with MM energy minimisation calculations was 
applied.218 
SA is based on a connection between statistical mechanics and the process of  crystallisation. If  a physical 
system is heated until it melts, and then cooled slowly, the entire arrangement can be made to produce the 
most stable arrangement, and not get trapped in a local minimum. The idea here is to randomly rotate 
bonds and bend rings within the molecule until a preferential (minimum energy) geometry is attained. 
Initially, during SA simulation, the molecule is considered to be in a high-temperature system; this means 
that it has enough energy to move from low to high energy conformations. This is important because often 
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the global minimum conformation of  a molecule may be very different from the initial conformation. As 
more conformations are explored, the temperature of  the system decreases, making the molecule less 
inclined to move out of  low energy conformations, and thus looking more closely at other minima. 
Accordingly, in SA, the temperature is altered in time increments from an initial temperature to a final 
temperature by adjusting the kinetic energy of  the structure (by rescaling the velocities of  the atoms) for 
identifying the minimum conformers.  
 
6.1.2 Conformational sampling procedure 
 
The conformational space of  all compounds is sampled through a number of  cycles of  simulated 
annealing calculations (ε = 80*r and ε = 1). The number of  cycles was selected on the bases of  the number 
of  torsional angles of  the compounds. The following protocol was applied: the system was heated to 1000 
K over 2000 fs (time step of  3.0 fs); a temperature of  1000 K was applied to the system for 2000 fs (time 
step of  3.0 fs) to surmount torsional barriers.; successively, temperature was linearly reduced to 300K in 
1000 fs (time step of  1.0 fs). Resulting conformations were then subjected to Molecular-mechanics (MM) 
energy minimisation within the Insight 2005 Discover Module until the maximum RMSd was less than 
0.001 kcal/Å, using Conjugate Gradient219 as minimisation algorithm. The resulting MM conformers were 
then subjected to a full geometry optimisation by semiempirical calculations, using the quantum mechanical 
method PM772 in the MOPAC2012 package73 and EF (eigenvector following routine)74 as geometry 
optimisation algorithm. GNORM value was set to 0.01. To reach a full geometry optimisation, the criterion 
for terminating all optimisations was increased by a factor of  100, using the keyword PRECISE.  
 
6.2 Monte Carlo/Simulated Annealing based docking protocol 
 
6.2.1 Theoretical Background 
 
Understanding the molecular mechanisms underlying conformational changes of  proteins is a critical issue 
for the design of  new drugs and for the investigation of  their mechanism of  action. Accordingly, in 
protein-protein and ligand-protein interaction simulations is essential to consider protein flexibility. At this 
aim, as already reported in the paragraph 1.2.1 “Classification of  CADD approaches”, several 
computational methods have been developed for the investigation of  ligand-protein or protein-protein 
interactions.35,36 The choice of  the most suitable method depends on the biological and physical 
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characteristics of  the protein under study and in order to improve the overall quality of  the simulations, 
hybrid approaches have also been developed.47-51 On the bases of  the above considerations, as docking 
procedure, a Monte Carlo minimisation/SA57,68,69 based docking protocol was applied (Affinity, 
SA_Docking; Insight 2005, Accelrys, San Diego, CA). Monte Carlo minimisation method is a combination 
of  random moves and energy minimization.69 This method moves the ligand by random combination of  
translation, rotation, and torsional changes. The random move of  ligand samples both the orientational 
and conformational spaces of  the ligand with respect to the target protein. The Monte Carlo moves are 
useful in getting over energy barriers, while energy minimisation is for locating energy minima. Then, 
following the principles of  statistical mechanics, Monte Carlo simulation produces acceptable different 
conformations of  ligand-protein or protein-protein complexes, which will be then subjected to the SA 
calculation. The combination of  such sampling method with SA  allows to evaluate ligand-induced large 
scale conformational changes enhancing the fixing of  the ligand into the binding site.70 
6.2.2 Dynamic docking procedure 
 
 The dynamic docking procedure formally requires a reasonable starting structure. Accordingly, the starting 
complex was subjected to a preliminary energy minimisation to generate roughly docked starting structure 
(Steepest Descent algorithm, maximum RMSd = 1 kcal/Å; ε=1; Discover_3 Module of  Insight2005). 
During these calculations, in order to fully explore all possible binding sites/modes (i.e., ligand flexibility) 
and to investigate the putative large-scale ligand induced motions in the protein (i.e., protein flexibility), the 
binding domain area was defined as the whole of  protein target.  
A Monte Carlo/minimisation approach for the random generation of  a maximum of  20 acceptable 
complexes was used. During the first step, the ligand was moved by a random combination of  translation, 
rotation, and torsional changes (Flexible_Ligand option, considering all rotatable bonds) to sample both 
the conformational space of  the ligand and its orientation with respect to the protein target (MxRChange 
= 3 Å; MxAngChange = 180°). Moreover, van der Waals (vdW) and Coulombic terms were scaled to a 
factor of  0.1 to avoid very severe divergences in the Coulombic and vdW energies. If  the energy of  a 
complex structure resulting from random moves of  the ligand was higher by the energy tolerance 
parameter than the energy of  the last accepted structure, it was not accepted for minimisation. To ensure a 
wide variance of  the input structures to be successively minimised, an energy tolerance value of  106 kcal 
mol-1, from the previous structure has been used. After the energy minimisation step (conjugate gradient, 
2500 iterations), the energy test, with an energy range of  50 kcal/mol, and a structure similarity check (rms 
tolerance = 0.3 kcal/Å) was applied to select the 20 acceptable structures.  Each subsequent structure was 
generated from the last accepted structure. All the accepted complexes resulting from the Monte 
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Carlo/minimisation approach were subjected to a molecular dynamic simulated annealing protocol, 
including 5 ps of  a dynamic run divided in 50 stages (100 fs each) during which the temperature of  the 
system was linearly decreased from 500 to 300 K (Verlet velocity integrator; time step of  1.0 fs). In 
simulated annealing, the temperature is altered in time increments from an initial temperature to a final 
temperature. The temperature is changed by adjusting the kinetic energy of  the structure (by rescaling the 
velocities of  the atoms). Molecular dynamics calculations were performed using a constant temperature 
and constant volume (NVT) statistical ensemble, and the direct velocity scaling as temperature control 
method (temp window = 10 K). In the first stage, initial velocities were randomly generated from the 
Boltzmann distribution, according to the desired temperature, while during the subsequent stages initial 
velocities were generated from dynamics restart data. The temperature of  500 K was applied with the aim 
of  surmounting torsional barriers, thus allowing an unconstrained rearrangement of  the “ligand” and the 
“protein” binding site (initial vdW and Coulombic scale factors = 0.1). Successively temperature was 
linearly reduced to 300 K in 5 ps, and, concurrently, the vdW and Coulombic scale factors have been 
similarly increased from their initial values (0.1) to their final values (1.0). A final round of  105 minimisation 
steps (Conjugate Gradient algorithm)219 followed the last dynamics steps, and the minimised structures 
were saved in a trajectory file. After this procedure, the resulting structures were analysed. 
 
6.3 Allosteric Inhibitors of the GBP1-PIM1 Complex: Experimental Procedure 
 
Conformational Analysis of  the New Aza-podophyllotoxin Derivatives. The apparent pKa values of  
aza-podophyllotoxin derivatives were calculated by using the ACD/pKa DB, version 12.00, software 
(Advanced Chemistry Development Inc., Toronto, Canada).220 All compounds were considered neutral in 
all calculations performed as a consequence of  the estimation of  percentage of  neutral/ionised forms 
computed at pH 7.4 (physiological value) and pH 7.2 (cytoplasmic value) using the Handerson-Hasselbalch 
equation. The compounds were built using the Insight 2005 Builder Module (Accelrys Software Inc., San 
Diego, CA). Atomic potentials and charges were assigned using the CVFF force field.130 The 
conformational space of  the compounds was sampled using 200 cycles of  SA and the dielectric constant 
of  the vacuum (ε = 1) (for details see the procedure described in the paragraph 6.1 “Sampling procedure of  the 
conformational space of  the ligands”). Resulting conformers were grouped into families on the basis of  their 
torsional angles and ranked by their potential energy values (i.e., ΔE from the GM).  
 
 
 
120 | P a g e  
 
Bioinformatics Analysis. The experimentally determined structures of  i) 1-Tubulin complex (PDB ID: 
1SA1), ii) 2-TopoIIβ complex (PDB ID: 3QX3), (iii) GBP1 (PDB IDs: 2B8W, 2B92, 2BC9, 2D4H, 1DG3, 
1F5N), and (iv) PIM1 (PDB IDs: 4MBL, 4K0Y, 4K18, 4K1B, 4JX7, 4JX3, 4GW8, 4ENX, 4ENY, 4DTK, 
4AS0, 4ALW, 4ALV, 4ALU, 4A7C, 3VC4, 3VBW, 3VBX, 3VBY, 3VBV, 3VBT, 3VBQ, 3UIX, 3UMW, 
3UMX, 3T9I, 3R00, 3R01, 3R02, 3R04, 3QF9, 3MA3, 3JXW, 3JY0, 3JYA, 3JPV, 3F2A, 3-DCV, 3CXW, 
3CY2, 3CY3, 3C4E, 3BWF, 3BGP, 3BGQ, 3BGZ, 3A99, 2XIZ, 2XIY, 2XIX, 2XJ0, 2XJ2, 2XJ1, 2J2I, 
2OI4, 2O3P, 2O63, 2O64, 2O65, 2OBJ, 2C3I, 2BZH, 2BZI, 2BZK, 2BZJ, 2BIK, 2BIL, 1YWV, 1YXS, 
1YXT, 1YXU, 1YXV, 1YXX, 1YHS, 1YI3, 1YI4, 1XWS, 1XQZ, 1XR1) were downloaded from the 
Protein Data Bank (PDB; http://www.rcsb.org/pdb/). Hydrogens were added to all the PDB structures 
assuming a pH of  7.2. These structures were analysed using Biopolymer and Homology Module of  Insight 
2005 (Accelrys, San Diego). Linear functional motifs present in i) Tubulin podophyllotoxin binding site 
(i.e., within a 5 Å radius from any given ligand atom), ii) TopoIIβ etoposide binding site, iii) GBP1, and iv) 
PIM1 were identified by using the Eukaryotic Linear Motif  server (http://elm.eu.org/),51 a resource for 
predicting small functional sites in eukaryotic proteins. The identified motifs in GBP1 and PIM1 were 
logically intersected with the union of  those present in the binding sites of  Tubulin and Topoisomerase. 
This allowed us to identify the putative binding site of  3 in GBP1, characterised by three linear functional 
motifs present in Tubulin and/or TopoIIβ binding sites. 
 
Modelling of  GBP1 and PIM1. The molecular models of  i) full-length human GBP1 in free form; ii) 
full-length human GBP1 in complex with GDP•AlF3, and iii) full-length human PIM1 in free form 
structures were built as described below. All subsequent structural calculations were performed using the 
CVFF force field.130 
 
Modelling of  GBP1 in free form. The molecular model of  full length human GBP1 in free form was built 
starting from the experimentally determined structure of  full-length human free GBP1 (hGBP1FL; PDB 
ID: 1DG3), which lacks four loops (aa63-73, 157-166, 190-193, and 244-256), the N-terminal region (aa1-
5) and the C-terminal region (aa584-592). The sequence of  1DG3 was aligned with the sequence of  
hGBP1FL downloaded from the UniProtKB/Swiss-Prot Data Bank (http://www.uniprot.org; entry 
P32455) by using the Multiple_Alignment algorithm (Homology Module, Accelrys, San Diego). 
Subsequently, the secondary structure prediction of  the hGBP1FL was performed using the Structure 
Prediction and Sequence Analysis server PredictProtein (http://www.predictprotein.org/). The coordinates 
of  the structurally conserved regions (SCRs) aa6-62, 74-156, 167-189, 194-243, and 257-583 of  hGBP1FL 
were accordingly assigned by the SCR-AssignCoords procedure (Homology Module) using 1DG3 as 
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template structure. The lacking loop segments aa63-73, 157-166, 190-193, and 244-256 were inserted by 
using the Generate Loops procedure. With the Generate Loops procedure, a peptide backbone chain is 
built between two conserved peptide segments using randomly generated values for all the loops' φ’s and 
ψ’s. The chain was defined starting from the N-terminal end of  the loop being built; the Start and Stop 
Residues were defined as the SCR residues of  the model protein at either end of  the loop itself. The 
geometry about the base was described by the four distances between Cα and N-termini of  the Start 
residue and the Cα and C-termini of  the Stop Residues. In the process of  closing the loop, the values for 
the generated φ’s and ψ’s are adjusted until the four distance criteria are met. Specifically, a function was 
defined for the distances in terms of  the dihedral angles (Scale Torsions = 60). The differences between 
the desired distances and their current values were minimised using a linearised Lagrange multiplier 
method. After a series of  1000 iterations, the loop was closed, except in the case where the distances 
between the ends of  the loop were not respected (Convergence = 0.05). The geometry at the base of  the 
loop is then checked for proper chirality. Finally, the loops were screened on the basis of  steric overlap 
violations. All loops that are found to have unacceptable contacts were rejected. Since successive 
calculations can correct some bad contacts, a fairly large overlap factor was used (Internal and External 
overlap = 0.6). A bump check of  the 10 generated loops together with the evaluation of  their 
conformational energy were used as selection criteria. The lowest conformational energy loop presenting 
no steric overlap with the rest of  the protein, was selected. Finally, the coordinates of  the N-terminal and 
C-terminal amino acids (aa1-5 and aa584-592, respectively) were assigned using the EndRepair command 
in Homology Module of  Insight 2005. In particular, according to results obtained from the secondary 
structure prediction, the residues aa584-585 (with the standard geometry of  an α-helix) and the residues 1-
5 and 584-592 (with an extended chain conformation) were appended to the molecular model of  hGBP1FL. 
The molecular model of  hGBP1FL was completed inserting the water molecules of  GBP1 experimentally 
determined structure (PDB ID: 1DG3) through the Modify/UnMerge and Modify/Merge commands 
(Biopolymer Module, Accelrys, San Diego). The entire GBP1 model was then subjected to a full energy 
minimisation within Insight 2005 Discover_3 Module (Steepest Descent algorithm, maximum RMSd = 10 
kcal/Å; Conjugate Gradient algorithm, maximum RMSd = 1 kcal/Å; ε = 1). During the minimisation, only 
the whole disordered N- and C-terminal and loop backbone and side chains were left free to move, 
whereas the SCRs of  GBP1 were fixed to avoid unrealistic results. Each step of  refining procedure was 
followed by a structural check by using the Struct_Check command of  the ProStat pull down in the 
Homology Module to verify the correctness of  the geometry optimisation procedure before moving to the 
next step. Checks included φ, ψ, χ1, χ2, χ3 and ω dihedral angles, Cα virtual torsions, and Kabsch and 
Sander main chain H-bond energy evaluation. The final generated model was checked for quality using 
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Procheck structure evaluator software.70 The obtained hGBP1FL model was used for successive dynamic 
docking studies. 
Modelling of  GBP1 in complex with GDP•AlF3. The molecular model of  full-length human GBP1 in complex 
with GDP•AlF3 was built using as template the experimentally determined structure of  full-length human 
GBP1 in complex with the substrate analogue GppNHp (PDB ID: 1F5N), which lacks one loop (aa158-
164), the N-terminal region (aa1-6) and the C-terminal region (aa584-592). The sequence of  1F5N was 
aligned with the sequence of  hGBP1FL downloaded from the UniProtKB/ Swiss-Prot Data Bank 
(http://www.uniprot.org; entry P32455) by using the Multiple_Alignment algorithm (Homology Module, 
Accelrys, San Diego). Then, the secondary structure prediction of  the hGBP1FL was performed using the 
Structure Prediction and Sequence Analysis server PredictProtein (http://www.predictprotein.org/). The 
coordinates of  the structurally conserved regions aa7-157 and aa165-583 of  hGBP1FL were accordingly 
assigned by the SCR-AssignCoords procedure of  Homology using 1F5N as template structure. Thus, the 
obtained model of  hGBP1FL, in which the lacking loop segment aa158-164, was inserted by using the 
Generate Loops procedure (for the procedure see previous paragraph). Finally, the coordinates of  the N-
terminal and C-terminal (aa1-6 and aa584-592, respectively) were assigned using the EndRepair command 
in Homology Module of  Insight 2005. In particular, the residues aa584-585 (with the standard geometry 
of  an α-helix) and the residues aa1-6 and aa584-592 (with an extended chain conformation) were appended 
to the molecular model of  hGBP1FL. The obtained model of  hGBP1FL was completed inserting, through 
the Modify/UnMerge and Modify/Merge commands (Biopolymer Module, Accelrys, San Diego), i) 
GDP•AlF3 and Mg
2+ ion of  hGBP1LG experimentally determined structure (PDB ID: 2B92) and ii) the 
water molecules, combining those of  hGBP1FL in complex with the substrate analogue GppNHp (PDB 
ID: 1F5N) with those of  hGBP1LG in complex with GDP•AlF3 (PDB ID: 2B92). The obtained model of  
GDP•AlF3-bound hGBP1
FL was then subjected to a full energy minimisation within Insight 2005 
Discover_3 Module (Steepest Descent algorithm, maximum RMSd = 10 kcal/Å; Conjugate Gradient 
algorithm, maximum RMSd = 1 kcal/Å; ε = 1). The partial charges to the nucleotide, were assigned by 
comparing partial charges assigned by CVFF force field with those estimated by MNDO221 semi-empirical 
1 SCF calculations for ionised nucleotide. In particular, CVFF force field partial charges were added to the 
algebraic difference between MNDO partial charges of  the tri-anionic and di-anionic form for GDP. 
During the minimisation, quadratic distance or torsion restraints were applied on the SCRs to avoid 
unrealistic results. To identify the SCRs, the hGBP1FL sequence (UniProtKB/Swiss-Prot Data Bank; entry 
code GBP1: P32455) was analysed using the Structure Prediction and Sequence Analysis Server Predict 
Protein (http://www.predictprotein.org/). In GBP1, sixteen α-helix and seven β-sheet secondary structures 
were predicted to be conserved (α0: aa25-33; α1: aa51-59; α2: aa112-123; α3: aa136-151; α3’: aa169-172; α4: 
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aa198-207; a4’: aa221-229; α5: aa260-272; α6: aa290-306; α7: aa312-343; α8: aa349-372; α9: aa375-426; α10: 
aa 431-450; α11: 456-479; α12: aa483-562; α13: aa566-585; β-1: aa11-15; β0: aa21-23; β1: aa38-44; β2: aa78-
83; β3: aa92-97; β5: aa178-184; β6 aa235-238). Accordingly, for the α-helices, the distance between H-bond 
donors and acceptors was restrained within 2.5 Å by means of  distance restraints. On the other hand, for 
the β-sheets, the φ and ψ torsional angles, according to the parallel or anti-parallel conformation, were 
restrained within -119° and +113°, or -139° and +135°, respectively (Restrain command; Discover_3 
Module, Accelrys, San Diego). According to the reliability index values obtained from secondary structure 
prediction analysis, the following set of  restraint force constants was used: i) force constants of  1 
kcal/mol/Å2-10 kcal/mol/Å2 for reliability index values from 0 to 3, ii) force constants of  10 
kcal/mol/Å2-100 kcal/mol/Å2 for reliability index values from 4 to 6, and iii) force constants of  100 
kcal/mol/Å2-1000 kcal/mol/Å2 for reliability index values from 7 to 9. Moreover, during these 
calculations, the interaction distances among GDP•AlF3, Mg
2+ ion, the active site amino acids, and the 
active site water molecules were restrained to the values of  reference crystal structure (i.e. PDB ID: 2B92) 
by means of  quadratic distance restraints (100 kcal/mol/Å2 -1000 kcal/mol/Å2). Finally, GDP•AlF3 and 
Mg2+ ion were tethered with a force constant of  100 kcal/mol/Å2. GDP•AlF3-bound hGBP1
FL model was 
subjected to the same structural check procedure previously described for the model of  unbound GBP1, 
and then used for the subsequent dynamic docking studies. 
 
Modelling of  PIM1. The molecular model of  full length human PIM1 was built using as template the 
experimentally determined structure of  human PIM1 (hPIM1) in free form (PDB ID: 1XQZ), which lacks 
of  N-terminal (aa1-122) and C-terminal (aa400-404) regions. The sequence of  1XQZ was aligned with the 
sequence of  hPIM1 downloaded from the UniProtKB/Swiss-Prot Data Bank (http://www.uniprot.org; 
entry P11309) by using the Multiple_Alignment algorithm (Homology Module, Accelrys, San Diego). 
Secondly, the secondary structure prediction of  the hPIM1 was performed using the Structure Prediction 
and Sequence Analysis server PredictProtein (http://www.predictprotein.org/). The coordinates of  i) the 
structurally conserved regions (aa123-399) of  hPIM1 sequence were accordingly assigned by the SCR-
AssignCoords procedure of  Homology using 1XQZ as template structure and ii) the N-terminal and C-
terminal amino acids (aa1-122 and aa400-404, respectively) were assigned using the EndRepair command 
of  Homology Module. Finally, the obtained model of  hPIM1 was completed inserting the water molecules 
of  PIM1 experimentally determined structure (PDB ID: 1XQZ) through the Modify/UnMerge and 
Modify/Merge commands (Biopolymer Module, Accelrys, San Diego). PIM1 homology model was then 
subjected to the same full energy minimisation and structural check procedure previously described for the 
homology model of  GBP1 in free form. 
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Docking studies. The docking studies on i) GBP1:PIM1 complex; ii) GBP1 in complex with GDP•AlF3 
and iii) GBP1 in Complex with 3 were performed as described below. 
 
Docking studies on GBP1:PIM1 complex. In order to build a starting GBP1-PIM1 complex for dynamic 
docking studies, the experimentally determined structure of  p110γ catalytic subunit in complex with H-
Ras-1 (PDB ID: 1HE8) was downloaded from the Protein Data Bank (PDB; http://www. rcsb.org/pdb/). 
Hydrogens were added to the PDB structure assuming a pH of  7.2. This structure was analysed and 
compared with the obtained homology models of  PIM1 and GBP1 (free form), by using Biopolymer and 
Homology Module of  Insight 2005 (Accelrys, San Diego). In particular, a sequence alignment and a 
structural superimposition were performed between: i) the homology model of  PIM1 and p110γ kinase 
domain (PDB ID: 1HE8) and ii) the homology model of  GBP1 (free form) and H-Ras-1 (PDB ID: 
1HE8). Water molecules overlapping the proteins in the obtained starting GBP1-PIM1 dimeric complex 
model were removed. The resulting structure was used for successive dynamic docking studies. The 
docking methodology is described in the paragraph 6.2 “Monte Carlo/Simulated Annealing based docking 
protocol”. Although in the subsequent dynamic docking protocol all the systems were perturbed by means 
of  Monte Carlo and simulated annealing procedures, nevertheless the dynamic docking procedure formally 
requires a reasonable starting structure. Accordingly, the starting model of  GBP1-PIM1 complex was 
subjected to a preliminary energy minimisation to generate roughly docked starting structure (Steepest 
Descent algorithm, maximum RMSd = 10 kcal/Å; Conjugate Gradient algorithm, maximum RMSd = 1 
kcal/Å; ε = 1). During the minimisation, the whole system was left free to move, whereas a quadratic 
distance or torsional restraints were applied on the SCRs to avoid unrealistic results (Restrain command; 
Discover_3 Module, Accelrys, San Diego). To identify the SCRs, we analysed the hGBP1FL and hPIM1 
sequences (UniProtKB/Swiss- Prot Data Bank; entry code GBP1: P32455; entry code PIM1: P11309) 
using the Structure Prediction and Sequence Analysis Server Predict Protein 
(http://www.predictprotein.org/). In GBP1, as reported in the paragraph “Modelling of  GBP1 in complex with 
GDP•AlF3” sixteen α-helix and seven β-sheet secondary structures were predicted to be conserved (α0: 
aa25-33; α1: aa51-59; α2: aa112-123; α3: aa136-151; α3’: aa169-172; α4:  aa198-207; α4’: aa221-229; α5: 
aa260-272; α6: aa290-306; α7: aa312-343; α8: aa349-372; α9: aa375-426; α10: aa431-450; α11: aa456-479; 
α12: aa483-562; α13: aa566-585; β-1: aa11-15; β0: aa21-23; β1: aa38-44; β2: aa78-83; β3: aa92-97; β5: aa178-
184; β6: aa235-238) In PIM1, seven α-helix and eight β-sheet secondary structures were predicted to be 
conserved (αC: aa178-187; αD: aa219-226; αE: aa232-251; αEF: aa300-304; αF: aa319-323; αH: aa352-362; 
αI: aa372-376; β1: aa129-134; β2: aa140-149; β3: aa153-161; β4: aa194-201; β5: aa206-213; β7: aa254-256; 
β8: aa264-267, β9: aa274-276). The parameters of  the restraints applied on the SCRs during these 
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calculations were the same as those previously described in the paragraph “Modelling of  GBP1 in complex with 
GDP•AlF3”. Moreover, in order to analyse the role of  the water molecules within the binding sites of  
GBP1 and PIM1, during these calculations, also the water molecules within the active sites of  GBP1 and 
PIM1 were tethered with a force constant of  100 kcal/mol/Å2. In particular, all the water molecules within 
a 6 Å radius from any given nucleotide atom (i.e., GppNHp for GBP1 (PDB ID: 1F5N); AppNHp for 
PIM1 (PDB ID: 1XR1)) were considered. Since the docking protocol included a Monte Carlo based 
conformational search of  a “ligand” within a “protein”, then the docking procedure was performed 
employing GBP1 as “ligand” and PIM1 as “protein”. The binding domain area was defined as a subset 
including all residues of  the “protein”. All atoms included in the binding domain area were left free to 
move during the entire course of  docking calculations, whereas, in order to avoid unrealistic results, a 
tethering restraint was applied on the SCRs of  each protein. The set of  restraints applied was the same as 
for the preliminary energy minimisation. The non-bonded interactions were calculated using 
Quartic_vdW_no_Coul method (vdW CUT_OFF: 5). The resulting docked structures were ranked by their 
conformational energy and were analysed by a structural check by using the Struct_Check command of  the 
ProStat pulldown in the Homology Module to verify the correctness of  their dihedral angles values. 
Structures characterised by unrealistic backbone geometry were discarded. Selected complexes were 
checked for quality using Procheck structure evaluator software.70 In order to allow the whole relaxation of  
the proteins, the resulting docked complexes were then subjected to Molecular-mechanics (MM) energy 
minimisation within Insight 2005 Discover Module (Steepest Descent algorithm; ε = 1) firstly, until the 
maximum RMSd less than 0.5 kcal/Å using the set of  structural restraints applied for docking calculations, 
secondly, until the maximum RMSd was less than 0.1 kcal/Å without structural restraints. Optimised 
complexes were checked for quality using Procheck structure evaluator software.70 Finally, in order to test 
the thermodynamic stability of  the resulting docked complexes, these latter were subjected also to a 
molecular dynamics SA protocol using the Cell_Multipole method for non-bonded interactions69 and the 
dielectric constant of  the water (ε = 80*r). A tethering restraint was applied on the SCRs of  the complex 
and on the water molecules within the nucleotide binding sites. The set of  structural restraints applied was 
the same as for previous docking calculations. In order to allow the whole relaxation of  the complexes, the 
resulting annealed complexes were then subjected to Molecular-mechanics (MM) energy minimisation 
within Insight 2005 Discover Module using the same protocol reported for the resulting docked 
complexes. The optimised complexes were checked for quality using Procheck structure evaluator software. 
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Docking studies on GBP1 in complex with GDP•AlF3.  The starting GBP1-GDP•AlF3 complex was subjected to 
dynamic docking studies (Affinity, SA_Docking; Insight 2005, Accelrys, San Diego). The applied docking 
and SA protocol as well as, the parameters were the same as those previously described in the “Docking 
studies on GBP1-PIM1 complex” paragraph. The docking protocol included a Monte Carlo-based 
conformational search of  the “ligand” (i.e., GDP•AlF3) within the obtained homology model of  GBP1. 
The binding domain area was defined as a subset including all residues of  GBP1 protein (aa1-592). All 
atoms included in the binding domain area were left free to move during the entire course of  docking 
calculations, whereas, in order to avoid unrealistic results, quadratic distance or torsional restraints were 
applied on the SCRs of  the protein. The parameters of  restraints applied on the SCRs were the same as for 
the preliminary energy minimisation (see paragraph “Modelling of  GBP1 in complex with GDP•AlF3”). 
Moreover, in order to preserve the key interactions among GDP•AlF3, Mg
2+ ion, the active site amino acids 
and the active site water molecules, during these calculations, GDP•AlF3, Mg
2+ ion and the atoms of  amino 
acids or of  water molecules involved in these interactions were tethered with a force constant of  100 
kcal/mol/Å2. The resulting docked and annealed complexes were checked for quality using Procheck 
structure evaluator software. 
 
Docking Studies on GBP1 in Complex with 3. The putative 3-GBP1 complex was subjected to dynamic docking 
studies (Affinity, SA_Docking; Insight 2005, Accelrys, San Diego). The applied docking and simulated 
annealing protocol as well as, the parameters were the same as those previously described in the “Docking 
studies on GBP1-PIM1 complex” paragraph. The docking protocol included a Monte Carlo-based 
conformational search of  the “ligand” (i.e., 3) within the obtained homology model of  GBP1. The binding 
domain area was defined as a subset including all residues of  GBP1 protein (aa1-592). All atoms included 
in the binding domain area were left free to move during the entire course of  docking calculations, 
whereas, in order to avoid unrealistic results, quadratic distance or torsional restraints were applied on the 
SCRs of  the protein. The parameters of  restraints applied on the SCRs were the same as for the 
preliminary energy minimisation (see paragraph “Modelling of  GBP1 in complex with GDP•AlF3”). Moreover, 
in order to analyse the role of  the water molecules within the binding site of  GBP1, for each set of  
docking, two typologies of  calculations were performed: one, where all water molecules were left free to 
move, another, where the water molecules within the active site of  GBP1, were tethered with a force 
constant of  100 kcal/Å2 as for the preliminary energy minimisation. The non-bonded interactions were 
calculated using three different methods: i) Quartic_vdW_no_Coul (vdW CUT_OFF: 5), ii) 
Cell_Multipole, and iii) Group Based (vdW and Coul CUT_OFF: 15). The resulting docked and annealed 
complexes were checked for quality using Procheck structure evaluator software. 
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6.4 Cationic Porphyrins as Tunable Gatekeepers of the 20S Proteasome: Experimental Procedure 
 
Calculation of  the chemical-physical properties of  cationic porphyrins. The apparent pKa values 
were estimated by using the ACD/Percepta software.220 The compounds were considered in their cationic 
form in all calculations performed, as a consequence of  the estimation of  percentage of  neutral/ionised 
forms computed at pH 7.4 and pH 7.2 (physiological and cytoplasmic values, respectively) using the 
Handerson-Hasselbalch equation. Atomic potentials were assigned using the CVFF force field, while the 
partial charges were assigned using the partial charges estimated by MNDO semi-empirical 1 SCF 
calculations.221 The conformational space of  the compounds was sampled using 200 cycles of  SA and the 
dielectric constant of  the water (ε = 80*r) (for details see the procedure described in the paragraph 6.1 
“Sampling procedure of  the conformational space of  the ligands”). The resulting PM7 conformers were subsequently 
ranked by: i) conformational energy (ΔE from the GM < 5 kcal/mol), ii) inter-atomic distances between 
the charged nitrogen atoms, and iii) conformation of  porphyrin ring.  
 
Structural and bioinformatics analysis of  20S proteasome. The experimentally determined structures 
of  20S proteasome in free form and 20S human proteasome in complex with its regulatory particles (RPs), 
such as: i) 19S (PDB IDs: 5L4G (Cryo-EM; resolution 3.9 Å), 5GJQ (Cryo-EM; resolution 4.35 Å), 5GJR 
(Cryo-EM; resolution 3.5 Å), 5T0C (Cryo-EM; resolution 3.88 Å), 5T0G (Cryo-EM; resolution 4.4 Å), 
5T0H (Cryo-EM; resolution 6.8 Å), 5T0I (Cryo-EM; resolution 8.0 Å), and 5T0J (Cryo-EM; resolution 8.0 
Å)), ii) Saccharomyces cerevisiae 20S proteasome in complex with its RPs (i.e., PA26, 19S and Blm10) and 
regulatory peptides (i.e., PR-VI and Blm-Pep) (PDB IDs: 1Z7Q (X-ray diffraction; resolution 3.22 Å), 
4V70 (X-ray diffraction; resolution 3.01 Å), 4CR2 (Cryo-EM; resolution 7.7 Å), 4CR3 (Cryo-EM; 
resolution 9.3 Å), 4CR4 (Cryo-EM; resolution 8.8 Å), 3JCO (Cryo-EM; resolution 4.8 Å), 3JCP (Cryo-EM; 
resolution 4.6 Å)), 4X6Z  (X-ray diffraction; resolution 2.7 Å), and 4ZZG (X-ray diffraction; resolution 3.0 
Å) were downloaded from the Protein Data Bank (PDB; http://www.rcsb.org/pdb/). Hydrogens were 
added to all the PDB structures assuming a pH of  7.2. These structures were analysed using Biopolymer 
and Homology Modules of  Insight 2005 (Accelrys, San Diego). In order to define the putative binding site 
of  cationic porphyrins to the 20S proteasome, we analysed: i) the binding mode of  inhibitors co-
crystallised with 20S proteasome creating, for each inhibitor/enzyme complex, a subset around the ligand 
including all protein amino acids and water molecules having at least one atom within a 5 Å radius from 
any given ligand atom (Interface command of  the Subset pulldown; Insight2005) and ii) the ionic 
interactions between 20S proteasome and its modulators creating, for each co-crystallised complex a subset 
around the 20S charged residues including all RP amino acids having at least one atom within a 5 Å radius 
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from any given 20S charged residue. In particular, in the analysis of  yeast 20S proteasome in complex with 
the RPs PA26 and Blm10, in order to verify if  such interactions are conserved between 20S human and its 
modulators, we considered both the X-ray structures of  20S yeast and homology models of  20S human 
(see “Modelling of  human 20S proteasome in the closed conformation” and “Modelling of  human 20S proteasome in the 
open conformation” paragraphs) superimposed on yeast 20S in complex with activators. In addition, a 
structural superimposition, where it was possible, between human (PA28, PDB ID:1AVO; X-ray 
diffraction; resolution 2.8 Å) and non human RPs (PA26, PDB ID: 1ZTQ). Then, the new identified 
charged residues were introduced in the yeast RPs (Replace Residue command; Biopolymer Module; 
Insight2005) and the putative ionic interactions were analysed using different charged residue side chain 
rotamers (Manual_Rotamer command; Biopolymer Module; Insight2005). Finally, all charged amino acids 
involved in these interactions were mapped on human 20S proteasome, in the closed and open 
conformation. Combining these results with those obtained from porphyrins pharmacophoric property 
analysis, the putative starting complexes were generated for the cationic porphyrins. In particular, we 
selected the gate as starting point for the docking studies of  H2T4, meta-H2T4, and ortho-H2T4 as well as the 
α4-α5 groove for the docking studies of  2. 
  
Modelling of  20S human proteasome. It must be mentioned here that, at the beginning of  this research 
activity concerning the first class of  cationic porphyrins (H2T4, meta-H2T4, ortho-H2T4), the X-ray structure 
of  the human 20S proteasome was not solved and only after our modelling studies it was determined and 
deposited in the Brookhaven Protein Data Bank (PDB ID:4R3O). All subsequent structural calculations 
were performed using the CVFF force field.130 
 
Modelling of  20S human proteasome α1-α7 subunits. The molecular models of  α1-α7 subunits of  20S human 
proteasome were built starting from the experimentally determined structure of  20S mouse proteasome 
(PDB ID: 3UNE). The sequences of  3UNE α1-α7 subunits were aligned with the sequences of  20S 
human proteasome α1-α7 subunits downloaded from the UniProtKB/Swiss-Prot Data Bank 
(http://www.uniprot.org; entry P60900 (α1); P25787 (α2); P25789 (α3); O14818 (α4); P28066 (α5); P25786 
(α6) and P25788 (α7); by using the Multiple_Alignment algorithm, Homology Module, Accelrys, San 
Diego). Subsequently, the secondary structural prediction of  20S human proteasome α1- α7 subunits was 
performed using the Structure Prediction and Sequence Analysis server PredictProtein 
(http://www.predictprotein.org/). The coordinates of  the structurally conserved regions (α1: aa2-244; α2: 
aa2-233; α3: aa2-249; α4: aa2-240; α5: aa9-240; α6: aa4-241; α7: aa2-245) were accordingly assigned by the 
SCR-AssignCoords procedure (Homology Module, Insight 2005) using 3UNE as template structure. On 
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the other hand, the coordinates of  the N- and C-terminal amino acids (α1: aa1 and aa245-246; α2: aa1 and 
aa234; α3: aa1 and aa250-261; α4: aa1 and aa241-248; α5: aa1-8 and aa241; α6: aa1-3 and aa242-263; α7: aa1 
and 246-255) were assigned using the EndRepair command (Homology Module, Insight 2005). The 
obtained homology model was refined inserting the water molecules of  experimentally determined 
structure 20S mouse proteasome α1-α7 subunits (PDB ID: 3UNE) through the UnMerge and Merge 
commands (Biopolymer Module, Accelrys, San Diego). The obtained homology model was then subjected 
to a full energy minimisation within Insight 2005 Discover_3 Module (Steepest Descent algorithm, 
maximum RMSd = 1 kcal/Å; ε=1). During the minimisation, only the whole disordered N- and C- 
terminals and the SCRs side chains were left free to move, whereas the SCRs backbone were fixed to avoid 
unrealistic results. Each step of  refining procedure was followed by a structural check by using the 
Struct_Check command of  the ProStat pulldown in the Homology Module to verify the correctness of  the 
geometry optimisation procedure before moving to the next step. Checks included φ, ψ, χ1, χ2, χ3, and ω 
dihedral angles, Cα virtual torsions, and Kabsch and Sander main chain H-bond energy evaluation. The 
quality of  the resulting complexes was then checked using Molprobity structure evaluator software71 and 
compared to that of  the reference PDB structure. The obtained homology model was used for successive 
dynamic docking studies (i.e., H2T4-20S complex, meta-H2T4-20S complex and ortho-H2T4-20S complex). 
 
Modelling of  human 20S proteasome in the closed conformation. The molecular model of  20S human proteasome in 
the closed conformation was built starting from the experimentally determined structure of  20S human 
proteasome (PDB ID: 4R3O), which lacks the N-terminal regions (α1: aa1; α2: aa1; α3: aa1; α4: aa1; α5: 
aa1-7; α6: aa1-3; α7: aa1), C-terminal regions (α1: aa246; α3: aa252-261; α4: aa245-248; α6: aa242-263; α7: 
aa247-255; β1: aa203-205; β2: aa221-234; β4: aa200-201; β5: aa202-204; β7: aa218-219), and the side chains 
of  several residues (α1: aa2, 3, 45, 46, 55, 59, 62, 63, 146, 181,186-188, 196, 223, and 245; α2: aa4, 18, 36, 
52-55, 60, 139-141, 143, 163, 176-178, 184, 193, 195, 196, 199, 200, 202, 226, 227, 230, and 233; α3: aa13, 
37, 51, 52, 54, 177, 184, 194, 197, 201, 205, 210, 222, 229-231, 250, and 251; α4: aa27, 40, 42, 43, 46-50, 53, 
54, 56, 61, 68, 84, 136-138, 141, 157, 163, 166, 169, 170, 174, 181-183, 185, 187-189, 192, 193, 195-199, 
204, 207, 208, 211-213, 216, 218, 223-227, 229, and 231-244; α5: aa8, 86, 187, 192, 208, 209, and 231; α6: 
aa208, 217, 218, 237, 238, and 241; α7: aa109, 143, 203, 205, 207, 223, and 245; β1: aa201-202; β2: aa9, 180, 
206, and 214; β3: aa47; β4: aa41, 95, 109, 185, 198, and 199; β5: aa106, 150, and 185; β6: aa45, 161, 166, 
and 200; β7: aa44, 156, 170, 195, and 216). The sequence of  4R3O was aligned with the sequences of  20S 
human proteasome downloaded from the UniProtKB/Swiss-Prot Data Bank (http://www.uniprot.org; 
entry P60900 (α1); P25787 (α2); P25789 (α3); O14818 (α4); P28066 (α5); P25786 (α6); P25788 (α7); P28072 
(β1); Q99436 (β2); P49720 (β3); P49721 (β4); P28074 (β5); P20618 (β6), and P28070 (β7)) by using the 
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Multiple_Alignment algorithm (Homology Module, Accelrys, San Diego). Subsequently, the secondary 
structural prediction of  20S human proteasome was performed using the Structure Prediction and 
Sequence Analysis server PredictProtein (http://www.predictprotein.org/). The coordinates of  the 
structurally conserved regions (α1: aa2-245; α2: aa2-234; α3: aa2-251; α4: aa2-244; α5: aa8-241; α6: aa4-241; 
α7: aa2-246; β1: aa1-202; β2: aa1-220; β3: aa1-204; β4: aa1-199; β5: aa1-201; β6: aa1-213; β3: aa1-217) were 
accordingly assigned by the Structurally Conserved Regions (SCRs)-AssignCoords procedure (Homology 
Module, Insight 2005) using 4R3O as template structure. On the other hand, the coordinates of  the lacking 
N-terminal and C-terminal amino acids were assigned using the EndRepair command (Homology Module, 
Insight 2005). The obtained homology model was completed inserting the missing residue side chains by 
using the Replace command (Biopolymer Module, Accelrys, San Diego), and the water molecules of  
experimentally determined structure 20S human proteasome (PDB ID: 4R69) through the UnMerge and 
Merge commands (Biopolymer Module, Accelrys, San Diego). The obtained homology model was then 
subjected to a full energy minimisation within Insight 2005 Discover_3 Module (Steepest Descent 
algorithm, maximum RMSd = 0.5 kcal/Å; ε = 80*r). During the minimisation, only the whole disordered 
N- and C- terminals and the SCRs side chains were left free to move, whereas the SCRs backbone were 
fixed to avoid unrealistic results. Each step of  refining procedure was followed by a structural check by 
using the Struct_Check command of  the ProStat pulldown in the Homology Module to verify the 
correctness of  the geometry optimisation procedure before moving to the next step. Checks included φ, ψ, 
χ1, χ2, χ3, and ω dihedral angles, Cα virtual torsions, and Kabsch and Sander main chain H-bond energy 
evaluation. The quality of  the resulting complexes was then checked using Molprobity structure evaluator 
software and compared to that of  the reference PDB structure. The obtained homology model was used 
for successive dynamic docking studies (i.e., 2-20S complex). 
 
Modelling of  human 20S proteasome in the open conformation. According to the reference structure (PDB ID: 
5T0J), it must be highlighted that the molecular model of  20S in the open conformation was built 
considering only two packed rings (i.e., one α subunit ring and one β subunit ring). The molecular model of  
20S human proteasome in the open conformation was built starting from the experimentally determined 
structure of  20S human proteasome (PDB ID: 5T0J), which lacks the N-terminal regions (α1: aa1-4; α2: 
aa1-2; α3: aa1; α4: aa1-2; α5: aa1-8; α6: aa1-3; α7: aa1-5), C-terminal regions (α1: aa245-246; α3: aa252-261; 
α4: aa241-248; α6: aa242-263; α7: aa246-255; β1: aa192-205; β2: aa221-234; β4: aa200-201; β5: aa202-204; 
β7: aa216-219), one loop region (α5: aa128-133), and the side chains of  several residues (α1: aa45, 46, 55, 
59, 63, 146, 181, 186-188, 196, and 223; α2: aa18, 36, 52-55, 60, 139-141, 143, 163, 176-178, 184, 193, 195, 
196, 199, 200, 202, 226, 227, 230, and 233; α3: aa13, 37, 51, 52, 54, 177, 184, 194, 197, 201, 205, 210, 222, 
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229-231, and 250-251; α4: aa27, 40, 42, 46-50, 53, 136, 138, 141, 157, 163, 166, 169, 170, 174, 181-183, 185, 
187, 189, 192-193, 195-199, 204, 207, 208, 212-213, 216, 218, 223, 225-227, 229, 232-237, and 239-240; α5: 
aa8, 86, 187, 192, 208-209, and 231; α6: aa208, 217-218, 237-238, and 241; α7: aa109, 143, 203, 205, 207, 
and 223; β2: aa9, 180, 206, and 214; β3: aa47; β4: aa41, 95, 109, 185, 198, and 199; β5: aa106, 150, and 185; 
β6: aa45, 161, 166, and 200; β7: aa44, 156, and 195).  
The sequence of  5T0J was aligned with the sequences of  20S human proteasome downloaded from the 
UniProtKB/Swiss-Prot Data Bank (http://www.uniprot.org; entry P60900 (α1); P25787 (α2); P25789 (α3); 
O14818 (α4); P28066 (α5); P25786 (α6); P25788 (α7); P28072 (β1); Q99436 (β2); P49720 (β3); P49721 (β4); 
P28074 (β5); P20618 (β6), and P28070 (β7)) by using the Multiple_Alignment algorithm (Homology 
Module, Accelrys, San Diego). Subsequently, the secondary structural prediction of  20S human 
proteasome was performed using the Structure Prediction and Sequence Analysis server PredictProtein 
(http://www.predictprotein.org/). The coordinates of  the structurally conserved regions (α1: aa5-244; α2: 
aa3-234; α3: aa2-251; α4: aa3-240; α5: aa9-127 and aa134-241; α6: aa4-241; α7: aa6-245; β1: aa1-191; β2: 
aa1-220; β3: aa1-204; β4: aa1-199; β5: aa1-201; β6: aa1-213; β3: aa1-215) were accordingly assigned by the 
SCRs-AssignCoords procedure (Homology Module, Insight 2005) using 5T0J as template structure. The 
lacking loop segment in the α5 subunit (aa128-133) was inserted by using the Generate Loops procedure. 
With the Generate Loops procedure, a peptide backbone chain is built between two conserved peptide 
segments using randomly generated values for all the loops' φ’s and ψ’s. The chain was defined starting 
from the N-terminal end of  the loop being built; the Start and Stop Residues were defined as the SCR 
residues of  the model protein at either end of  the loop itself. The geometry about the base was described 
by the four distances between Cα and N-termini of  the Start residue and the Cα and C-termini of  the Stop 
Residues. In the process of  closing the loop, the values for the generated φ’s and ψ’s are adjusted until the 
four distance criteria are met. Specifically, a function was defined for the distances in terms of  the dihedral 
angles (Scale Torsions: 60). The differences between the desired distances and their current values were 
minimised using a linearised Lagrange multiplier method. After a series of  1000 iterations, the loop was 
closed, except in the case where the distances between the ends of  the loop were not respected 
(Convergence = 0.05). The geometry at the base of  the loop is then checked for proper chirality. Finally, 
the loops were screened on the basis of  steric overlap violations. All loops that are found to have 
unacceptable contacts were rejected. Since successive calculations can correct some bad contacts, a fairly 
large overlap factor was used (Internal and External overlap = 0.6). A bump check of  the 10 generated 
loops together with the evaluation of  their conformational energy were used as selection criteria. The 
lowest conformational energy loop presenting no steric overlap with the rest of  the protein, was selected. 
Finally, the coordinates of  the lacking N-terminal and C-terminal amino acids were assigned using the 
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EndRepair command (Homology Module, Insight 2005). The obtained homology model was completed 
inserting the missing residue side chains by using the Replace command (Biopolymer Module, Accelrys, 
San Diego). The obtained homology model was subjected to the same full energy minimisation and 
structural check procedure previously described in “Modelling of  human 20S proteasome in the closed 
conformation”, and, then, used for the subsequent dynamic docking studies. (i.e., 2-20S complex). During the 
minimisation, the whole disordered N- and C- terminals, the inserted loop region and the SCRs side chains 
were left free to move, whereas the SCRs backbone were fixed to avoid unrealistic results. 
 
Docking studies on human 20S proteasome in complex with H2T4, meta-H2T4, ortho-H2T4 and 2. 
The putative starting complexes (H2T4-20S human proteasome α1-α7 subunits; meta-H2T4-20S human 
proteasome α1-α7 subunits, ortho-H2T4-20S human proteasome α1-α7 subunits, and 2-20S human 
proteasome in closed and open conformation) was subjected to dynamic docking studies. The docking 
methodology is described in the paragraph 6.2 “Monte Carlo/Simulated Annealing based docking 
protocol”. During the Monte Carlo approach the dielectric constant of  the vacuum (ε = 1) was used while, 
during the simulated annealing protocol, the dielectric constant of  the water (ε = 80*r). The non-bonded 
interactions were calculated using the Cell Multipole method.69 The binding domain area was defined as a 
subset including all residues of  20S human proteasome. All atoms included in the binding domain area 
were left free to move during the entire course of  docking calculations, whereas, in order to avoid 
unrealistic results, a tethering restraint was applied on the SCRs of  protein. To identify SCRs, the 20S 
human proteasome sequences were analysed using the Structure Prediction and Sequence Analysis server 
PredictProtein (http://www.predictprotein.org/). In α1 subunits, 6 α-helix and 10 β-sheet secondary 
structures were predicted to be highly conserved (α1, aa23-33; α2, aa85-104; α3, aa111-128; α4, aa172-183; 
α5, aa191-207; α6, aa232-243; β1, aa13-16; β2, aa38-43; β3, aa48-53; β4, aa68-72; β5, aa76-80; β6, aa135-
143; β7, aa150-154; β8, aa160-168; β9, aa215-222; β10, aa226-229). In α2 subunits, 6 α-helix and 10 β-sheet 
secondary structures were predicted to be highly conserved (α1, aa20-30; α2, aa81-100; α3, aa107-124; α4, 
aa167-178; α5, aa184-198; α6, aa223-231; β1, aa9-13; β2, aa34-39; β3, aa44-49; β4, aa66-68; β5, aa72-76; β6, 
aa131-139; β7, aa145-149; β8, aa155-163; β9, aa208-214; β10, aa219-220). In α3 subunits, 6 α-helix and 10 
β-sheet secondary structures were predicted to be highly conserved (α1, aa18-29; α2, aa80-100; α3, aa107-
124; α4, aa168-178; α5, aa186-200; α6, aa230-248; β1, aa10-12; β2, aa33-38; β3, aa43-48; β4, aa66-68; β5, 
aa72-76; β6, aa131-139; β7, aa146-150; β8, aa157-164; β9, aa211-217; β10, aa224-227). In α4 subunits, 6 α-
helix and 10 β-sheet secondary structures were predicted to be highly conserved (α1, aa17-27; α2, aa78-97; 
α3, aa104-121; α4, aa165-176; α5, aa183-198; α6, aa222-243; β1, aa6-10; β2, aa31-36; β3, aa41-46; β4, aa62-
65; β5, aa69-73; β6, aa128-136; β7, aa143-147; β8, aa154-161; β9, aa206-212; β10, aa217-219). In α5 
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subunits, 6 α-helix and 10 β-sheet secondary structures were predicted to be highly conserved (α1, aa22-32; 
α2, aa83-102; α3, aa109-120; α4, aa174-185; α5, aa191-206; α6, aa231-240; β1, aa11-15; β2, aa36-41; β3, 
aa46-51; β4, aa66-70; β5, aa74-78; β6, aa138-146; β7, aa152-156; β8, aa162-170; β9, aa215-221; β10, aa226-
228). In α6 subunits, 6 α-helix and 10 β-sheet secondary structures were predicted to be highly conserved 
(α1, aa19-30; α2, aa79-98; α3, aa105-122; α4, aa165-176; α5, aa184-199; α6, aa226-236; β1, aa10-13; β2, 
aa35-39; β3, aa45-49; β4, aa62-66; β5, aa70-74; β6, aa129-137; β7, aa143-147; β8, aa154-161; β9, aa210-216; 
β10, aa221-223). In α7 subunits, 6 α-helix and 10 β-sheet secondary structures were predicted to be highly 
conserved (α1, aa22-32; α2, aa83-102; α3, aa109-124; α4, aa170-180; α5, aa187-202; α6, aa229-245; β1, aa13-
15; β2, aa36-41; β3, aa46-51; β4, aa67-70; β5, aa74-78; β6, aa133-141; β7, aa148-152; β8, aa160-166; β9, 
aa212-219; β10, aa224-227). In β1 subunits, 5 α-helix and 11 β-sheet secondary structures were predicted to 
be highly conserved (α1, aa52-69; α2, aa76-90; α3, aa132-143; α4, aa149-166; α5, aa191-200; β1, aa2-8; β2, 
aa12-16; β3, aa25-27; β4, aa34-37; β5, aa41-45; β6, aa95-103; β7, aa110-114; β8, aa120-122; β9, aa124-128; 
β10, aa174-180; β11, aa185-189). In β2 subunits, 5 α-helix and 12 β-sheet secondary structures were 
predicted to be highly conserved (α1, aa52-67; α2, aa76-90; α3, aa131-142; α4, aa148-165; α5, aa194-201; 
β1, aa2-8; β2, aa12-17; β3, aa25-27; β4, aa33-37; β5, aa41-45; β6, aa95-103; β7, aa109-113; β8, aa123-127; 
β9, aa173-179; β10, aa184-186; β11, aa210-213; β12, aa215-225). In β3 subunits, 4 α-helix and 10 β-sheet 
secondary structures were predicted to be highly conserved (α1, aa56-76; α2, aa83-97; α3, aa142-152; α4, 
aa159-175; β1, aa9-14; β2, aa18-24; β3, aa32-34; β4, aa41-44; β5, aa48-52; β6, aa103-111; β7, aa119-123; β8, 
aa134-138; β9, aa184-190; β10, aa194-199). In β4 subunits, 5 α-helix and 10 β-sheet secondary structures 
were predicted to be highly conserved (α1, aa32-35; α2, aa50-70; α3, aa77-93; α4, aa136-147; α5, aa153-170; 
β1, aa3-8; β2, aa12-17; β3, aa26-27; β4, aa36-38; β5, aa42-46; β6, aa99-107; β7, aa114-118; β8, aa129-132; 
β9, aa178-184; β10, aa189-190). In β5 subunits, 6 α-helix and 11 β-sheet secondary structures were 
predicted to be highly conserved (α1, aa31-34; α2, aa49-69; α3, aa76-91; α4, aa132-143; α5, aa149-166; α6, 
aa189-200; β1, aa2-8; β2, aa12-16; β3, aa25-26; β4, aa35-37; β5, aa41-45; β6, aa96-104; β7, aa110-114; β8, 
aa120-122; β9, aa124-128; β10, aa174-180; β11, aa185-186). In β6 subunits, 4 α-helix and 11 β-sheet 
secondary structures were predicted to be highly conserved (α1, aa58-77; α2, aa85-99; α3, aa142-152; α4, 
aa168-184; β1, aa5-6; β2, aa11-16; β3, aa20-26; β4, aa34-36; β5, aa42-46; β6, aa50-54; β7, aa105-113; β8, 
aa120-124; β9, aa134-138; β10, aa193-199; β11, aa203-210). In β7 subunits, 6 α-helix and 10 β-sheet 
secondary structures were predicted to be highly conserved (α1, aa39-41; α2, aa57-77; α3, aa85-100; α4, 
aa143-154; α5, aa162-179; α6, aa207-216; β1, aa10-16; β2, aa20-25; β3, aa33-35; β4, aa42-45; β5, aa49-53; 
β6, aa107-115; β7, aa121-125; β8, aa136-139; β9, aa187-193; β10, aa198-199). Accordingly, for the alpha-
helices, the distance between backbone H-bond donors and acceptors was restrained within 2.5 Å. On the 
other hand, for the β-sheets, the φ and ψ torsional angles, according to the parallel or anti-parallel 
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conformation, were restrained within -119° and +113°, or -139° and +135°, respectively (Restrain 
command; Discover_3 Module, Accelrys, San Diego). According to the reliability index values obtained 
from secondary structure prediction analysis, the following set of  restraint force constants was used: i) 
force constants of  1 kcal/mol/Å2-10 kcal/mol/Å2 for reliability index values from 0 to 3, ii) force 
constants of  10 kcal/mol/Å2-100 kcal/mol/Å2 for reliability index values from 4 to 6, and iii) force 
constants of  100 kcal/mol/Å2-1000 kcal/mol/Å2 for reliability index values from 7 to 9. In order to allow 
the whole relaxation of  the protein, the resulting annealed complexes were then subjected to MM energy 
minimisation without restraints (Steepest Descent algorithm; ε = 80*r) until the maximum RMSd was less 
than 0.5 kcal/Å (Discover Module; Insight 2005). The resulting docked and annealed structures were 
ranked by their conformational energy and analysed considering the non-bonded interaction energies 
between the ligand and the enzyme (vdW and electrostatic energy contribution; Group Based method; 
CUT_OFF = 10 and 100; ε = 2*r; Discover_3 Module of  Insight2005). The complex with the best 
compromise between the non-bonded interaction energies obtained by Monte Carlo and SA calculations 
was selected as the structure representing the most probable binding mode. 
 
6.5 Design of Redox-active Chemotherapeutics: Experimental Procedure 
 
Conformational analysis of  the new antimalarial endoperoxides. Apparent pKa and log D values of  
new endoperoxides were calculated by using ACD/Percepta software.220 Accordingly, percentage of  
neutral/ionised forms were computed at pH 7.4 (blood), at pH 7.2 (cytoplasm), and at pH 5.5 (Pf FV) 
using the Henderson-Hasselbalch.  
The new endoperoxides were built, taking into account the prevalent ionic forms at the considered 
different pH values, using the Insight 2005 Builder Module (Accelrys Software Inc., San Diego). Since 9h, 
9r and 9s were tested as mixture of  two diastereomers, both diastereomers of  these compounds were built. 
Atomic potentials and charges were assigned using the CFF91 force field.222 The conformational space of  
the compounds was sampled using 200 cycles of  SA and the dielectric constant of  the vacuum (ε = 1) (for 
details see the procedure described in the paragraph 6.1 “Sampling procedure of  the conformational space of  the 
ligands”). The resulting conformers were ranked by their potential energy values (i.e., ΔE from the GM) and 
all conformers within 5 kcal mol-1 from the GM were classified on the basis of: i) 1,2-dioxane ring 
conformation; ii) intra-molecular H-bonds, and iii) distance between endoperoxide oxygens (O1 or O2) 
and possible partners for a “through space” intra-molecular radical shift (≤ 3 Å). Then, the occurrence 
rates were calculated. 
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Docking procedure. In order to further investigate the role of  the conformational behaviour on 
antimalarial activity, docking studies were carried out on 9c di-protonated form and on 9r diastereomer 
protonated form in complex with heme, using the docking methodology described in the paragraph 6.2 
“Monte Carlo/Simulated Annealing based docking protocol” and the dielectric constant of  the vacuum (ε 
= 1). Atomic potentials of  heme were assigned using the Heme29.frc;223 a force field including heme 
parameters and atomic partial charges were assigned using the QM method PM7. Heme apparent pKa 
values were calculated by using ACD/Percepta software. Accordingly, one propionic chain was considered 
protonated and the heme net total charge was set at +1. Although during the subsequent dynamic docking 
protocol all the systems were perturbed by means of  Monte Carlo and SA procedures, a reasonable starting 
structure is anyway required. Thus, the PM7 lowest energy conformer of  9c and 9r diastereomers meeting 
the hypothesised pharmacophoric requirements for antimalarial activity was selected as the ligand starting 
conformation. The ligand was then placed above the heme, taking as template the crystal structure of  a 
peroxo-bridged heme-copper dinuclear complex (CSD code UKACIS) and considering the O2/O7 iron 
coordination complex. During the entire docking calculations, all atoms in the complex were left free to 
move with the exception of  heme pyrrolic carbons, which were kept fixed and, in order to avoid unrealistic 
results, the distance between the iron and the interacting oxygens (i.e., O2 and O7) was restrained within 
2.0 Å (100-1000 kcal mol-1 Å-2). The Cell_Multipole method69 has been used to calculate the non-bonded 
interactions. The resulting annealed structures were ranked by their conformational energy. The complex 
with the best conformational energy was selected as structure representing the most probable binding 
mode. The selected complex was then subjected to a full geometry optimisation by semi-empirical 
calculations, using the QM method PM772 in the Mopac2012 package73 and EF (Eigenvector Following 
routine)74 as geometry optimisation algorithm. GNORM value was set to 0.01. To reach a full geometry 
optimisation the criteria for terminating all optimisations was increased by a factor of  100, using the 
keyword PRECISE. 
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Appendix I: Ramachandran plots and Main Chain parameters of  Human GBP1 X-ray structure (PDB ID: 
1DG3). 
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Appendix II: Ramachandran plots and Main Chain parameters of  Structure of  NSC756093/GBP1 
docked complex. 
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